

Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study

Received: 5 November 2024

Accepted: 27 October 2025

Published online: 6 January 2026

 Check for updates

Jiyeon Oh^{1,1180}, Soeun Kim^{1,1180}, Yesol Yim^{2,1180}, Min Seo Kim^{3,4,1180}, GBD 2023 Global Chronic Respiratory Disease and Covid Collaborators*, Simon I. Hay^{5,6}, Jae Il Shin^{7,1181}✉ & Dong Keon Yon^{8,1181}✉

Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease (ILD) and pulmonary sarcoidosis, are major global causes of mortality and morbidity. Although the COVID-19 pandemic has influenced acute respiratory health, its impact on chronic respiratory conditions remains unclear. We estimated the global, regional and national burden of chronic respiratory diseases from 1990 to 2023, including risk factors, and evaluated how these burdens have shifted during the COVID-19 pandemic using the Global Burden of Disease Study 2023. In 2023, chronic respiratory diseases accounted for 569.2 million (95% uncertainty interval (UI), 508.8–639.8) cases and 4.2 million (3.6–5.1) deaths. The age-standardized death rate declined by 25.7% globally from 1990 to 2023 despite an increase in ILD and pulmonary sarcoidosis. Mortality declined in younger males, especially for asthma, whereas older adults experienced a rise in ILD and pulmonary sarcoidosis. Smoking was the primary risk factor for COPD, whereas high body mass index and silica exposure were key risk factors for asthma and pneumoconiosis. During the pandemic, the incidence of chronic respiratory diseases increased modestly, but the decline in mortality rates became less pronounced, highlighting the need for sustained global attention and action to address their long-term burden.

The lungs are continually exposed to numerous irritants, including pollutants, tobacco smoke and infections, throughout the lifespan¹. Despite substantial efforts to understand the pathophysiology of chronic respiratory diseases and to reduce their burden over the past decades^{2,3}, chronic respiratory diseases—including chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease (ILD) and pulmonary sarcoidosis—remain a leading cause of mortality among non-communicable diseases (NCDs)⁴.

Global initiatives aim to enhance the prevention, diagnosis, and management of chronic respiratory diseases. For instance, the World

Health Organization's Global Alliance against Chronic Respiratory Diseases (GARD)⁵ focuses on reducing exposure to risk factors while strengthening healthcare systems to ensure equitable access to treatment and care. To achieve this goal, it is crucial to minimize the prevalence and disability-adjusted life years (DALYs) associated with chronic respiratory diseases by addressing modifiable risk factors such as smoking, air pollution, and occupational exposure to dust and chemicals.

The COVID-19 pandemic underscored the vulnerability of the lungs and the importance of respiratory health on a global scale. Beyond the direct effects of SARS-CoV-2, there has been increased attention to

A full list of affiliations appears at the end of the paper. ✉ e-mail: SHINJI@yuhs.ac; yonkkang@gmail.com

chronic respiratory diseases, as well as a greater emphasis on prevention, early diagnosis, and treatment in clinical settings⁶. Two previous studies have also reported a decrease in the incidence of non-COVID lower respiratory infections and tuberculosis during the COVID-19 pandemic^{7,8}. As airway infections are major triggers for COPD exacerbations, they may similarly contribute to some of the changes observed in the chronic respiratory disease burden.

Hence, this study examined the trends and levels of the chronic respiratory disease burden before and during the COVID-19 pandemic. We also explored attributable risk factors globally and by region and Socio-demographic Index (SDI) between 1990 and 2023 across 204 countries and territories, using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023.

Results

Overview

Globally, in 2019, before the onset of the COVID-19 pandemic, we estimated 522.7 million (95% uncertainty interval (UI), 469.3–586.3) prevalent cases of chronic respiratory disease, corresponding to an age-standardized rate of 6,610.6 (5,926.5–7,459.7) per 100,000 population. In 2020, this rate remained stable (6,610.0 [5,917.4–7,464.6] per 100,000 population), indicating a plateau following the long-term decline in prevalence observed since 1990. However, this long-term downward trend reversed sharply thereafter; by 2023, the global prevalence rate had risen notably, reaching 6,742.2 (6,011.7–7,630.45) per 100,000 population. Across GBD regions in 2023, the age-standardized rate ranged from 4,216.9 per 100,000 in Central Asia to 15,186.4 per 100,000 in Australasia. Among 204 countries and territories, the age-standardized prevalence rate in 2023 ranged from 3,690.3 per 100,000 population in Mongolia to 16,884.8 per 100,000 population in New Zealand.

Among the four major chronic respiratory diseases, asthma accounted for more than half of chronic respiratory disease cases in 2023, with 362.7 million (309.8–427.6) cases and an age-standardized rate of 4,457.1 (3,786.4–5,246.3) per 100,000 population (Fig. 1). COPD ranked second, with 214.6 million (193.5–232.1) cases and an age-standardized rate of 2,373.0 (2,143.9–2,565.1) per 100,000 population. In 2023, the global age-standardized prevalence rate was 50.4 (45.0–56.7) per 100,000 population for ILD and pulmonary sarcoidosis and 11.2 (8.9–14.5) per 100,000 population for pneumoconiosis. The age-standardized prevalence rates for all diseases showed a minimal change from 1900 to 2023, with a percentage change ranging from –6.9% (–13.8 to 1.2) to 1.6% (0.2–3.0).

Chronic respiratory diseases were the fourth leading cause of death in 2023, accounting for 4.2 million (3.6–5.2) deaths. The global age-standardized death rate decreased from 63.0 per 100,000 population in 1990 to 46.8 per 100,000 population in 2023 (–25.7% (–40.0 to –2.0)). However, this trend was not universal; the Caribbean region showed a 15.6% (2.7–33.1) increase in age-standardized death rates over the same period (Fig. 2 and Table 1). COPD remained the leading contributor to the mortality burden, accounting for 82.3% of the deaths due to all chronic respiratory diseases (Supplementary Table 1 and Fig. 3). Asthma ranked second, accounting for 10.6% of the mortality cases. From 1990 to 2023, pneumoconiosis showed the most substantial decline in age-standardized mortality rates, with a reduction of –42.4% (–63.9 to –21.1). In contrast, the age-standardized mortality rates for ILD and pulmonary sarcoidosis increased by 89.2% (25.1–140.0), marking them as the only chronic respiratory disease with rising mortality trends during this period. Further details on the age-standardized estimates by region can be found in Extended Data Figs. 1–5 and Supplementary Table 1.

Trends in age and sex-specific burden

Figure 3 presents the trends in age and sex-specific death rates for four chronic respiratory diseases from 1990 to 2023. For COPD, age-specific

death rates were higher in males across all age groups. Males aged 50 to 74 years had the greatest reduction of 49.1%, from 170.8 per 100,000 population in 1990 to 87.0 per 100,000 population in 2023, among all age-sex groups. For asthma, death rates remained stable for most age-sex groups, whereas males aged 0 to 14 years were the only age-sex group with a decline (1.3 per 100,000 population in 1990; 0.6 per 100,000 in 2023; –53.3% (–74.9 to –7.9)). Pneumoconiosis also showed stable trends for females and declining trends for males. Males had a greater mortality burden than females of all ages, and this gap became larger with advanced age. Last, age-sex-specific death rates for ILD and pulmonary sarcoidosis increased in most groups, most pronounced in those aged ≥ 75 years, with an increase of 158.8% in females and 137.4% in males from 1990 to 2023. Details on the global age and sex distributions of COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis prevalence and death are shown in Extended Data Figs. 6–8.

Disease burden before and during the COVID-19 pandemic

We examined the average annual percentage change (AAPC) in age-standardized incidence and death rates before (2010–2019) and during the COVID-19 pandemic (2020–2023). Globally, age-standardized incidence rates of chronic respiratory diseases remained relatively stable, with a slight increase from an AAPC of 0.05 before the pandemic to 0.13 during the pandemic. In contrast, the AAPC of age-standardized death rates of chronic respiratory diseases showed a less pronounced decreasing trend during the pandemic (AAPC, –1.23) compared with before the pandemic (AAPC, –3.04; Extended Data Fig. 9). This pattern in mortality trends was also observed for COPD, for which the AAPC in deaths changed from –3.27 to –1.34. Similarly, asthma showed a shift in death rates from –1.92 to –1.26, whereas asthma remained stable (AAPC: 0.20 before the pandemic, 0.21 during the pandemic). Pneumoconiosis showed a reversing trend in mortality from a decline before the pandemic (AAPC, 0.21) to a minimal increase (AAPC, –1.26) during the pandemic, whereas its incidence consistently decreased over the past decade. For ILD and pulmonary sarcoidosis, mortality trends reversed from a modest increase (AAPC, –1.99) to a slight decline (AAPC, 1.05; Fig. 4).

Risk factors for COPD, asthma and pneumoconiosis

In GBD 2023, risk factor estimation is available for COPD, asthma and pneumoconiosis (Fig. 5). For COPD, smoking remained the leading global risk factor for males, accounting for over half of the global age-standardized DALY rates (473.0 (379.0–603.4) per 100,000 population). In contrast, ambient particulate matter pollution was the leading risk factor for females globally (143.7 (103.9–198.0)) and in some regions, including Andean Latin America, Central Asia, Central Latin America, East Asia, North Africa and Middle East and Southern Sub-Saharan Africa. Ambient particulate matter (PM_{2.5}) pollution was a substantial risk factor for COPD for both sexes, consistently ranking high across multiple regions. Regional disparities were observed in the rankings of other COPD risk factors. For instance, although low temperature ranked seventh out of eight major risk factors for COPD globally for males and sixth for females, it was a prominent risk factor in Australasia, Western Europe and high-income North America for both sexes.

For asthma, high body mass index (BMI) was the leading global risk factor for age-standardized DALY rates globally (39.0 (19.3–63.8) per 100,000 population in males; 56.2 (25.5–92.9) in females) and in most regions for both sexes. Although the rankings of asthma risk factors were consistent across regions, the proportion of DALYs associated with high BMI was higher in regions such as North Africa and Middle East, and high-income North America than the global estimate. Occupational asthmagens, substances in the workplace that can trigger asthma, ranked second globally and across most regions for both males and females. For pneumoconiosis, occupational exposure to silica was the top global risk factor for males (7.9 (5.9–10.2)




Fig. 1 | World map of age-standardized prevalence rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis in 2023. a–d, World map depicting the 2023 age-standardized prevalence rates for COPD (a), asthma (b), pneumoconiosis (c) and ILD and pulmonary sarcoidosis (d). The color gradient, ranging from dark blue, red, purple or green (high value) to pale yellow (low

value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean and Northern Europe.

per 100,000 population), whereas it ranked second for females (0.35 (0.20–0.62)). Occupational particulate matter, gases and fumes were the second leading global risk factor for males (2.5 (1.8–3.4) per 100,000 population) but ranked first for females (0.45 (0.25–0.86)).

Discussion

We provided estimates of chronic respiratory disease burden at the global, regional, and national levels from 1990 to 2023. Although global age-standardized incidence rates for chronic respiratory disease increased modestly during the COVID-19 pandemic, the age-standardized mortality rates, which had been declining before the pandemic, showed a reversal and began to rise during the pandemic period. Despite notable progress in reducing the global age-standardized death rate, the Caribbean region has shown a considerable increase of 15.6% from 1990 to 2023, particularly in ILD and pulmonary sarcoidosis. We further observed that this progress substantially varied by age; individuals aged <15 years had the greatest reductions, primarily in deaths due to asthma, whereas those aged ≥ 75 years had the most minor declines or even increases in some diseases, such as ILD and pulmonary sarcoidosis. Smoking, high BMI and occupational exposure to silica were leading risk factors for COPD, asthma and pneumoconiosis, respectively. Disparities in key risk factors according to SDI levels were observed; for instance, household air pollution from solid fuels was a key risk factor for COPD among females and in low-SDI settings, highlighting that region- and demography-specific public health measures are warranted to mitigate the disease burden effectively.

Globally, substantial progress has been made in reducing the burden of asthma, COPD and pneumoconiosis. This achievement may partly be attributed to various efforts to improve prevention and therapeutics through targeted strategies and actions⁵. For instance, the adoption of the World Health Organization Framework Convention on Tobacco Control in 2005, which includes raising taxes on tobacco and enforcing a ban on advertising, marked a turning point for enhancing global tobacco control efforts in the prevention of chronic respiratory diseases, from which smoking is a major risk factor⁹. Considering that some resource-limited countries have shown slow implementation of policies⁹, there is potential for further reduction in the disease burden through improvements in preventive measures and treatment accessibility, as well as enhanced patient education on managing chronic respiratory diseases. In the past two decades, innovations in targeted therapies have contributed to a better prognosis for patients with chronic respiratory conditions. Novel targeted treatments, such as anti-IgE or anti-IL-5 monoclonal antibodies, represent a substantial advancement for patients with asthma refractory to conventional treatments, which could further contribute to a reduction in premature deaths¹⁰. For severe COPD, triple therapy, a combination of a long-acting muscarinic antagonist, a long-acting beta-agonist and an inhaled corticosteroid in a single inhaler, has shown improved outcomes¹¹.

Nevertheless, global age-standardized death rates from ILD and pulmonary sarcoidosis have substantially increased from 1990 to 2023. This may be due to the relatively recent recognition of the disease




Fig. 2 | World map of age-standardized death rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis in 2023. a–d, World map depicting the 2023 age-standardized death rates for COPD (a), asthma (b), pneumoconiosis (c) and ILD and pulmonary sarcoidosis (d). The color gradient, ranging from dark blue, red, purple or green (high value) to pale yellow (low

value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean and Northern Europe.

compared to asthma and COPD¹². Advances in radiology and pathology might have increased recognition and more accurate diagnosis of ILD and pulmonary sarcoidosis¹³. Moreover, the broader use of antimetabolites and cytotoxic agents—known to contribute to lung tissue scarring—has likely influenced this rise in ILD burden, especially among the older population¹⁴.

Australasia had the highest age-standardized prevalence rate of chronic respiratory diseases, which is primarily due to asthma. Asthma has been historically more common in Western countries due to a complex interplay of genetic and environmental factors¹⁵. In addition, high-income North America exhibited the largest increase in age-standardized mortality rates for ILD and pulmonary sarcoidosis rose markedly, whereas those for asthma and pneumoconiosis experienced declines. This trend is also evident in other high-income regions, such as high-income North America and Western Europe (Fig. 2), suggesting heightened recognition and clinical awareness of these diseases in these countries, where advances in diagnostic technologies and improved healthcare infrastructure have led to better identification of previously underdiagnosed conditions¹². Additionally, genetic and ethnic factors may also contribute to the rising mortality of pulmonary sarcoidosis¹⁶. Furthermore, Australasia had the highest age-standardized rate of chronic respiratory diseases in 2023 but ranked lower in age-standardized mortality rates (Fig. 2), likely due to advances in diagnostic measures and improvements in disease management and chronic disease care. In contrast, South Asian countries,

such as India and Pakistan, despite having a lower age-standardized prevalence rate, ranked higher in age-standardized mortality rates, which may be attributed to limited access to early diagnosis and timely treatment compared to high-income countries.

The higher death rates of COPD, pneumoconiosis, ILD and pulmonary sarcoidosis in males than females, which are especially pronounced in advanced age, can be attributed to several factors, including more notable physiological lung function impairment with aging, historically higher smoking rates and greater occupational exposure to potential irritants in males¹⁷. However, the prevalence and mortality rates of asthma were both higher in female adults, resulting from the transition of sex discordance in prevalence, which reverses with puberty¹⁷. This difference may be due to the influence of sex hormones. Androgens can improve bronchodilation and attenuate airway inflammation¹⁸, whereas hormonal fluctuations during menstruation, pregnancy and menopause can increase the risk in women¹⁷.

During the COVID-19 pandemic, we observed a rise in age-standardized incidence rates of chronic respiratory diseases, which may be driven by enhanced healthcare engagement and high priority placed on respiratory health in clinical settings⁶. Individuals affected by COVID-19 or risk factors¹⁹ may have prompted more frequent hospital visits, along with the increased number of CT scans performed²⁰, which has led to incidental diagnoses of underlying conditions, such as asthma or COPD²¹. This increased healthcare engagement and heightened awareness and monitoring of pulmonary health during

Table 1 | Global and regional age-standardized mortality rates from chronic respiratory diseases in 1990, 2019, 2020 and 2023, and the percentage change from 1990 to 2023 for both sexes combined

Location	1990	2019	2020	2023	Percentage change (1990–2023)
Chronic respiratory disease					
Global	62.97 (50.04–72.28)	47.24 (41.75–56.19)	42.78 (37.29–51.27)	46.79 (40.56–57.70)	–25.68 (–40.00 to –1.97)
Central Asia	39.66 (36.34–43.24)	40.76 (37.49–43.54)	39.27 (36.54–41.64)	34.31 (31.31–38.53)	–13.49 (–22.24 to –3.67)
Central Europe	37.62 (35.51–39.32)	18.51 (17.29–19.85)	17.21 (16.11–18.17)	16.38 (15.20–17.84)	–56.47 (–58.88 to –53.21)
Eastern Europe	32.58 (29.95–35.56)	13.44 (12.45–14.42)	13.27 (12.31–14.25)	12.64 (11.34–13.67)	–61.22 (–65.37 to –56.84)
Australasia	36.30 (34.01–37.82)	24.04 (21.29–25.83)	21.89 (19.32–23.57)	22.85 (20.08–24.89)	–37.04 (–41.43 to –32.95)
High-income Asia Pacific	24.07 (21.60–26.71)	12.57 (10.71–14.63)	11.81 (10.04–13.41)	14.28 (11.72–17.42)	–40.67 (–49.12 to –26.34)
High-income North America	30.87 (28.61–32.54)	36.69 (32.67–39.85)	34.59 (30.91–37.57)	33.36 (29.63–36.47)	8.06 (–0.69 to 16.44)
Southern Latin America	34.28 (31.92–36.32)	29.52 (27.17–31.71)	24.98 (22.77–26.86)	27.43 (23.81–32.43)	–19.98 (–28.80 to –4.66)
Western Europe	30.09 (27.90–31.49)	22.43 (19.93–24.25)	20.50 (18.36–22.14)	21.19 (18.64–23.36)	–29.57 (–34.55 to –23.60)
Andean Latin America	31.38 (26.81–36.98)	29.51 (25.63–32.86)	25.16 (20.78–28.68)	32.47 (27.86–36.90)	3.49 (–14.13 to 20.84)
Caribbean	24.08 (21.98–26.19)	25.17 (23.03–27.64)	23.49 (21.41–25.94)	27.82 (25.02–31.70)	15.56 (2.65–33.11)
Central Latin America	43.39 (41.00–45.25)	31.37 (28.49–33.82)	27.94 (26.09–29.42)	28.27 (25.55–31.48)	–34.86 (–39.34 to –28.21)
Tropical Latin America	47.33 (42.75–51.36)	31.20 (28.24–33.31)	29.17 (26.18–30.75)	29.01 (25.90–30.96)	–38.71 (–43.28 to –34.54)
North Africa and Middle East	48.38 (31.31–65.03)	36.93 (30.83–44.19)	33.25 (27.25–39.51)	35.00 (28.51–42.95)	–27.65 (–49.32 to 10.35)
South Asia	138.62 (100.32–172.88)	120.30 (101.45–137.18)	106.03 (84.23–123.43)	120.81 (99.95–148.17)	–12.85 (–34.79 to 22.99)
East Asia	114.13 (78.38–148.38)	49.85 (41.31–66.32)	45.10 (36.57–61.55)	48.53 (37.77–68.60)	–57.48 (–71.95 to –26.65)
Oceania	141.27 (106.27–186.45)	111.55 (87.60–139.64)	107.25 (83.33–134.84)	109.94 (84.66–141.31)	–22.18 (–43.36 to 7.40)
Southeast Asia	70.08 (54.71–88.61)	49.74 (41.39–62.82)	45.75 (37.21–57.04)	48.10 (40.09–61.10)	–31.35 (–49.39 to –8.98)
Central Sub-Saharan Africa	90.74 (64.62–124.05)	77.06 (58.09–99.85)	74.20 (55.72–96.38)	71.81 (54.84–96.40)	–20.86 (–44.27 to 14.00)
Eastern Sub-Saharan Africa	32.38 (23.82–43.09)	30.33 (23.42–39.02)	28.07 (21.07–35.21)	28.05 (21.03–37.45)	–13.39 (–43.16 to 28.12)
Southern Sub-Saharan Africa	54.52 (43.12–66.69)	49.08 (42.29–60.62)	39.26 (31.58–48.38)	44.88 (38.30–56.36)	–17.69 (–36.90 to 2.14)
Western Sub-Saharan Africa	45.29 (33.58–59.17)	35.77 (27.48–45.85)	33.27 (25.69–42.91)	33.16 (25.28–45.14)	–26.78 (–51.32 to 5.34)
COPD					
Global	52.42 (41.57–60.13)	38.78 (33.61–46.16)	34.92 (29.97–42.11)	38.42 (33.18–45.77)	–26.71 (–40.77 to –1.85)
Central Asia	29.87 (27.31–32.81)	32.05 (29.39–34.30)	30.17 (27.88–32.12)	26.02 (23.41–29.44)	–12.89 (–23.62 to –0.55)
Central Europe	31.03 (29.31–32.60)	16.36 (15.32–17.45)	15.07 (14.07–15.85)	14.25 (13.20–15.45)	–54.08 (–56.83 to –50.87)
Eastern Europe	27.23 (25.21–29.78)	12.42 (11.52–13.32)	12.21 (11.31–13.10)	11.60 (10.45–12.53)	–57.41 (–62.10 to –52.50)
Australasia	29.63 (27.72–30.87)	18.81 (16.57–20.25)	16.91 (14.84–18.24)	17.71 (15.56–19.29)	–40.23 (–44.46 to –36.18)
High-income Asia Pacific	14.25 (12.31–15.70)	6.80 (5.80–7.89)	6.21 (5.24–7.08)	7.65 (6.23–9.32)	–46.30 (–53.56 to –33.34)
High-income North America	26.26 (24.30–27.70)	30.82 (27.39–33.66)	28.84 (25.68–31.39)	27.70 (24.47–30.26)	5.45 (–2.19 to 13.70)
Southern Latin America	27.78 (25.75–29.64)	22.75 (20.83–24.57)	19.11 (17.48–20.67)	20.85 (18.02–24.49)	–24.93 (–34.23 to –10.32)
Western Europe	24.34 (22.61–25.60)	18.38 (16.35–19.86)	16.69 (14.90–17.99)	17.25 (15.21–18.98)	–29.12 (–34.00 to –23.04)
Andean Latin America	17.03 (14.38–20.25)	12.72 (10.93–15.17)	10.71 (8.97–13.20)	13.57 (11.41–16.85)	–20.33 (–34.76 to –1.05)
Caribbean	17.31 (15.70–18.86)	19.85 (18.10–21.57)	18.27 (16.63–20.06)	22.13 (19.89–25.18)	27.81 (14.24–47.39)
Central Latin America	34.32 (32.34–35.76)	26.53 (23.99–28.57)	23.37 (21.66–24.66)	23.38 (21.03–26.03)	–31.87 (–36.52 to –25.17)
Tropical Latin America	42.80 (38.63–46.54)	27.35 (24.60–29.20)	25.30 (22.65–26.66)	25.27 (22.40–26.99)	–40.96 (–45.16 to –36.85)
North Africa and Middle East	33.08 (20.15–45.63)	28.12 (23.74–33.36)	25.34 (20.55–30.08)	26.67 (21.31–32.37)	–19.36 (–45.17 to 30.46)
South Asia	111.38 (77.49–143.62)	98.93 (78.84–116.81)	86.88 (66.23–105.35)	99.97 (81.38–123.57)	–10.24 (–33.36 to 26.77)
East Asia	110.60 (74.61–143.73)	47.43 (39.17–63.38)	42.74 (34.63–58.26)	46.24 (35.83–65.87)	–58.20 (–72.62 to –26.56)
Oceania	110.94 (75.62–148.51)	89.37 (66.90–113.90)	85.76 (62.70–110.81)	89.07 (62.35–118.12)	–19.72 (–41.92 to 14.30)
Southeast Asia	50.02 (37.70–64.36)	35.40 (29.21–41.98)	32.24 (25.10–39.25)	34.29 (27.29–41.94)	–31.46 (–50.49 to –10.26)
Central Sub-Saharan Africa	66.88 (43.19–95.89)	57.31 (40.32–76.49)	55.12 (38.77–74.31)	53.88 (37.33–76.41)	–19.43 (–45.11 to 17.21)
Eastern Sub-Saharan Africa	11.38 (4.75–18.99)	11.01 (5.00–16.31)	10.05 (5.00–15.35)	10.31 (5.04–16.28)	–9.38 (–49.63 to 65.93)
Southern Sub-Saharan Africa	35.62 (26.81–46.07)	32.04 (27.14–38.85)	24.98 (19.86–31.48)	28.77 (23.61–35.87)	–19.23 (–39.71 to 4.79)
Western Sub-Saharan Africa	27.65 (18.74–41.09)	23.65 (16.97–32.23)	21.76 (15.82–29.91)	21.95 (15.19–30.35)	–20.60 (–51.25 to 18.85)

Table 1 (continued) | Global and regional age-standardized mortality rates from chronic respiratory diseases in 1990, 2019, 2020 and 2023, and the percentage change from 1990 to 2023 for both sexes combined


Location	1990	2019	2020	2023	Percentage change (1990–2023)
Asthma					
Global	7.93 (5.07–11.62)	5.20 (3.77–7.55)	4.75 (3.46–6.90)	4.98 (3.46–7.45)	–37.22 (–61.34 to –3.06)
Central Asia	7.41 (6.07–9.04)	6.20 (5.35–7.06)	6.32 (5.44–7.27)	5.33 (4.50–6.26)	–28.06 (–42.16 to –9.77)
Central Europe	4.67 (4.17–5.15)	0.91 (0.78–1.15)	0.91 (0.79–1.10)	0.86 (0.75–1.09)	–81.50 (–84.23 to –77.05)
Eastern Europe	3.83 (3.29–4.39)	0.48 (0.43–0.54)	0.47 (0.42–0.53)	0.40 (0.34–0.47)	–89.49 (–91.32 to –87.14)
Australasia	4.17 (3.89–4.44)	1.17 (1.04–1.31)	1.08 (0.96–1.20)	1.04 (0.90–1.16)	–75.05 (–78.33 to –72.17)
High-income Asia Pacific	6.20 (4.42–7.66)	0.67 (0.45–1.34)	0.60 (0.41–1.21)	0.64 (0.40–1.39)	–89.65 (–94.17 to –72.21)
High-income North America	1.65 (1.48–1.82)	0.84 (0.74–0.94)	0.89 (0.78–1.00)	0.79 (0.70–0.88)	–52.30 (–59.22 to –44.97)
Southern Latin America	2.32 (1.95–2.67)	0.94 (0.84–1.05)	0.84 (0.74–0.94)	0.83 (0.70–0.98)	–64.28 (–70.48 to –56.08)
Western Europe	3.07 (2.79–3.38)	0.70 (0.62–0.79)	0.66 (0.57–0.73)	0.65 (0.57–0.73)	–78.76 (–81.30 to –75.87)
Andean Latin America	3.35 (2.53–4.45)	0.90 (0.70–1.29)	0.78 (0.59–1.10)	0.92 (0.67–1.35)	–72.59 (–82.04 to –55.32)
Caribbean	4.77 (3.86–5.70)	3.14 (2.56–4.10)	3.08 (2.45–4.01)	3.31 (2.70–4.31)	–30.63 (–46.42 to –10.35)
Central Latin America	5.98 (5.52–6.49)	1.14 (1.01–1.36)	1.15 (1.02–1.34)	1.09 (0.95–1.32)	–81.81 (–84.40 to –78.01)
Tropical Latin America	2.74 (2.40–3.12)	1.19 (1.08–1.31)	1.19 (1.07–1.29)	1.17 (1.07–1.27)	–57.47 (–62.07 to –51.62)
North Africa and Middle East	12.85 (5.94–20.26)	6.29 (4.49–8.60)	5.61 (3.85–7.69)	5.77 (3.99–8.13)	–55.09 (–74.56 to –4.65)
South Asia	23.24 (10.73–48.05)	16.33 (9.50–28.61)	14.37 (8.72–25.11)	15.40 (8.43–26.91)	–33.72 (–66.43 to 31.67)
East Asia	2.61 (1.32–4.23)	1.25 (0.90–2.04)	1.19 (0.76–2.02)	1.14 (0.72–1.94)	–56.46 (–78.26 to 14.42)
Oceania	27.66 (15.07–45.30)	19.47 (11.76–31.58)	18.82 (11.43–30.55)	18.13 (10.61–32.19)	–34.46 (–62.54 to 5.43)
Southeast Asia	19.10 (11.87–28.60)	13.16 (9.32–20.19)	12.36 (8.79–19.48)	12.58 (8.90–19.50)	–34.11 (–62.54 to 11.79)
Central Sub-Saharan Africa	21.08 (9.11–36.81)	16.91 (8.33–28.31)	16.28 (8.55–27.42)	15.15 (7.51–25.58)	–28.14 (–60.38 to 26.34)
Eastern Sub-Saharan Africa	18.29 (9.94–28.86)	16.33 (10.21–24.75)	15.18 (9.26–22.70)	14.79 (9.18–23.26)	–19.11 (–49.97 to 32.19)
Southern Sub-Saharan Africa	15.87 (10.28–22.93)	13.46 (10.98–18.33)	11.25 (8.34–15.36)	12.58 (9.55–16.44)	–20.74 (–48.51 to 24.17)
Western Sub-Saharan Africa	14.59 (8.78–21.66)	9.36 (6.10–13.51)	8.86 (5.70–12.64)	8.51 (5.56–13.22)	–41.64 (–65.99 to –0.39)
Pneumoconiosis					
Global	0.36 (0.27–0.49)	0.22 (0.18–0.26)	0.21 (0.17–0.25)	0.21 (0.16–0.28)	–42.41 (–63.88 to –21.13)
Central Asia	0.20 (0.12–0.29)	0.20 (0.16–0.26)	0.19 (0.15–0.25)	0.14 (0.11–0.18)	–29.13 (–55.74 to 26.46)
Central Europe	0.43 (0.37–0.50)	0.09 (0.08–0.10)	0.09 (0.07–0.09)	0.08 (0.07–0.09)	–81.66 (–84.96 to –77.87)
Eastern Europe	0.09 (0.07–0.14)	0.06 (0.05–0.07)	0.05 (0.04–0.07)	0.04 (0.04–0.06)	–53.62 (–70.65 to –26.05)
Australasia	0.20 (0.18–0.23)	0.30 (0.26–0.34)	0.28 (0.25–0.32)	0.28 (0.24–0.32)	37.34 (13.08–63.25)
High-income Asia Pacific	0.56 (0.44–0.68)	0.22 (0.18–0.26)	0.21 (0.17–0.25)	0.22 (0.17–0.28)	–60.40 (–72.04 to –45.54)
High-income North America	0.37 (0.32–0.42)	0.11 (0.09–0.14)	0.11 (0.09–0.13)	0.10 (0.08–0.12)	–73.53 (–79.82 to –66.26)
Southern Latin America	0.31 (0.24–0.39)	0.15 (0.13–0.17)	0.13 (0.11–0.14)	0.13 (0.10–0.17)	–60.12 (–72.86 to –42.40)
Western Europe	0.66 (0.58–0.74)	0.17 (0.15–0.19)	0.16 (0.14–0.18)	0.15 (0.13–0.18)	–77.26 (–80.99 to –72.75)
Andean Latin America	0.22 (0.12–0.38)	0.29 (0.22–0.41)	0.24 (0.18–0.32)	0.30 (0.21–0.43)	38.50 (–32.41 to 148.10)
Caribbean	0.04 (0.03–0.06)	0.03 (0.02–0.04)	0.03 (0.02–0.04)	0.03 (0.02–0.04)	–30.13 (–55.88 to 2.60)
Central Latin America	0.31 (0.25–0.38)	0.09 (0.08–0.10)	0.08 (0.07–0.10)	0.08 (0.06–0.09)	–75.41 (–81.14 to –67.26)
Tropical Latin America	0.16 (0.12–0.20)	0.17 (0.15–0.19)	0.16 (0.14–0.18)	0.15 (0.13–0.17)	–6.30 (–24.38 to 16.66)
North Africa and Middle East	0.15 (0.07–0.29)	0.15 (0.10–0.22)	0.13 (0.09–0.21)	0.14 (0.09–0.22)	–9.11 (–62.50 to 127.23)
South Asia	0.10 (0.03–0.26)	0.12 (0.05–0.24)	0.10 (0.04–0.21)	0.12 (0.05–0.23)	20.40 (–50.80 to 234.14)
East Asia	0.47 (0.18–1.03)	0.44 (0.33–0.56)	0.43 (0.30–0.56)	0.42 (0.28–0.58)	–10.71 (–65.84 to 150.83)
Oceania	0.01 (0.00–0.02)	0.01 (0.00–0.03)	0.01 (0.00–0.03)	0.01 (0.00–0.03)	47.02 (–50.31 to 346.72)
Southeast Asia	0.01 (0.01–0.03)	0.01 (0.01–0.02)	0.01 (0.01–0.02)	0.01 (0.01–0.02)	2.67 (–55.87 to 145.92)
Central Sub-Saharan Africa	0.29 (0.09–0.81)	0.28 (0.10–0.56)	0.27 (0.10–0.52)	0.26 (0.10–0.54)	–10.96 (–65.68 to 144.95)
Eastern Sub-Saharan Africa	0.26 (0.07–0.63)	0.30 (0.11–0.65)	0.28 (0.10–0.58)	0.28 (0.10–0.60)	6.41 (–60.91 to 209.76)
Southern Sub-Saharan Africa	0.39 (0.21–0.70)	0.42 (0.28–0.62)	0.35 (0.22–0.53)	0.40 (0.23–0.59)	2.31 (–52.61 to 119.59)
Western Sub-Saharan Africa	0.31 (0.08–0.75)	0.27 (0.09–0.55)	0.25 (0.09–0.53)	0.24 (0.08–0.56)	–21.30 (–66.26 to 131.72)

Table 1 (continued) | Global and regional age-standardized mortality rates from chronic respiratory diseases in 1990, 2019, 2020 and 2023, and the percentage change from 1990 to 2023 for both sexes combined


Location	1990	2019	2020	2023	Percentage change (1990–2023)
ILD and pulmonary sarcoidosis					
Global	1.27 (1.00–2.04)	2.30 (1.93–2.80)	2.18 (1.84–2.69)	2.40 (1.98–2.93)	89.16 (25.10–139.76)
Central Asia	1.16 (0.93–1.40)	1.46 (1.23–1.78)	1.72 (1.46–2.07)	2.03 (1.66–2.44)	74.22 (35.91–120.94)
Central Europe	1.01 (0.88–1.16)	1.02 (0.93–1.11)	1.03 (0.93–1.13)	1.06 (0.96–1.16)	4.66 (–9.45 to 21.56)
Eastern Europe	0.87 (0.72–1.04)	0.36 (0.32–0.42)	0.41 (0.35–0.48)	0.49 (0.40–0.58)	–43.67 (–56.95 to –27.22)
Australasia	1.14 (1.03–1.25)	3.34 (2.96–3.67)	3.20 (2.84–3.50)	3.40 (3.00–3.76)	199.07 (164.24–231.85)
High-income Asia Pacific	2.73 (2.39–3.06)	4.62 (3.96–5.22)	4.53 (3.89–5.11)	5.48 (4.46–6.53)	100.85 (68.12–144.01)
High-income North America	2.23 (2.01–2.40)	4.38 (3.85–4.88)	4.21 (3.72–4.61)	4.25 (3.70–4.75)	90.91 (70.09–111.97)
Southern Latin America	2.60 (2.18–3.03)	5.09 (4.57–5.60)	4.36 (3.86–4.76)	5.06 (4.29–6.12)	94.80 (61.32–148.63)
Western Europe	1.08 (0.97–1.18)	2.93 (2.59–3.21)	2.76 (2.49–2.99)	2.89 (2.56–3.23)	168.56 (137.83–199.13)
Andean Latin America	5.94 (3.97–8.65)	14.58 (10.67–17.35)	12.53 (8.63–15.17)	16.56 (12.29–19.80)	178.80 (80.89–358.17)
Caribbean	0.59 (0.48–0.82)	1.14 (0.97–1.44)	1.08 (0.89–1.41)	1.31 (1.11–1.63)	123.14 (69.98–178.92)
Central Latin America	1.38 (1.26–1.53)	2.67 (2.48–2.88)	2.51 (2.32–2.68)	2.91 (2.62–3.28)	111.13 (89.20–138.14)
Tropical Latin America	0.92 (0.82–1.03)	1.92 (1.72–2.08)	1.94 (1.75–2.08)	1.85 (1.65–2.00)	100.70 (77.73–130.70)
North Africa and Middle East	1.07 (0.55–2.00)	1.51 (1.04–2.25)	1.39 (0.98–2.01)	1.57 (1.09–2.35)	46.89 (–39.34 to 166.77)
South Asia	2.33 (0.94–7.44)	3.51 (1.96–6.10)	3.35 (1.87–5.80)	3.79 (2.08–6.50)	62.44 (–31.81 to 236.71)
East Asia	0.19 (0.11–0.32)	0.47 (0.32–0.62)	0.47 (0.30–0.63)	0.47 (0.31–0.70)	153.05 (33.02–382.78)
Oceania	1.25 (0.71–2.31)	1.16 (0.65–2.00)	1.13 (0.64–2.00)	1.18 (0.61–1.98)	–5.44 (–53.70 to 47.71)
Southeast Asia	0.19 (0.07–0.42)	0.39 (0.16–0.84)	0.38 (0.16–0.83)	0.41 (0.15–0.91)	111.65 (–14.75 to 319.01)
Central Sub-Saharan Africa	1.28 (0.26–3.56)	1.39 (0.40–3.14)	1.38 (0.38–3.16)	1.37 (0.40–2.73)	6.61 (–50.75 to 118.56)
Eastern Sub-Saharan Africa	1.19 (0.20–3.02)	1.45 (0.46–2.98)	1.38 (0.44–2.82)	1.43 (0.45–2.77)	19.90 (–44.24 to 215.81)
Southern Sub-Saharan Africa	1.47 (0.79–2.27)	1.87 (1.33–2.70)	1.50 (1.04–2.17)	1.87 (1.27–2.76)	26.93 (–31.40 to 108.24)
Western Sub-Saharan Africa	1.35 (0.32–3.12)	1.32 (0.51–2.52)	1.27 (0.48–2.41)	1.28 (0.52–2.35)	–5.12 (–59.72 to 114.51)
Other chronic respiratory disease					
Global	0.98 (0.71–1.33)	0.74 (0.55–1.03)	0.72 (0.51–1.02)	0.79 (0.58–1.11)	–19.55 (–44.05 to 14.91)
Central Asia	1.01 (0.78–1.31)	0.85 (0.70–1.02)	0.87 (0.69–1.03)	0.78 (0.61–0.97)	–22.12 (–42.33 to 6.35)
Central Europe	0.47 (0.41–0.54)	0.13 (0.11–0.17)	0.12 (0.10–0.16)	0.12 (0.10–0.16)	–74.08 (–79.39 to –66.82)
Eastern Europe	0.56 (0.42–0.73)	0.12 (0.09–0.14)	0.12 (0.09–0.14)	0.11 (0.08–0.14)	–80.98 (–86.23 to –72.65)
Australasia	1.16 (1.02–1.34)	0.42 (0.36–0.48)	0.41 (0.35–0.47)	0.42 (0.35–0.48)	–63.87 (–70.86 to –55.84)
High-income Asia Pacific	0.34 (0.29–0.42)	0.25 (0.20–0.31)	0.25 (0.21–0.31)	0.29 (0.23–0.37)	–15.10 (–37.65 to 13.73)
High-income North America	0.36 (0.30–0.44)	0.54 (0.44–0.62)	0.54 (0.45–0.64)	0.53 (0.44–0.62)	45.71 (13.45–88.17)
Southern Latin America	1.28 (1.11–1.46)	0.58 (0.51–0.67)	0.54 (0.47–0.64)	0.57 (0.45–0.72)	–55.66 (–65.13 to –42.02)
Western Europe	0.94 (0.85–1.02)	0.24 (0.21–0.28)	0.24 (0.20–0.27)	0.24 (0.21–0.28)	–73.98 (–77.46 to –69.92)
Andean Latin America	4.83 (3.50–6.50)	1.02 (0.75–1.56)	0.89 (0.64–1.36)	1.12 (0.79–1.72)	–76.77 (–85.92 to –58.42)
Caribbean	1.37 (1.02–1.79)	1.01 (0.71–1.44)	1.02 (0.71–1.48)	1.04 (0.74–1.46)	–23.51 (–48.33 to 15.49)
Central Latin America	1.41 (1.26–1.57)	0.94 (0.84–1.04)	0.84 (0.74–0.93)	0.81 (0.72–0.92)	–42.37 (–49.84 to –32.67)
Tropical Latin America	0.71 (0.63–0.83)	0.58 (0.51–0.64)	0.58 (0.52–0.65)	0.58 (0.52–0.65)	–18.66 (–30.51 to –5.20)
North Africa and Middle East	1.23 (0.74–1.87)	0.85 (0.56–1.21)	0.78 (0.52–1.08)	0.85 (0.54–1.18)	–30.77 (–62.77 to 38.38)
South Asia	1.58 (0.83–3.18)	1.41 (0.87–2.42)	1.33 (0.77–2.31)	1.53 (0.94–2.55)	–2.98 (–47.94 to 70.26)
East Asia	0.25 (0.15–0.42)	0.27 (0.21–0.37)	0.26 (0.19–0.36)	0.26 (0.20–0.39)	3.33 (–42.55 to 103.65)
Oceania	1.42 (0.72–2.64)	1.53 (0.76–2.71)	1.53 (0.75–2.65)	1.56 (0.78–2.83)	10.25 (–45.15 to 141.79)
Southeast Asia	0.75 (0.47–1.19)	0.77 (0.44–1.18)	0.76 (0.44–1.15)	0.81 (0.46–1.27)	8.35 (–42.81 to 82.39)
Central Sub-Saharan Africa	1.21 (0.58–2.26)	1.17 (0.57–2.31)	1.15 (0.54–2.28)	1.15 (0.56–2.17)	–4.19 (–48.04 to 82.59)
Eastern Sub-Saharan Africa	1.26 (0.41–2.81)	1.23 (0.47–2.93)	1.19 (0.42–2.84)	1.23 (0.44–2.76)	–2.20 (–53.66 to 84.03)
Southern Sub-Saharan Africa	1.17 (0.76–1.75)	1.29 (0.89–1.79)	1.18 (0.79–1.64)	1.26 (0.85–1.76)	7.87 (–32.63 to 90.48)
Western Sub-Saharan Africa	1.40 (0.70–2.33)	1.18 (0.63–1.87)	1.14 (0.62–1.84)	1.17 (0.63–1.92)	–16.02 (–53.74 to 50.64)

Values in parentheses represent 95% uncertainty intervals.


a COPD



b Asthma



c Pneumoconiosis



d ILD and pulmonary sarcoidosis




Fig. 3 | Global age-sex-specific COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis death rates, 1990–2023. a–d. The 1990–2023 global age- and sex-specific death rate trends for COPD (a), asthma (b), pneumoconiosis (c) and ILD and pulmonary sarcoidosis (d). Blue indicates males, and pink indicates females. The bold line represents the mean death rate (derived from

the GBD 2023), and the lighter shading denotes the 95% UI. For age groups whose trends are not clearly visible due to y-axis scaling, inset figures are provided. These data are population-level estimates (no separate biological or technical replicates), and the unit of study is the entire population in each region-year. No control group was used, as this is an observational, population-based analysis.






Fig. 4 | AAPC of age-standardized incidence and death rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis by GBD region during the pre-COVID-19 (2010–2019) and pandemic period (2020–2023). AAPC in age-standardized incidence and death rates for COPD, asthma, pneumoconiosis, ILD and pulmonary sarcoidosis, divided into the pre-COVID-19 period (2010–2019)

and the pandemic period (2020–2023). The x-axis represents the AAPC, and the y-axis indicates the GBD regions. The purple bars correspond to the AAPC during the pre-COVID-19 period (2010–2019), and the green bars correspond to the AAPC during the pandemic period (2020–2023). GBD, Global Burden of Disease, Injuries, and Risk Factors Study.

a COPD



b Asthma



c Pneumoconiosis




Fig. 5 | Global and regional distribution of age-standardized DALY rates for COPD, asthma, and pneumoconiosis by risk factor in males and females, 2023. Heatmap illustrating the 2023 age-standardized DALY rates rankings for risk factors associated with COPD (a), asthma (b) and pneumoconiosis (c). The x-axis shows global and GBD regions, and the y-axis lists disease-specific risk

factors. In each heatmap, male data appear at the top, and female data appear at the bottom. The number in each cell represents the rank of risk factors associated with the disease. More detailed DALY rates for each disease-specific risk factor are provided in the legend at the bottom of each heatmap.

the pandemic might have contributed to better detection of previously undiagnosed cases.

Although age-standardized incidence rates for chronic respiratory diseases remained stable, age-standardized death rates, which had been declining steadily in the pre-pandemic period, began to rise. This reversal pattern of mortality rates could suggest that pandemic-related factors, such as exacerbations triggered by respiratory infections, offset some of the progress made in reducing chronic respiratory disease-related deaths. This is particularly evident for COPD, where the pandemic may have increased the frequency of exacerbations while still reducing mortality overall due to heightened healthcare focus^{6,22,23}. In contrast, for ILD and pulmonary sarcoidosis, which had exhibited rising mortality trends before the pandemic, the observed deceleration in mortality increases may reflect changes in environmental exposures (for example, reduced occupational and outdoor pollutants) linked to pandemic-related behavioral shifts such as increased mask usage and reduced industrial activity^{24,25}.

Overall, the impact of the COVID-19 pandemic on chronic respiratory diseases is less pronounced than in tuberculosis and non-COVID-19 lower respiratory infections^{7,8}. Unlike these acute conditions, the nature of chronic diseases may have made them less immediately affected by the pandemic. In addition, the interactions between COVID-19 and chronic respiratory diseases are complex and bidirectional. Individuals with a history of COVID-19 are more likely to develop a range of pulmonary sequelae^{26,27}, whereas those with pre-existing chronic respiratory diseases are more susceptible to severe COVID-19 outcomes as a result of infection^{28,29}. These factors may lead to an underestimation of the true extent of excess mortality related to chronic respiratory diseases, as some of these cases may be recorded as COVID-19-related fatalities³⁰. Therefore, further studies are needed to better understand the full impact of the COVID-19 pandemic on chronic respiratory diseases and clarify the factors contributing to variations in disease outcomes across different chronic respiratory diseases.

Although the burden of chronic respiratory disease remains large, they have received less attention compared to other major NCDs, such as cancer and cardiovascular diseases, in research³¹. Decreasing respiratory function is a natural part of the aging process; however, it can be delayed by dietary, behavioral and environmental approaches, which prevent additional exposure to risk factors³². Furthermore, as most chronic respiratory diseases are not fully curable, it is important to focus on prevention to mitigate the burden. This study provides estimates of modifiable risk factors contributing to chronic respiratory diseases globally and by SDI levels, which highlight the potential impact of health interventions in reducing disease burden and provide a strategic roadmap for targeting the most notable risk factors by region.

For instance, we noted that household air pollution from solid fuels, rather than smoking, was estimated to be the primary contributor to the COPD burden among females in low SDI regions. Therefore, using cleaner fuels or technology for domestic work is required to reduce solid fuel exposure in these countries³³, which aligns with the Clean Cooking Alliance, a leading global initiative to make clean cooking more accessible³⁴. Enhancing access to modern energy for cooking is crucial to meet the United Nations' Sustainable Development Goal (SDG) by 2030, and this shift can reduce the disease burden, contribute to climate change mitigation, and protect terrestrial ecosystems. High DALY rates for asthma, COPD, and pneumoconiosis in low-SDI regions, despite lower prevalence, suggest that poor healthcare access, suboptimal treatment, and unhealthy environments amplify the burden³⁵. Therefore, prevention, diagnostic, and therapeutic approaches for chronic respiratory diseases in limited-resource settings should be addressed at a global level.

This study has several limitations, primarily due to the limited availability of data and high variability in input data across regions.

First, despite the use of international vital registration and insurance claims data to construct the GBD model, numerous locations and several of the time periods examined lack primary data, particularly in low- and middle-income countries (LMICs). This led to lower certainty and generalizability of our findings, highlighting the importance of improving data collection in LMICs to ensure that the estimates from the modeling process are grounded in more primary data. Second, although evidence suggests an association between air pollution and ILD and occupational risk and pneumoconiosis, the GBD currently links occupational risk factors only to specific subtypes—namely asbestosis, silicosis and pneumoconiosis due to particulates—whereas other potential environmental and occupational risk–outcome pairs remain unincorporated³⁶. This gap limits our understanding of how broader environmental factors contribute to these diseases³⁷. Meanwhile, this lag in risk factor integration may reflect the rigorous selection criteria of the GBD framework³⁸, which requires sufficient evidence of causation for each risk–outcome pair, as determined by the Bradford Hill criteria. These criteria also mandate the availability of risk exposure data and ensure the relevance of the risk for modification and policy implementation³⁹. As such, emerging exposures, such as vaping and cannabis use, remain excluded due to the lack of standardized global data or insufficient evidence to satisfy these criteria⁴⁰. Expanding the list of established risk factors is a strong motivation for the GBD, and more risk factors are expected to be included in future GBD iterations³⁸. Third, the criteria used to diagnose chronic respiratory diseases and the methods by which spirometry results are interpreted varied across data sources and regions, which may affect the accuracy of our estimates. Although the GBD 2023 framework implemented adjustments for datasets that did not adhere to the reference definition, residual bias may still persist due to the underutilization of spirometry in specific settings, as well as evolving diagnostic practices and coding systems (for example, transitioning from ICD-9 to ICD-10). Additionally, the broader availability of advanced imaging in regions such as North America may lead to earlier or more frequent detection of chronic respiratory diseases (for example, ILD), affecting the comparability of estimates across different settings. Fourth, despite the association between some chronic respiratory diseases and pulmonary hypertension, we excluded pulmonary hypertension from the chronic respiratory disease category. Pulmonary hypertension is primarily classified as a cardiovascular disease, especially in the context of heart failure, and was categorized in the GBD framework.

Finally, our findings regarding the impact of the COVID-19 pandemic on chronic respiratory disease should be interpreted with caution for several reasons. The complex relationship between COVID-19 and chronic respiratory disease, such as COVID-19 may be associated with long-term respiratory complications and increases the risk of severe infection in individuals with preexisting respiratory conditions, may complicate interpretation. Additionally, deaths from chronic respiratory diseases may be underreported, as individuals with these conditions who were infected with SARS-CoV-2—particularly older adults—might have been classified as COVID-19-related fatalities. These limitations highlight the importance of cautious interpretation of post-pandemic trends rather than suggesting changes to the GBD modeling framework.

In conclusion, although the overall burden of chronic respiratory diseases has decreased over time, the number of people affected by chronic respiratory diseases still remains substantial, with variations depending on subcategories and regions. Despite the lower prevalence in limited-resource settings, the DALY was relatively high in these regions, suggesting that lower socioeconomic status influences disease prevention and management. During the COVID-19 pandemic, age-standardized incidence rates for chronic respiratory disease have remained relatively stable, whereas age-standardized death rates, which had been declining steadily in the pre-pandemic

period, showed a reversal and began to rise. The disease burden estimates across pre-COVID-19 and pandemic periods provided by this study may help guide healthcare policymaking and prioritization to reduce premature mortality from NCDs through prevention and treatment, in line with the United Nations' SDG 3.4.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-025-04077-9>.

References

1. Cho, M. H. et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. *Am. J. Respir. Crit. Care Med.* **192**, 559–569 (2015).
2. Soriano, J. B. et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir. Med.* **8**, 585–596 (2020).
3. Momtazmanesh, S. et al. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. *eClinicalMedicine* **59**, 101936 (2023).
4. Hay, S. I. et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet* **406**, 1873–1922 (2025).
5. Bousquet, J., Dahl, R. & Khaltaev, N. Global Alliance against Chronic Respiratory Diseases. *Eur. Respir. J.* **29**, 233–239 (2007).
6. Greene, C. M. & Abdulkadir, M. Global respiratory health priorities at the beginning of the 21st century. *Eur. Respir. Rev.* **33**, 230205 (2024).
7. Bender, R. G. et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. *Lancet Infect. Dis.* **24**, 974–1002 (2024).
8. Ledesma, J. R. et al. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Infect. Dis.* **24**, 698–725 (2024).
9. Gravely, S. et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. *Lancet Public Health* **2**, e166–e174 (2017).
10. Reddel, H. K. et al. Global Initiative for Asthma Strategy 2021: Executive Summary and rationale for key changes. *Am. J. Respir. Crit. Care Med.* **205**, 17–35 (2022).
11. Ferguson, G. T. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. *Lancet Respir. Med.* **6**, 747–758 (2018).
12. Martinez, F. J. et al. Idiopathic pulmonary fibrosis. *Nat. Rev. Dis. Primers* **3**, 17074 (2017).
13. Akhter, N. & Rizvi, N. Interstitial lung diseases misdiagnosed as tuberculosis. *Eur. Respir. J.* **50**, PA2716 (2018).
14. Gerke, A. K., Judson, M. A., Cozier, Y. C., Culver, D. A. & Koth, L. L. Disease burden and variability in sarcoidosis. *Ann. Am. Thorac. Soc.* **14**, S421–S428 (2017).
15. Schaub, B., Lauener, R. & von Mutius, E. The many faces of the hygiene hypothesis. *J. Allergy Clin. Immunol.* **117**, 969–977 (2006).
16. Spagnolo, P. & Schwartz, D. A. Genetic predisposition to sarcoidosis: another brick in the wall. *Eur. Respir. J.* **41**, 778–780 (2013).
17. Chowdhury, N. U., Guntur, V. P., Newcomb, D. C. & Wechsler, M. E. Sex and gender in asthma. *Eur. Respir. Rev.* **30**, 210067 (2021).
18. Zein, J. G. et al. Benefits of airway androgen receptor expression in human asthma. *Am. J. Respir. Crit. Care Med.* **204**, 285–293 (2021).
19. Azoulay, E. et al. Diagnosis of severe respiratory infections in immunocompromised patients. *Intensive Care Med.* **46**, 298–314 (2020).
20. Guillo, E. et al. COVID-19 pneumonia: diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. *Eur. J. Radiol.* **131**, 109209 (2020).
21. Kim, M. S. et al. Long-term autoimmune inflammatory rheumatic outcomes of COVID-19. *Ann. Intern. Med.* **177**, 291–302 (2024).
22. Alqahtani, J. S. et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. *PLoS ONE* **16**, e0255659 (2021).
23. Sykes, D. L., Faruqi, S., Holdsworth, L. & Crooks, M. G. Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective. *ERJ Open Res.* **7**, 00822–2020 (2021).
24. Brooks, J. T. & Butler, J. C. Effectiveness of mask wearing to control community spread of SARS-CoV-2. *JAMA* **325**, 998–999 (2021).
25. Lee, H. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. *Eur. Respir. J.* **58**, 2004125 (2021).
26. Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. *Nat. Commun.* **15**, 4499 (2024).
27. Oh, J. et al. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK. *Nat. Commun.* **15**, 2830 (2024).
28. Izquierdo, J. L. et al. The impact of COVID-19 on patients with asthma. *Eur. Respir. J.* **57**, 2003142 (2021).
29. Yang, J. M. et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. *J. Allergy Clin. Immunol.* **146**, 790–798 (2020).
30. Aveyard, P. et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. *Lancet Respir. Med.* **9**, 909–923 (2021).
31. Boehm, A. et al. Assessing global COPD awareness with Google Trends. *Eur. Respir. J.* **53**, 1900351 (2019).
32. Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. *Cell* **159**, 709–713 (2014).
33. Balmes, J. R. Household air pollution from domestic combustion of solid fuels and health. *J. Allergy Clin. Immunol.* **143**, 1979–1987 (2019).
34. Ramirez, C. et al. Achieving Nepal's clean cooking ambitions: an open source and geospatial cost-benefit analysis. *Lancet Planet Health* **8**, e754–e765 (2024).
35. Alupo, P. et al. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries. *Expert Rev. Respir. Med.* **18**, 873–882 (2024).
36. Naghavi, M. et al. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet* **406**, 1811–1872 (2025).
37. Harari, S. et al. Fibrotic interstitial lung diseases and air pollution: a systematic literature review. *Eur. Respir. Rev.* **29**, 200093 (2020).

38. Brauer, M. et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* **403**, 2162–2203 (2024).
39. Kim, M. S. et al. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Glob. Health* **11**, e1553–e1565 (2023).
40. Pérez, A., Valencia, S., Jani, P. P. & Harrell, M. B. Use of electronic nicotine delivery systems and age of asthma onset among US adults and youths. *JAMA Netw. Open* **7**, e2410740 (2024).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2026, modified publication 2026

¹Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea. ²Center for Digital Health, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea. ³Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁴Massachusetts General Hospital, Boston, MA, USA. ⁵Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ⁶Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ⁷Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea. ⁸Department of Pediatrics, Kyung Hee University, Seoul, South Korea. ¹¹⁸⁰These authors contributed equally: Jiyeon Oh, Soeun Kim, Yesol Yim, Min Seo Kim. ¹¹⁸¹These authors jointly supervised this work: Jae Il Shin, Dong Keon Yon. *A list of authors and their affiliations appears at the end of the paper. ✉e-mail: SHINJI@yuhs.ac; yonkang@gmail.com

GBD 2023 Global Chronic Respiratory Disease and Covid Collaborators

Jiyeon Oh^{1,1180}, Soeun Kim^{1,1180}, Yesol Yim^{2,1180}, Min Seo Kim^{3,4,1180}, Simon I. Hay^{5,6}, Jae Il Shin⁷, Dong Keon Yon^{8,1181}, Ahmed A. J. Jabbar⁹, Hasan Aalruz¹⁰, Mohammadreza Abbasian^{11,12}, Abdallah H. A. Abd Al Magied¹³, Samar Abd ElHafeez¹⁴, Atef Abdelkader¹⁵, Mawada Hassan Abdelmagied¹⁶, Parsa Abdi¹⁷, Mohammad-Amin Abdollahifar¹⁸, Deldar Morad Abdulah¹⁹, Auwal Abdullahi^{20,21}, Nigusie Abebaw²², Roberto Ariel Abeldaño Zuñiga^{23,24}, Richard Gyan Aboagye^{25,26}, Hassan Abolhassani^{27,28}, Mohamed Abouzid²⁹, Lucas Guimarães Abreu³⁰, Dariush Abtahi³¹, Rana Kamal Abu Farha³², Ibrahim Jatau Abubakar³³, Eman Abu-Gharbieh^{34,35}, Hana J. Abukhadajah³⁶, Salahdein Aburuz^{37,38}, Ahmed Abu-Zaid^{39,40}, Juan Manuel Acuna^{41,42}, Mesafint Molla Adane⁴³, Isaac Yeboah Addo^{44,45}, Oyelola A. Adegboye⁴⁶, Victor Adekanmbi⁴⁷, Charles Oluwaseun Adetunji⁴⁸, Temitayo Esther Adeyeoluwa^{49,50}, Rishan Adha⁵¹, Kishor Adhikari^{52,53}, Ripon Kumar Adhikary^{54,55}, Qorinah Estiningtyas Sakilah Adnani⁵⁶, Aanuoluwapo Adeyimika Afolabi⁵⁷, Rotimi Felix Afolabi⁵⁸, Fatemeh Afrashteh⁵⁹, Arya Afrooghe⁶⁰, Anurag Agrawal^{61,62}, Williams Agyemang-Duah⁶³, Aqeel Ahmad⁶⁴, Muayyad M. Ahmad⁶⁵, Sajjad Ahmad^{66,67}, Shahzaib Ahmad^{68,69}, Ali Ahmadi^{70,71}, Ayman Ahmed^{72,73}, Haroon Ahmed⁷⁴, Ibrar Ahmed^{75,76}, Mohammed Ahmed⁷⁷, Oli Ahmed⁷⁸, Sindew Mahmud Ahmed^{79,80}, Syed Anees Ahmed⁸¹, Abdullateef Abiodun Ajadi^{82,83}, Ruslan Akhmedullin⁸⁴, Karolina Akinosoglou^{85,86}, Mohammed Ahmed Al-Kaif⁸⁷, Ashley E. Akrami^{88,89}, Hanadi Al Hamad^{90,91}, Syed Mahfuz Al Hasan⁹², Muaaz M. Alajlani⁹³, Yazan Al-Ajlouni^{94,95}, Khurshid Alam⁹⁶, Mohammad Khursheed Alam⁹⁷, Nazmul Alam^{98,99}, Rasmieh Mustafa Al-amer^{100,101}, Ayman Al-Eyadhy¹⁰², Abdelazeem M. Algammal¹⁰³, Adel Ali Saeed Al-Gheethi^{104,105}, Fadwa Naji Alhalaqa¹⁰⁶, Endale Alemayehu Ali¹⁰⁷, Mohammad Daud Ali¹⁰⁸, Mohammed Usman Ali^{109,110}, Rafat Ali¹¹¹, Syed Shujait Ali¹¹², Waad Ali¹¹³, Akram Al-Ibraheem^{114,115}, Sheikh Mohammad Alif^{116,117}, Samah W. Al-Jabi¹¹⁸, Mohamad Aljofan¹¹⁹, Syed Mohamed Aljunid^{120,121}, Sabah Al-Marwani¹²², Hesham M. Al-Mekhlafi^{123,124}, Mohmmad Minwer Alnaeem¹²⁵, Mahmoud A. Alomari^{126,127}, Jaber S. Alqahtani¹²⁸, Abdullah A. Alqarni¹²⁹, Ahmad Alrawashdeh¹³⁰, Sahel Majed Alrousan¹³¹, Mohammed A. Alsabri^{132,133}, Najim Z. Alshahrani¹³⁴, Zaid Altaany¹³⁵, Awais Altaf¹³⁶, Khaled Altartoor¹³⁷, Jaffar A. Al-Tawfiq^{138,139}, Khalid A. Altirkawi¹⁴⁰, Farrukh Jawad Alvi¹⁴¹, Nelson Alvis-Guzman^{142,143}, Hassan Alwafi¹⁴⁴, Mohammad Al-Wardat¹⁴⁵, Yaser Mohammed Al-Worafi^{146,147}, Hany Aly¹⁴⁸, Mohammad Sharif Ibrahim Alyahya¹⁴⁹, Abdallah Alzoubi^{149,150}, Karem H. Alzoubi^{151,152}, Reza Amani^{153,154}, Isha Amatya¹⁵⁵, Amr Amin¹⁵⁶, Hubert Amu¹⁵⁷, Robert Ancuceanu¹⁵⁸, Michael Anderson¹⁵⁹, Abhishek Anil^{160,161}, Adnan Ansari^{162,163}, Mohammed Tahir Ansari¹⁶⁴, Sameera Ansari^{165,166}, Boluwatife Stephen Anuoluwa¹⁶⁷, Iyadunni Adesola Anuoluwa¹⁶⁸, Saeid Anvari¹⁶⁹, Saleha Anwar^{170,171}, Anayochukwu Edward Anyasodor¹⁷², Geminn Louis Carace Apostol^{173,174}, Jalal Arabloo¹⁷⁵, Elshaima A. Arafa^{176,177}, Mosab Arafat¹⁷⁸, Aleksandr Y. Aravkin^{5,6,179}, Demelash Arede^{180,181}, Benedetta Armocida¹⁸², Mahwish Arooj¹⁸³, Idowu Thomas Aruleba¹⁸⁴, Ashokan Arumugam^{185,186}, Akeza Awealom Asgedom¹⁸⁷, Mona Asghariahmadabad¹⁸⁸, Akram Ashames¹⁸⁹, Muhammad Abdul Basit Ashraf¹⁹⁰, Tahira Ashraf¹⁹⁰, Bernard Kwadwo Yeboah Asiamah-Asare¹⁹¹, Dereje Zewdu Assefa¹⁹², Alok Atreya¹⁹³, Engi Farouk Attia¹⁹⁴, Marcel Ausloos^{195,196}, Lemessa Assefa A. Ayana^{197,198}, Sadat Abdulla Aziz^{199,200}, Zaharaddeen Shuaibu Babandi²⁰¹, Giridhara Rathnaiah Babu²⁰², Muhammad Badar²⁰³, Atif Amin Baig²⁰⁴, Aleksandra Barac^{205,206}, Mainak Bardhan²⁰⁷, Hiba Jawdat Barqawi²⁰⁸, Zarrin Basharat²⁰⁹, Rehana Basri²¹⁰, Mohammad-Mahdi Bastan^{59,211}, Mohammad Amin Bayat Tork²¹², Nebiyu Simegnaw Bayleyegn²¹³, Payam Behzadi²¹⁴,

Asnake Gashaw Belayneh²¹⁵, Muhammad Bashir Bello^{216,217}, Olorunjuwon Omolaja Bello¹⁶⁸, Apostolos Beloukas^{218,219}, Maryam Bemanalizadeh^{220,221}, Habib Benzian²²², Robert S. Bernstein^{223,224}, Paulo J. G. Bettencourt^{225,226}, Kebede A. Beyene^{227,228}, Ajeet Singh Bhadoria^{229,230}, Akshaya Srikanth Bhagavathula^{231,232}, Pankaj Bhardwaj^{233,234}, Ashish Bhargava²³⁵, Jasvinder Singh Bhatti²³⁶, Obasanjo Afolabi Bolarinwa²³⁷, Hamed Borhany²³⁸, Souad Bouaoud^{239,240}, Edward J. Boyko^{241,242}, Hermann Brenner²⁴³, Tsion Samuel Bunare²⁴⁴, Yasser Bustanji^{245,246}, Nadeem Shafique Butt²⁴⁷, Zahid A. Butt^{248,249}, Mehtap Çakmak Barsbay²⁵⁰, Daniela Calina²⁵¹, Luis Alberto Cámera^{252,253}, Ismael Campos-Nonato²⁵⁴, Angelo Capodici^{255,256}, Joao Mauricio Castaldelli-Maia²⁵⁷, Carlos A. Castañeda-Orjuela^{258,259}, Luca Cegolon^{260,261}, Muthia Cenderadewi^{262,263}, Ester Cerin^{264,265}, Chiranjib Chakraborty^{266,267}, Sandip Chakraborty²⁶⁸, Jeffrey Shi Kai Chan²⁶⁹, Eeshwar K. Chandrasekar²⁷⁰, Anis Ahmad Chaudhary²⁷¹, Hana Chen²⁷², Haowei Chen²⁷³, Shanquan Chen²⁷⁴, Esther T. W. Cheng²⁷⁵, Nicholas WS Chew²⁷⁶, Gerald Chi²⁷⁷, Patrick R. Ching²⁷⁸, Jesus Lorenzo Chirinos-Caceres²⁷⁹, Abdulaal Chitheer²⁸⁰, Yuen Yu Chong²⁸¹, Sonali Gajanan Choudhari²⁸², Sreshtha Chowdhury²⁸³, Devasahayam J. Christopher²⁸⁴, Dinh-Toi Chu^{285,286}, Ting-Wu Chuang²⁸⁷, Isaac Sunday Chukwu²⁸⁸, Sunghyun Chung²⁸⁹, Muhammad Chutiya²⁹⁰, Aaron J. Cohen^{5,291}, Joao Conde²⁹², Natalia Cruz-Martins^{293,294}, Alanna Gomes da Silva²⁹⁵, Nour Dababo^{296,297}, Omid Dadras^{298,299}, Siyu Dai^{275,300}, Xiaochen Dai^{5,6}, Zhaoli Dai^{26,301}, Koustuv Dalal³⁰², Samuel Demissie Darcho³⁰³, Ana Maria Dascalu^{304,305}, Cornelius Dassah³⁰⁶, Juana Maria Delgado-Saborit³⁰⁷, Vinoth Gnana Chellaiyan Devanbu³⁰⁸, Pradeep Kumar Devarakonda³⁰⁹, Devananda Devegowda³¹⁰, Rakhi Dey³¹¹, Arkadeep Dhali³¹², Kuldeep Dhama³¹³, Amol S. Dhane³¹⁴, Samath Dhamminda Dharmaratne^{5,6,315}, Meghnath Dhimal^{155,316}, Marcello Di Pompeo³¹⁷, Mostafa Dianatinasab^{318,319}, Daniel Diaz³²⁰, Michael J. Diaz³²¹, Thanh Chi Do³²², Thao Huynh Phuong Do³²³, Sushil Dohare³²⁴, Ojas Prakashbhai Doshi³²⁵, Robert Kokou Dowou³²⁶, Viola Savy Dsouza³²⁷, Sulagna Dutta³²⁸, Abdel Rahman E'mar¹⁴⁸, Hooman Ebrahimi³²⁹, Hisham Atan Edinur³³⁰, Diyan Ermawan Effendi³³¹, Foolad Eghbali³³², Ashkan Eighaei Sedeh^{4,333}, Taymmia Ejaz³³⁴, Temitope Cyrus Ekundayo¹⁶⁸, Ibrahim Farahat El Bayoumy^{335,336}, Omar Abdelsadek Abdou El Meligy^{337,338}, Mohamed Ahmed Eladl^{339,340}, Said El-Ashker³⁴¹, Noha Mousaad Elemam³⁴², Muhammed Elhadi^{343,344}, Ibrahim Elsohaby^{345,346}, Chadi Eltaha³⁴⁷, Theophilus I. Emeto³⁴⁸, Talha Bin Emran³⁴⁹, Majid Eslami^{350,351}, Maysa Eslami³⁵², Sayed Vahid Esmaeili³⁵³, Adewale Oluwaseun Fadaka^{354,355}, Adeniyi Francis Fagbamigbe^{58,356}, Ayesha Fahim³⁵⁷, Razana Faiz³⁵⁸, Ildar Ravisovich Fakhradiyev^{359,360}, Mohammad Farahmand³⁶¹, Mohsen A. Farghaly³⁶², Andre Faro³⁶³, Hossein Farrokhpour^{364,365}, Rana Farsakoury³⁶⁶, Kiana Fasihi³⁶⁷, Modupe Margaret Fasina³⁶⁸, Zareen Fatima³⁶⁹, Nelsensius Klau Fauk^{370,371}, Pietro Ferrara^{372,373}, Nuno Ferreira³⁷⁴, Florian Fischer³⁷⁵, Morenike Oluwatoyin Folayan^{376,377}, Marco Fonzo³⁷⁸, Arianna Fornari³⁷⁹, Daniela Fortuna³⁸⁰, Matteo Foschi^{381,382}, Maryam Fotouhi^{383,384}, Jinming Fu³⁸⁵, G. Sridevi³⁸⁶, Muktar A. Gadanya^{387,388}, Abduzhappar Gaipov³⁸⁹, Silvano Gallus³⁹⁰, Aravind P. Gandhi³⁹¹, Balasankar Ganesan³⁹², Zisis Gatziofias³⁹³, Rupesh K. Gautam³⁹⁴, Miglas Welay Gebregergis³⁹⁵, Molla Getie³⁹⁶, Delaram J. Ghadimi³⁹⁷, Seyyed-Hadi Ghamari^{211,398}, Ramy Mohamed Ghazy^{399,400}, Gloria Gheno⁴⁰¹, Maryam Gholamalizadeh⁴⁰², Ali Gholamrezanezhad³⁸³, Elena Ghotbi⁴⁰³, Arun Ghuge^{404,405}, Artyom Urievich Gil⁴⁰⁶, Richard F. Gillum^{407,408}, Alem Abera Girmay⁴⁰⁹, Mahaveer Golechha⁴¹⁰, MReza Goodarzi⁴¹¹, Amador Goodridge⁴¹², Ayman Grada⁴¹³, Michal Grivna^{414,415}, Ashna Grover⁴¹⁶, Zhongyang Guan⁴¹⁷, Giovanni Guarducci⁴¹⁸, Mohammed Ibrahim Mohialdeen Gubari⁴¹⁹, Stefano Guicciardi^{420,421}, Snigdha Gulati⁴²², Damitha Asanga Gunawardane⁴²³, Cui Guo⁴²⁴, Anish Kumar Gupta^{425,426}, Bhawna Gupta⁴²⁷, Lalit Gupta⁴²⁸, Rajeev Gupta^{429,430}, Veer Bala Gupta⁴³¹, Vivek Kumar Gupta⁴³², Robert Steven Gutiérrez-Murillo⁴³³, Farrokh Habibzadeh⁴³⁴, Mostafa Hadei⁴³⁵, Dariush Haghmorad^{351,436}, Sebastian Haller^{437,438}, Rabih Halwani^{156,208}, Nadia M. Hamdy⁴³⁹, Ahmad Hammoud⁴⁴⁰, Changwoo Han⁴⁴¹, Fahad Hanna⁴⁴², Arief Hargono⁴⁴³, Josep Maria Haro^{444,445}, Md. Kamrul Hasan^{446,447}, Mohammad Jahid Hasan⁴⁴⁸, Hamidreza Hasani⁴⁴⁹, Ali Hasanpour-Dehkordi⁴⁵⁰, Nageeb Hassan⁴⁵¹, Shoaib Hassan^{452,453}, Johannes Haubold^{454,455}, Jiawei He⁵, Wen-Qiang He⁴⁵⁶, Behzad Heibati⁴⁵⁷, Bartosz Helfer^{458,459}, Mehdi Hemmati^{460,461}, Yuta Hiraike⁴⁶², Minh Hoang⁴⁶³, Ramesh Holla⁴⁶⁴, Nobuyuki Horita^{465,466}, Sabbir Hossain⁴⁶⁷, Md. Belal Hossain^{468,469}, Mehdi Hosseinzadeh^{470,471}, Sorin Hostiuc^{472,473}, Vivian Chia-rong Hsieh⁴⁷⁴, Junjie Huang⁴⁷⁵, Ayesha Humayun⁴⁷⁶, Tsegaye Gebreyes Hundie⁴⁷⁷, Kiavash Hushmandi⁴⁷⁸, Javid Hussain⁴⁷⁹, Nawfal R. Hussein⁴⁸⁰, Mohamed Ibrahim Husseiny^{481,482}, Le Duc Huy^{483,484}, Hong-Han Huynh⁴⁸⁵, Bing-Fang Hwang^{486,487}, Ivo Iavicoli⁴⁸⁸, Segun Emmanuel Ibitoye⁴⁸⁹, Anel Ibrayeva⁴⁹⁰, Kevin S. Ikuta^{5,491}, Olayinka Stephen Ilesanmi^{492,493}, Irena M. Ilic²⁰⁶, Milena D. Ilic⁴⁹⁴, Mustapha Immurana⁴⁹⁵, Arit Inok⁴⁹⁶, Muhammad Iqhrammullah⁴⁹⁷, Mustafa Alhaji Isa^{498,499}, Md. Rabiul Islam⁵⁰⁰, Nahlah Elkudssiah Ismail^{501,502}, Zhanat Bakhitovna Ispayeva⁵⁰³, Asefa N. Iyasu⁴⁰⁹, Mahalaxmi Iyer⁵⁰⁴, Vinothini J³⁸⁶, Louis Jacob^{505,506}, Abdollah Jafarzadeh^{507,508}, Haitham Jahrami^{509,510}, Nityanand Jain⁵¹¹, Vikash Jaiswal^{512,513}, Mihajlo Jakovljevic^{514,515}, Sepide Javankiani⁵¹⁶, Talha Jawaid⁵¹⁷, Sathish Kumar Jayapal⁵¹⁸, Shubha Jayaram⁵¹⁹, Felix K. Jebasingh^{520,521}, Sun Ha Jee⁵²², Ravi Prakash Jha^{523,524}, Yusheng Jia^{525,526}, Wenyi Jin^{527,528}, Jost B. Jonas^{529,530}, Tamas Joo^{531,532}, Jobinse Jose⁵³³, Nitin Joseph⁵³⁴, Anupam Jyoti⁵³⁵, Vaishali K¹⁸⁶, Billingsley Kaambwa^{536,537}, Zubair Kabir⁵³⁸, Gebisa Guyasa Kabito⁵³⁹,

Rajesh Kamath^{540,541}, Saddam Fuad Kanaan⁵⁴², Samuel Berchi Kankam⁵⁴³, Edmund Wedam Kanmiki^{544,545}, Kehinde Kazeem Kanmodi^{546,547}, Surya Kant⁵⁴⁸, Rami S. Kantar^{549,550}, Srikanta Kanungo⁵⁵¹, Arman Karimi Behnagh^{552,553}, Joonas H. Kauppila^{554,555}, Foad Kazemi⁵⁵⁶, Peter Njenga Keiyoro⁵⁵⁷, Yousef Saleh Khader⁵⁵⁸, Himanshu Khajuria⁵⁵⁹, Hazim O. Khalifa^{560,561}, Alireza Khalilian⁵⁶², Faham Khamesipour⁵⁶³, M. Nuruzzaman Khan^{564,565}, Maseer Khan⁵⁶⁶, Mohammad Jobair Khan¹¹⁰, Moien AB Khan^{567,568}, Vishnu Khanal^{569,570}, Khaled Khatab^{571,572}, Moawiah Mohammad Khatatbeh⁵⁷³, Feriha Fatima Khidri⁵⁷⁴, Majid Khosravi^{575,576}, Kwanghyun Kim⁵⁷⁷, Yun Jin Kim⁵⁷⁸, Ruth W. Kimokoti⁵⁷⁹, Tadele Kinati⁵⁸⁰, Adnan Kisa^{581,582}, Sezer Kisa⁵⁸³, Mika Kivimäki^{584,585}, Luke D. Knibbs⁵⁸⁶, Ali-Asghar Kolahi³⁹⁸, Farzad Kompani⁵⁸⁷, Isaac Koomson⁵⁸⁸, Vladimir Andreevich Korshunov⁵⁸⁹, Oleksii Korzh⁵⁹⁰, Karel Kostev^{591,592}, Nikhil Kothari⁵⁹³, Kewal Krishan⁵⁹⁴, Neoklis Kritikos^{595,596}, Mohammed Kuddus⁵⁹⁷, Ilari Kuitunen^{598,599}, Mukhtar Kulimbet^{600,601}, Dewesh Kumar⁶⁰², Jogender Kumar⁶⁰³, Rakesh Kumar⁶⁰⁴, Satyajit Kundu⁶⁰⁵, Setor K. Kunutsor^{606,607}, Almagul Kurmanova⁶⁰⁸, Om P. Kurmi^{609,610}, Maria Dyah Kurniasari^{611,612}, Frank Kyei-Arthur⁶¹³, Ville Kytö^{614,615}, Carlo La Vecchia⁶¹⁶, Muhammad Awwal Ladan⁶¹⁷, Chandrakant Lahariya^{618,619}, Hanpeng Lai^{620,621}, Judit Lám^{531,622}, Qing Lan⁶²³, Francesco Lanfranchi⁶²⁴, Kamaluddin Latief^{625,626}, Kaveh Latifinaibin⁶²⁷, Paolo Lauriola⁶²⁸, Huu-Hoai Le^{629,630}, Nhi Huu Hanh Le^{629,630}, Thao Thi Thu Le⁶³¹, Trang Diep Thanh Le^{631,632}, Caterina Ledda⁶³³, Seung Won Lee⁶³⁴, Wei-Chen Lee⁶³⁵, Vasileios Leivaditis^{636,637}, Elvynna Leong⁶³⁸, Jiaying Li⁶³⁹, Ming-Chieh Li⁶⁴⁰, Wei Li⁶⁴¹, Virendra S. Ligade⁶⁴², Stephen S. Lim^{5,6}, Jialing Lin⁶⁴³, Queran Lin^{644,645}, Ro-Ting Lin^{646,647}, Chaojie Liu⁶⁴⁸, Gang Liu⁶⁴⁹, Jue Liu⁶⁵⁰, Xuefeng Liu^{651,652}, José Francisco López-Gil^{653,654}, Platon D. Lopukhov⁵⁸⁹, Paulo A. Lotufo⁶⁵⁵, Giancarlo Lucchetti⁶⁵⁶, Alessandra Lugo³⁹⁰, Hong Luo⁶⁵⁷, Zheng Feei Ma⁶⁵⁸, Mahmoud Mabrok^{659,660}, Firoozeh Madadi⁶⁶¹, Mehrdad Mahalleh⁶⁶², Iram Malik⁶⁶³, Andrei Malinovski⁶⁶⁴, Deborah Carvalho Malta⁶⁶⁵, Abdullah A. Mamun⁵⁴⁴, Yosef Manla⁶⁶⁶, Kamaruddeen Mannethodi⁶⁶⁷, Wahid Mansouri⁶⁶⁸, Lorenzo Giovanni Mantovani^{669,670}, Emmanuel Manu¹⁵⁷, Bishnu P. Marasini^{155,671}, Hamid Reza Marateb^{672,673}, Bernardo Alfonso Martinez-Guerra⁶⁷⁴, Santi Martini^{675,676}, Miquel Martorell^{677,678}, Winfried März^{679,680}, Roy Rillera Marzo^{681,682}, Sammer Marzouk⁶⁸³, Alireza Masoudi⁶⁸⁴, Yasith Mathangasinghe^{685,686}, Alexander G. Mathioudakis^{687,688}, Medha Mathur⁶⁸⁹, Fernanda Penido Matozinhos⁶⁶⁵, Rita Mattiello⁶⁹⁰, Richard James Maude^{691,692}, Andrea Maugeri⁶⁹³, Juergen May^{694,695}, Steven M. McPhail^{696,697}, Enkeleint A. Mechili^{698,699}, Asim Mehmood³²⁴, Tesfahun Mekene Meto⁷⁰⁰, Hadush Negash Meles⁷⁰¹, Addisu Melese⁷⁰², Endalkachew Belayneh Melese^{703,704}, Ritesh G. Menezes⁷⁰⁵, Alexios-Fotios A. Mentis⁷⁰⁶, Mohsen Merati³⁶⁴, Atte Meretoja^{707,708}, Tuomo J. Meretoja^{709,710}, Tomislav Mestrovic^{5,711}, Chamila Dinushi Kukulege Mettananda^{712,713}, Sachith Mettananda^{714,715}, Adquate Mhlanga⁷¹⁶, Laurette Mhlanga^{717,718}, Ted R. Miller^{719,720}, Giuseppe Minervini^{721,722}, Le Huu Nhat Minh^{723,724}, GK Mini^{725,726}, Awoke Misganaw^{6,727}, Arup Kumar Misra⁷²⁸, Ankit Mittal⁷²⁹, Madhukar Mittal⁷³⁰, Nouh Saad Mohamed^{731,732}, Ameen Mosa Mohammad⁷³³, Ibrahim Mohammadzadeh⁷³⁴, Mustapha Mohammed⁷³⁵, Aleenah Mohsin^{736,737}, Ali H. Mokdad^{5,6}, Sabrina Molinaro⁷³⁸, Shaheer Momani^{739,740}, Lorenzo Monasta⁷⁴¹, AmirAli Moodi Ghalibaf⁷⁴², Maryam Moradi⁷⁴³, Yousef Moradi⁷⁴⁴, Lidia Morawska⁷⁴⁵, Freiser Eceomo Cruz Mosquera⁷⁴⁶, Elias Mossialos^{747,748}, Parsa Mousavi²¹¹, Ahmed Msherghi⁷⁴⁹, Lorenzo Muccioli⁴²¹, Sumoni Mukherjee^{750,751}, George Duke Mukoro⁷⁵², Francesk Mulita^{753,754}, Yanjinlkhamb Munkhsaikhan⁷⁵⁵, Efen Murillo-Zamora^{756,757}, Christopher J. L. Murray^{5,6}, Ghulam Mustafa^{758,759}, Saravanan Muthupandian^{760,761}, Woojae Myung^{762,763}, Mohsen Naghavi^{5,6}, Pirouz Naghavi⁷⁶⁴, Ganesh R. Naik^{537,765}, Gurudatta Naik⁷⁶⁶, Firzan Nainu⁷⁶⁷, Soroush Najdaghi^{768,769}, Gopal Nambi⁷⁷⁰, Vinay Nangia⁷⁷¹, Sreenivas Narasimha Swamy⁷⁷², Shumaila Nargus¹⁴¹, Delaram Narimani Davani⁷⁶⁸, Gustavo G. Nascimento⁷⁷³, Abdulqadir J. Nashwan⁷⁷⁴, Ali Nasrollahizadeh^{175,775}, Amir Nasrollahizadeh^{776,777}, Zuhair S. Natto^{778,779}, Javid Nauman^{780,781}, Samidi Nirasha Kumari Navaratna^{423,782}, Biswa Prakash Nayak⁵⁵⁹, Shalini Ganesh Nayak⁷⁸³, Vinod C. Nayak⁷⁸⁴, Ashish Kumar Nayyar⁷⁸⁵, Athare Nazri-Panjaki⁷⁸⁶, Masoud Negahdary^{787,788}, Ionut Negoii^{789,790}, Ruxandra Irina Negoii^{791,792}, Samata Nepal⁷⁹³, Josephine W. Ngunjiri⁷⁹⁴, Dang Nguyen^{795,796}, Hau Thi Hien Nguyen^{797,798}, Phuong The Nguyen^{799,800}, Van Thanh Nguyen^{801,802}, Quan Nguyen Khoi⁴⁸³, Nafise Niknam⁸⁰³, Ali Nikoobar³⁹⁸, Nasrin Nikravangolsefid⁸⁰⁴, Chukwudi A. Nnaji^{805,806}, Shuhei Nomura^{807,808}, Chisom Adaobi Nri-Ezedi⁸⁰⁹, Mengistu H. Nunemo⁸¹⁰, Dieta Nurrika^{811,812}, Bogdan Oancea^{813,814}, Mary Aigbiremo Oboh⁸¹⁵, Ismail A. Odetokun⁸¹⁶, Michael Safo Oduro⁸¹⁷, Akinyemi O. D. Ofakunrin^{818,819}, Oluwaseun Adeolu Ogundijo⁸²⁰, Tolulope R. Ojo-Akosile⁸²¹, Sylvester Reuben Okeke^{45,822}, Akinkunmi Paul Okekunle^{823,824}, Osaretin Christabel Okonji⁸²⁵, Patrick Godwin Okwute^{826,827}, Andrew T. Olagunju^{828,829}, Matthew Idowu Olatubi⁸³⁰, Goran Latif Omer^{831,832}, Sok King Ong^{833,834}, Michal Ordak⁸³⁵, Verner N. Orish^{836,837}, Alberto Ortiz^{838,839}, Esteban Ortiz-Prado⁸⁴⁰, Uchechukwu Levi Osuagwu^{841,842}, Amel Ouyahia^{843,844}, Tope Oyelade^{845,846}, Mahesh P. A⁸⁴⁷, Alicia Padron-Monedero⁸⁴⁸, Songhomitra Panda-Jonas⁸⁴⁹, Seithikurippu R. Pandi-Perumal^{850,851}, Georgios D. Panos^{852,853}, Leonidas D. Panos^{854,855}, Paraskevi Papadopoulou^{856,857}, Pragyan Paramita Parija⁸⁵⁸, Romil R. Parikh⁸⁵⁹, Eun-Kee Park⁸⁶⁰, Sungchul Park⁸⁶¹, S. Yasamin Parvar⁸⁶², Maja Pasovic⁵, Roberto Passera^{863,864}, Shankargouda Patil⁸⁶⁵, Dimitrios Patoulias⁸⁶⁶, Uttam Paudel^{155,867}, Paolo Pedersini^{868,869}, Veincent Christian Filipino Pepito⁸⁷⁰, Prince Peprah⁸⁷¹,

Arokiasamy Perianayagam⁸⁷², Simone Perna⁸⁷³, Fanny Emily Petermann-Rocha^{874,875}, Hoang Nhat Pham^{876,877}, Tom Pham⁵, Anil K. Philip⁸⁷⁸, Dimitri Poddighe^{879,880}, Roman V. Polibin⁵⁸⁹, Arjun Pon Avudaiappan⁸⁸¹, Maarten J. Postma^{882,883}, Farzad Pourghazi⁸⁸⁴, Akram Pourshams⁶⁶⁸, Akila Prashant⁸⁸⁵, Elton Junio Sady Prates⁶⁶⁵, Jagadeesh Puvvula⁸⁸⁶, Nameer Hashim Qasim⁸⁸⁷, Asma Saleem Qazi⁸⁸⁸, Jia-Yong Qiu^{889,890}, R. Deepthi⁸⁹¹, Venkatraman Radhakrishnan⁸⁹², Alireza Rafiei^{893,894}, Zahra Rahimi^{895,896}, Md. Mosfequr Rahman⁸⁹⁷, Mohammad Hifz Ur Rahman⁸⁹⁸, Mosiur Rahman⁸⁹⁷, Muhammad Aziz Rahman^{162,899}, Mohammad Rahmanian⁹⁰⁰, Sunil Kumar Raina⁹⁰¹, Sathish Rajaa⁹⁰², Abin K. Rajan⁹⁰³, Vinoth Rajendran⁹⁰³, Prashant Rajput⁹⁰⁴, Mahmoud Mohammed Ramadan^{34,905}, Chitra Ramasamy⁹⁰⁶, Shakthi Kumaran Ramasamy⁹⁰⁷, Sheena Ramazanu^{908,909}, Kiana Ramezanzadeh⁹¹⁰, Kritika Rana⁹¹¹, Chhabi Lal Ranabhat^{912,913}, Nemanja Rancic^{914,915}, Usha Rani⁹¹⁶, Mithun Rao⁹¹⁷, Vahid Rashedi⁹¹⁸, Ahmed Mustafa Rashid^{919,920}, Mohammad-Mahdi Rashidi^{211,398}, Devarajan Rathish⁹²¹, Santosh Kumar Rauniyar⁸⁰⁸, Salman Rawaf^{922,923}, Lal Rawal⁹²⁴, Elrashdy M. Redwan^{925,926}, Aqeeb Ur Rehman^{927,928}, Luis Felipe Reyes^{929,930}, Nazila Rezaei²¹¹, Mohsen Rezaeian⁹³¹, Hermano Alexandre Lima Rocha⁹³², Thales Philippe Rodrigues da Silva^{933,934}, Jefferson Antonio Buendia Rodriguez^{935,936}, Leonardo Roever^{937,938}, Ravi Rohilla⁹³⁹, Mohsen Rokni^{940,941}, Luca Ronfani⁷⁴¹, Moustaq Karim Khan Rony⁹⁴², Himanshu Sekhar Rout^{943,944}, Nitai Roy⁹⁴⁵, Priyanka Roy⁹⁴⁶, Shubhanjali Roy⁹⁴⁷, Simanta Roy⁹⁴⁸, Tilleye Runghien^{5,692}, Adnan Saadeddin⁹⁴⁹, Farrukh Ishaque I. Saah⁹⁵⁰, Maha Mohamed Saber-Ayad^{208,951}, Cameron John Sabet⁴⁶¹, Siamak Sabour⁷¹, Basema Ahmad Saddik^{26,156}, Mohd Saeed⁹⁵², Umar Saeed^{953,954}, Maryam Saeedi⁹⁵⁵, Mehdi Safari⁹⁵⁶, Alireza Saghafi⁹⁵⁷, Dominic Sagoe⁹⁵⁸, Fatemeh Saheb Sharif-Askari⁹⁵⁹, Narjes Saheb Sharif-Askari²⁰⁸, Amirhossein Sahebkar^{960,961}, Pragyan Monalisa Sahoo⁹⁴³, Soumya Swaroop Sahoo⁹⁶², S. Mohammad Sajadi⁹⁶³, Refat Uz Zaman Sajib⁹⁶⁴, Mirza Rizwan Sajid⁹⁶⁵, Luciane B. Salaroli⁹⁶⁶, Mohamed A. Saleh^{156,967}, Aanuoluwa James Salemcity⁹⁶⁸, Sohrab Salimi³¹, Jayami Eshana Samaranayake^{782,969}, Saad Samargandy⁹⁷⁰, Waqas Sami⁹⁷¹, Abdallah M. Samy^{972,973}, Sathish Sankar⁹⁷⁴, Milena M. Santric-Milicevic^{206,975}, Bruno Piassi Sao Jose⁹⁷⁶, Aswini Saravanan^{160,977}, Gargi Sachin Sarode⁹⁷⁸, Sachin C. Sarode⁹⁷⁸, Benn Sartorius^{5,692,979}, Brijesh Sathian^{90,980}, Anudeep Sathyanarayan⁹⁸¹, Maheswar Satpathy^{982,983}, Jennifer Saulam^{984,985}, Monika Sawhney⁹⁸⁶, Ganesh Kumar Saya⁹⁸⁷, Abu Sayeed⁹⁸⁸, Benedikt Michael Schaarschmidt⁴⁵⁴, Christophe Schinckus^{989,990}, Ione Jayce Ceola Schneider⁹⁹¹, Mansour Sedighi⁹⁹², Siddharthan Selvaraj^{546,993}, Ashenafi Kibret Sendekie^{994,995}, Pallav Sengupta⁹⁹⁶, Dragos Serban^{789,997}, Yashendra Sethi⁹⁹⁸, Abubakar Sha'aban⁹⁹⁹, Mahan Shafie¹⁰⁰⁰, Muhammad Shahab^{1001,1002}, Shazlin Shahrudin¹⁰⁰³, Samiah Shahid^{136,1004}, Moyad Jamal Shahwan¹⁰⁰⁵, Masood Ali Shaikh¹⁰⁰⁶, Alireza Shakeri³¹, Muhammad Aaqib Shamim¹⁶⁰, Mehran Shams-Beyranvand¹⁰⁰⁷, Mohammad Ali Shamshirgaran¹⁰⁰⁸, Anas Shamsi^{170,1005}, Alfiya Shamsutdinova¹⁰⁰⁹, Nigussie Tadesse Sharew^{1010,1011}, Sadaf Sharfaei^{1012,1013}, Amin Sharifan^{1014,1015}, Javad Sharifi Rad³⁶⁰, Manoj Sharma¹⁰¹⁶, Vishal Sharma¹⁰¹⁷, Rajesh P. Shastry¹⁰¹⁸, Rekha Raghuvver Shenoy¹⁰¹⁹, Samendra P. Sherchan^{1020,1021}, Pavanchand H. Shetty¹⁰²², Premalatha K. Shetty¹⁰²³, Desalegn Shiferaw^{1024,1025}, Mika Shigematsu¹⁰²⁶, Aminu Shittu¹⁰²⁷, Zahra Shokati Eshkiki¹⁰²⁸, Sina Shool^{1029,1030}, Sunil Shrestha^{1031,1032}, Yafei Si¹⁰³³, Emmanuel Edwar Siddig^{1034,1035}, Mohammad Sidiq^{1036,1037}, Luis Manuel Lopes Rodrigues Silva^{1038,1039}, Amit Singh^{504,1040}, Baljinder Singh¹⁰⁴¹, Harmanjit Singh¹⁰⁴², Jasvinder A. Singh^{1043,1044}, Kalpana Singh¹⁰⁴⁵, Surjit Singh¹⁶⁰, Mukesh Kumar Sinha¹⁸⁶, Robert Sinto^{1046,1047}, Anna Aleksandrovna Skryabina¹⁰⁴⁸, Farrukh Sobia³²⁴, Anton Sokhan^{1049,1050}, Shipra Solanki¹⁰⁵¹, Solikhah Solikhah¹⁰⁵², Sameh S. M. Soliman¹⁰⁵³, Aayushi Sood¹⁰⁵⁴, Soroush Soraneh^{1055,1056}, Reed J. D. Sorensen^{5,1057}, Joan B. Soriano^{1058,1059}, Ireneous N. Soyiri¹⁰⁶⁰, Michael Spertalis¹⁰⁶¹, Sandra Spearman⁵, Bahadar S. Srichawla¹⁰⁶², Paschalis Steiropoulos¹⁰⁶³, Leo Stockfelt¹⁰⁶⁴, Vetriselvan Subramaniyan¹⁰⁶⁵, Jing Sun^{172,1066}, Zhong Sun¹⁰⁶⁷, Vinay Suresh¹⁰⁶⁸, Chandan Kumar Swain⁹⁴³, Lukasz Szarpak^{1069,1070}, Seyed Mohammad Tabatabaei^{1071,1072}, Seyed-Amir Tabatabaeizadeh^{1073,1074}, Celine Tabche⁹²², Mohammad Tabish^{64,1075}, Seyed Reza Taha¹⁰⁷⁶, Yasaman Taheri Abkenar¹⁰⁷⁷, Jabeen Taiba^{1078,1079}, Iman M. Talaat^{208,1080}, Jacques Lukenze Tamuzi^{1081,1082}, Ker-Kan Tan¹⁰⁸³, Nathan Y. Tat^{1084,1085}, Seyed Mohammad Tavangar¹⁰⁸⁶, Animut Takele Telayneh¹⁰⁸⁷, Worku Animaw Temesgen¹⁰⁸⁸, Mohamad-Hani Tamsah¹⁰², Kavumpurathu Raman Thankappan¹⁰⁸⁹, Mahalakshmi Thayumana Sundaram¹⁰⁹⁰, Sathish Thirunavukkarasu¹⁰⁹¹, Krishna Tiwari¹⁶⁰, Vikas Kumar Tiwari^{1092,1093}, Sojit Tomo¹⁰⁹⁴, Roman Topor-Madry^{1095,1096}, Jasmine T. Tran¹⁰⁹⁷, Ngoc Ha Tran¹⁰⁹⁸, Quynh Thuy Huong Tran¹⁰⁹⁹, Thang Huu Tran^{1100,1101}, Domenico Trico¹¹⁰², Jaya Prasad Tripathy³⁹¹, Samuel Joseph Tromans^{1103,1104}, Thien Tan Tri Tai Truyen¹¹⁰⁵, Munkhtuya Tumurkhuu¹¹⁰⁶, Aniefiok John Udoakang¹¹⁰⁷, Atta Ullah¹¹⁰⁸, Irfan Ullah¹¹⁰⁹, Saeed Ullah¹¹¹⁰, Umar Muhammad Umar¹¹¹¹, Eduardo A. Undurraga¹¹¹², Brigid Unim¹¹¹³, Bhaskaran Unnikrishnan⁹¹⁷, Era Upadhyay¹¹¹⁴, Dipan Uppal¹¹¹⁵, Jibrin Sammani Usman^{20,110}, Jef Van den Eynde¹¹¹⁶, Tommi Juhani Vasankari^{1117,1118}, Balachandar Vellingiri^{1119,1120}, Madhur Verma⁹⁶², Massimiliano Veroux⁶⁹³, Georgios-Ioannis Verras^{1121,1122}, Simone Villa¹¹²³, Jorge Hugo Villafañe¹¹²⁴, Francesco S. Violante^{1125,1126}, Xing Wang¹¹²⁷, Yanzhong Wang¹¹²⁸, Ahmed Bilal Waqar¹¹²⁹, Muhammad Waqas^{1130,1131}, Ronny Westerman¹¹³², Anggi Lukman Wicaksana^{612,1133}, Dakshitha Praneeth Wickramasinghe¹¹³⁴, Peter Willeit^{1135,1136}, Marcin W. Wojewodzic^{1137,1138}, Yihun Miskir Wubie¹¹³⁹, Sarah Wulf Hanson⁵, Zhijia Xia¹¹⁴⁰, Lishun Xiao¹¹⁴¹, Xiaoyue Xu^{26,1142}

Mingyang Xue¹¹⁴³, Lalit Yadav^{1144,1145}, Mukesh Kumar Yadav⁵⁰⁴, Yuichiro Yano¹¹⁴⁶, Yuichi Yasufuku¹¹⁴⁷, Sanni Yaya¹¹⁴⁸, Pengpeng Ye^{1149,1150}, Saber Yezli¹¹⁵¹, Naohiro Yonemoto^{1152,1153}, Mohammed Youssef^{1154,1155}, Chuanhua Yu¹¹⁵⁶, Fathiah Zakhm¹¹⁵⁷, Nazar Zaki¹¹⁵⁸, Michael Zastrozhin^{1159,1160}, Mohammed Zawiah^{1161,1162}, Jingya Zhang¹¹⁶³, Yunquan Zhang^{1164,1165}, Zhi-Jiang Zhang¹¹⁶⁶, Jinxin Zheng^{1167,1168}, Anthony Zhong¹¹⁶⁹, Claire Chenwen Zhong¹¹⁷⁰, Jiayan Zhou¹¹⁷¹, Bin Zhu¹¹⁷², Abzal Zhumagaliuly¹¹⁷³, Hafsa Zia^{1174,1175}, Magdalena Zielińska¹¹⁷⁶, Osama A. Zitoun^{248,1177}, Ghazal Zoghi¹¹⁷⁸, Sa'ed H. Zyoud^{118,1179} & Samer H. Zyoud¹⁰⁰⁵

⁹Department of Medical Laboratory Technology, Erbil Polytechnic University, Erbil, Iraq. ¹⁰Department of Nursing, Al Zaytoonah University of Jordan, Amman, Jordan. ¹¹Department of Orthopedic Surgery, Thomas Jefferson University, Philadelphia, PA, USA. ¹²Department of Orthopaedic Surgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹³College of Pharmacy, Ajman University, Ajman, United Arab Emirates. ¹⁴Department of Epidemiology, Alexandria University, Alexandria, Egypt. ¹⁵Department of Mathematics and Sciences, Ajman University, Ajman, United Arab Emirates. ¹⁶College of Dentistry, Ajman University, Ajman, United Arab Emirates. ¹⁷Department of Medicine, Memorial University, St John's, Newfoundland and Labrador, Canada. ¹⁸Department of Small Animal Clinical Sciences, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. ¹⁹Community and Maternity Nursing Unit, University of Duhok, Duhok, Iraq. ²⁰Department of Physiotherapy, Bayero University Kano, Kano, Nigeria. ²¹Department of Physiotherapy, Federal University Wukari, Wukari, Nigeria. ²²Department of Midwifery, Wollo University, Dessie, Ethiopia. ²³Postgraduate Department, University of Sierra Sur, Miahuatlan de Porfirio Diaz, Mexico. ²⁴Yhteiskuntatieteiden keskus (Centre for Social Data Science), University of Helsinki, Helsinki, Finland. ²⁵Department of Family and Community Health, University of Health and Allied Sciences, Ho, Ghana. ²⁶School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. ²⁷Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran. ²⁸Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. ²⁹Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznan, Poland. ³⁰Department of Pediatric Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil. ³¹Department of Anesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³²Clinical Pharmacy and Therapeutics Department, Applied Science Private University, Amman, Jordan. ³³School of Pharmacy and Pharmacology, University of Tasmania, Hobart, Tasmania, Australia. ³⁴Department of Clinical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ³⁵Department of Biopharmaceutics and Clinical Pharmacy, University of Jordan, Amman, Jordan. ³⁶Medical Research Center, Hamad Medical Corporation, Doha, Qatar. ³⁷Department of Pharmacology and Therapeutics, United Arab Emirates University, Al Ain, United Arab Emirates. ³⁸College of Pharmacy, University of Jordan, Amman, Jordan. ³⁹Department of Biochemistry and Molecular Medicine, Alfaisal University, Riyadh, Saudi Arabia. ⁴⁰College of Graduate Health Sciences, University of Tennessee, Memphis, TN, USA. ⁴¹Department of Clinical Medicine, American University of Antigua, Coolidge, Antigua and Barbuda. ⁴²FIU Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL, USA. ⁴³College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia. ⁴⁴School of Medicine, University of Sydney, Sydney, New South Wales, Australia. ⁴⁵Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia. ⁴⁶Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. ⁴⁷Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA. ⁴⁸Department of Microbiology, Edo State University Uzairue, Iyamho, Nigeria. ⁴⁹Department of Pharmacology and Therapeutics, University of Medical Sciences, Ondo, Ondo, Nigeria. ⁵⁰Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria. ⁵¹Department of Statistics, National Chengchi University, Taipei, Taiwan. ⁵²Department of Community Medicine, Tribhuvan University, Bharatpur, Nepal. ⁵³Public Health Section, Himalayan Environment and Public Health Network (HEPHN), Chitwan, Nepal. ⁵⁴Department of Fisheries and Marine Bioscience, Jashore University of Science and Technology, Jashore, Bangladesh. ⁵⁵Research School of Population Health, Australian National University, Canberra, ACT, Australia. ⁵⁶Department of Public Health, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia. ⁵⁷Technical Services Directorate, MSI Nigeria Reproductive Choices, Abuja, Nigeria. ⁵⁸Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria. ⁵⁹School of Medicine, Iran University of Medical Sciences, Tehran, Iran. ⁶⁰Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. ⁶¹Trivedi School of Biosciences, Council of Scientific & Industrial Research, Sonipat, India. ⁶²Section of General Internal Medicine, Baylor College of Medicine, Houston, TX, USA. ⁶³Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada. ⁶⁴College of Medicine, Shaqra University, Shaqra, Saudi Arabia. ⁶⁵School of Nursing, University of Jordan, Amman, Jordan. ⁶⁶Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan. ⁶⁷Department of Natural Sciences, Lebanese American University, Beirut, Lebanon. ⁶⁸Department of Medical Oncology, Miami Cancer Institute, Miami, FL, USA. ⁶⁹Department of Community Medicine and Preventive Health, King Edward Medical University Lahore, Lahore, Pakistan. ⁷⁰Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran. ⁷¹Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁷²Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. ⁷³Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland. ⁷⁴Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan. ⁷⁵Research and Development Department, Alpha Genomics Private Limited, Islamabad, Pakistan. ⁷⁶Microbiological Analysis Team, Korea Research Institute of Standards and Science (KRISS), Daejeon, South Korea. ⁷⁷Department of Medical Microbiology, Haramaya University, Harar, Ethiopia. ⁷⁸Department of Psychology, University of Chittagong, Chittagong, Bangladesh. ⁷⁹Department of Public Health Epidemiology, Debre Berhan University, Deberbirhan, Ethiopia. ⁸⁰Menelik II Medical and Health Science College, EpiMetrics, Inc., Addis Ababa, Ethiopia. ⁸¹Brody School of Medicine, East Carolina University, Greenville, NC, USA. ⁸²Department of Veterinary Pathology, University of Ibadan, Ilorin, Nigeria. ⁸³Veterinary Pathology, Stockholm County Council Surveillance and Analysis Centre for Epidemiology and Community Medicine, Ilorin, Nigeria. ⁸⁴Nazarbayev University, Department of Medicine, Nazarbayev University School of Medicine, Astana, Kazakhstan. ⁸⁵Department of Internal Medicine, University of Patras, Patras, Greece. ⁸⁶Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, Patras, Greece. ⁸⁷Department of Cardiology, Fudan University, Shanghai, China. ⁸⁸Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA. ⁸⁹Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. ⁹⁰Department of Geriatric and Long Term Care, Hamad Medical Corporation, Doha, Qatar. ⁹¹Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar. ⁹²Division of Public Health Sciences, Department of Surgery, Washington University in St Louis, St Louis, MO, USA. ⁹³Faculty of Pharmacy, Al-Sham Private University, Damascus, Syria. ⁹⁴School of Medicine, New York Medical College, Valhalla, NY, USA. ⁹⁵Department of Epidemiology, Columbia University, New York, NY, USA. ⁹⁶Murdoch Business School, Murdoch University, Perth, Western Australia, Australia. ⁹⁷Preventive Dentistry Department, Jouf University, Sakaka, Saudi Arabia. ⁹⁸Department of Public Health, Asian University for Women, Chittagong, Bangladesh. ⁹⁹Asian University for Women, McGill University, Chittagong, Bangladesh. ¹⁰⁰School of Nursing, Yarmouk University, Irbid, Jordan. ¹⁰¹School of Nursing and Midwifery, Western Sydney University, Sydney, New South Wales, Australia. ¹⁰²Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia. ¹⁰³Department of Bacteriology, Immunology, and Mycology, Suez Canal University, Ismailia, Egypt. ¹⁰⁴Global Centre for Environmental Remediation, University of Newcastle, Newcastle, New South Wales, Australia.

¹⁰⁵Cooperative Research Centre for Contamination Assessment and Remediation of the Environment, Newcastle, New South Wales, Australia. ¹⁰⁶College of Nursing, Qatar University, Doha, Qatar. ¹⁰⁷Department of Public Health and Primary Care, Katholieke Universiteit Leuven, Leuven, Belgium. ¹⁰⁸Department of Pharmacy, Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam, Saudi Arabia. ¹⁰⁹Department of Medical Rehabilitation (Physiotherapy), University of Maiduguri, Maiduguri, Nigeria. ¹¹⁰Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong, China. ¹¹¹Department of Biosciences, Jamia Millia Islamia, New Delhi, India. ¹¹²Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan. ¹¹³Department of Geography, Sultan Qaboos University, Muscat, Oman. ¹¹⁴Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan. ¹¹⁵Department of Diagnostic Radiology and Nuclear Medicine, The University of Jordan, Amman, Jordan. ¹¹⁶Institute of Health and Wellbeing, Federation University Australia, Melbourne, Victoria, Australia. ¹¹⁷School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ¹¹⁸Department of Clinical and Community Pharmacy, An-Najah National University, Nablus, Palestine. ¹¹⁹Department of Biomedical Sciences, Nazarbayev University, Astana, Kazakhstan. ¹²⁰Department of Public Health and Community Medicine, International Medical University, Kuala Lumpur, Malaysia. ¹²¹International Centre for Casemix and Clinical Coding, National University of Malaysia, Bandar Tun Razak, Malaysia. ¹²²Independent Consultant, Amman, Jordan. ¹²³Department of Parasitology, University of Malaya, Kuala Lumpur, Malaysia. ¹²⁴Department of Parasitology, Sana'a University, Sana'a, Yemen. ¹²⁵School of Nursing-Department of Clinical Nursing, Al-Zaytoonah University of Jordan, Amman, Jordan. ¹²⁶Department of Physical Therapy and Rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan. ¹²⁷Department of Rehabilitation Sciences and Physical Therapy, Jordan University of Science and Technology, Irbid, Jordan. ¹²⁸Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia. ¹²⁹Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. ¹³⁰Department of Allied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan. ¹³¹Macro-Fiscal Policy Department, Ministry of Finance, Dubai, United Arab Emirates. ¹³²Department of Emergency Medicine, Sana'a University, Sana'a, Yemen. ¹³³Pediatric Emergency Medicine Department, Drexel University, Philadelphia, PA, USA. ¹³⁴Department of Family and Community Medicine, University of Jeddah, Jeddah, Saudi Arabia. ¹³⁵Department of Basic Sciences, Yarmouk University, Irbid, Jordan. ¹³⁶Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. ¹³⁷Otolaryngology Department, Emory University, Atlanta, GA, USA. ¹³⁸Department of Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia. ¹³⁹Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ¹⁴⁰University of Sharjah, Sharjah, United Arab Emirates. ¹⁴¹University Institute of Public Health, The University of Lahore, Lahore, Pakistan. ¹⁴²Research Group in Health Economics, Universidad de Cartagena (University of Cartagena), Cartagena, Colombia. ¹⁴³Research Group in Hospital Management and Health Policies, Universidad de la Costa (University of the Coast), Barranquilla, Colombia. ¹⁴⁴Department of Clinical Pharmacology and Toxicology, Umm Al-Qura University, Makkah, Saudi Arabia. ¹⁴⁵Department of Rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan. ¹⁴⁶Department of Medical Sciences, Azal University for Human Development, Sana'a, Yemen. ¹⁴⁷Department of Clinical Sciences, University of Science and Technology of Fujairah, Fujairah, United Arab Emirates. ¹⁴⁸Department of Pediatrics, Cleveland Clinic, Cleveland, OH, USA. ¹⁴⁹Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. ¹⁵⁰Department of Pathological Sciences, Ajman University, Ajman, United Arab Emirates. ¹⁵¹Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates. ¹⁵²Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. ¹⁵³Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA. ¹⁵⁴Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. ¹⁵⁵Research Department, Nepal Health Research Council, Kathmandu, Nepal. ¹⁵⁶College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. ¹⁵⁷Department of Population and Behavioural Sciences, University of Health and Allied Sciences, Ho, Ghana. ¹⁵⁸Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ¹⁵⁹Centre for Primary Care & Health Services Research, University of Manchester, Manchester, UK. ¹⁶⁰Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. ¹⁶¹All India Institute of Medical Sciences, Bhubaneswar, India. ¹⁶²School of Nursing and Midwifery, La Trobe University, Melbourne, Victoria, Australia. ¹⁶³Special Interest Group International Health, Public Health Association of Australia, Canberra, Australian Capital Territory, Australia. ¹⁶⁴School of Pharmacy, University of Nottingham Malaysia, Semenyih, Malaysia. ¹⁶⁵School of Population Health, UNSW Sydney, University of New South Wales, Sydney, New South Wales, Australia. ¹⁶⁶Faculty of Health Sciences and Medicine, Bond University, Bond University, Gold Coast, Queensland, Australia. ¹⁶⁷Department of Environmental and Occupational Health, University of Medical Sciences, Ondo, Ondo, Nigeria. ¹⁶⁸Department of Microbiology, University of Medical Sciences, Ondo, Ondo, Nigeria. ¹⁶⁹Regenerative Medicine, Organ Procurement and Transplantation Multi-disciplinary Center, Guilan University of Medical Sciences, Rasht, Iran. ¹⁷⁰Centre for Interdisciplinary Research in Basic Sciences (CIRBS), Jamia Millia Islamia, New Delhi, India. ¹⁷¹School of Chemical and Life Sciences (SCLS), Jamia Hamdard, New Delhi, India. ¹⁷²Rural Health Research Institute, Charles Sturt University, Orange, New South Wales, Australia. ¹⁷³School of Medicine and Public Health, Ateneo De Manila University, Pasig City, Philippines. ¹⁷⁴Inter-Agency Committee on Environmental Health, Department of Health Philippines, Manila, Philippines. ¹⁷⁵Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ¹⁷⁶Department of Clinical Sciences, Ajman University, Ajman, United Arab Emirates. ¹⁷⁷Department of Pharmacology and Toxicology, Beni-Suef University, Beni-Suef, Egypt. ¹⁷⁸College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates. ¹⁷⁹Department of Applied Mathematics, University of Washington, Seattle, WA, USA. ¹⁸⁰College of Art and Science, Ottawa University, Surprise, AZ, USA. ¹⁸¹School of Life Sciences, Arizona State University, Tempe, AZ, USA. ¹⁸²Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità (ISS), Rome, Italy. ¹⁸³University College of Medicine & Dentistry, The University of Lahore, Lahore, Pakistan. ¹⁸⁴Department of Electrical and Electronics Engineering Science, University of Johannesburg, Johannesburg, South Africa. ¹⁸⁵Department of Physiotherapy, University of Sharjah, Sharjah, United Arab Emirates. ¹⁸⁶Department of Physiotherapy, Manipal Academy of Higher Education, Manipal, India. ¹⁸⁷Department of Environmental Health, Mekelle University, Mekelle, Ethiopia. ¹⁸⁸Neurological Surgery Department, University of California, San Francisco, San Francisco, CA, USA. ¹⁸⁹Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates. ¹⁹⁰Department of Physiology, Faisalabad Medical University, Faisalabad, Pakistan. ¹⁹¹Deakin Health Economics/School of Health and Social Development, Deakin University, Melbourne, Victoria, Australia. ¹⁹²Monash Addiction Research Center, Monash University, Melbourne, Victoria, Australia. ¹⁹³Department of Forensic Medicine, Lumbini Medical College, Palpa, Nepal. ¹⁹⁴Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA, USA. ¹⁹⁵School of Business, University of Leicester, Leicester, UK. ¹⁹⁶Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania. ¹⁹⁷Department of Public Health, Wollega University, Nekemte, Ethiopia. ¹⁹⁸Department of Health Behavior and Society, Jimma University, Jimma, Ethiopia. ¹⁹⁹Department of Anesthesia, Cihan University, Sulaymaniyah, Iraq. ²⁰⁰Department of Basic Sciences, College of Vet. Medicine, University of Sulaimani, Sulaymaniyah, Iraq. ²⁰¹Community Medicine Department, Ahmadu Bello University, Zaria, Nigeria. ²⁰²Department of Population Medicine, Qatar University, Doha, Qatar. ²⁰³Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan, Pakistan. ²⁰⁴International Medical School, Management and Science University, Shah Alam, Malaysia. ²⁰⁵Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade, Serbia. ²⁰⁶Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ²⁰⁷Miller School of Medicine, University of Miami, Miami, FL, USA. ²⁰⁸Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates. ²⁰⁹Alpha Genomics

Private Limited, Islamabad, Pakistan. ²¹⁰College of Medicine, Jouf University, Sakaka, Saudi Arabia. ²¹¹Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²¹²Biological Science Division, University of Chicago, Chicago, IL, USA. ²¹³Department of Surgery, Jimma University, Jimma, Ethiopia. ²¹⁴Department of Microbiology, Islamic Azad University, Shahr-e-Qods, Iran. ²¹⁵Department of Emergency and Critical Care Nursing, Bahir Dar University, Bahir Dar, Ethiopia. ²¹⁶Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ²¹⁷Department of Veterinary Microbiology, Usmanu Danfodiyo University, Sokoto, Nigeria. ²¹⁸Department of Biomedical Sciences, University of West Attica, Athens, Greece. ²¹⁹National AIDS Reference Center of Southern Greece, University of West Attica, Athens, Greece. ²²⁰Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran. ²²¹Department of Pediatric Neurology, Tehran University of Medical Sciences, Tehran, Iran. ²²²Department of Epidemiology and Health Promotion, New York University, New York, NY, USA. ²²³Hubert Department of Global Health, Emory University, Atlanta, GA, USA. ²²⁴Department of Global Health, George Washington University, Washington DC, USA. ²²⁵Faculty of Medicine, Universidade Católica Portuguesa (Catholic University of Portugal), Sintra, Portugal. ²²⁶Center for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa (Catholic University of Portugal), Lisbon, Portugal. ²²⁷Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St Louis, St Louis, MO, USA. ²²⁸School of Pharmacy, University of Auckland, Auckland, New Zealand. ²²⁹Department of Community and Family Medicine, All India Institute of Medical Sciences, Rishikesh, India. ²³⁰Community Health Department, University of South Wales, South Wales, UK. ²³¹Department of Public Health, North Dakota State University, Fargo, ND, USA. ²³²Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA. ²³³Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ²³⁴School of Public Health, All India Institute of Medical Sciences, Jodhpur, India. ²³⁵Department of Internal Medicine, Wayne State University, Gross Pointe Woods, MI, USA. ²³⁶Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India. ²³⁷Department of Demography and Population Studies, University of Witwatersrand, Johannesburg, South Africa. ²³⁸Internal Medicine Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²³⁹Department of Medicine, University Ferhat Abbas of Setif, Setif, Algeria. ²⁴⁰Department of Epidemiology and Preventive Medicine, University Hospital Saadna Abdenour, Setif, Algeria. ²⁴¹School of Medicine, University of Washington, Seattle, WA, USA. ²⁴²General Medicine Service, Department of Veterans Affairs, Seattle, WA, USA. ²⁴³Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. ²⁴⁴Department of Environmental Health, Bahir Dar University, Bahir Dar, Ethiopia. ²⁴⁵School of Pharmacy, The University of Jordan, Amman, Jordan. ²⁴⁶Department of Basic Biomedical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ²⁴⁷Department of Family and Community Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. ²⁴⁸School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. ²⁴⁹Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan. ²⁵⁰Faculty of Health Sciences Healthcare Management Department, Ankara University, Ankara, Turkey. ²⁵¹Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania. ²⁵²Department of Internal and Geriatric Medicine, Hospital Italiano de Buenos Aires (Italian Hospital of Buenos Aires), Buenos Aires, Argentina. ²⁵³Board of Directors, Argentine Society of Medicine, Buenos Aires, Argentina. ²⁵⁴Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Mexico. ²⁵⁵Unit of Hygiene and Public Health, Romagna Local Health Authority, Cesena, Italy. ²⁵⁶Interdisciplinary Research Center for Health Science, Sant'Anna School of Advanced Studies, Pisa, Italy. ²⁵⁷Department of Psychiatry, University of São Paulo, São Paulo, Brazil. ²⁵⁸Public Health Department, National University of Colombia, Bogota, Colombia. ²⁵⁹Epidemiology and Public Health Evaluation Group, National University of Colombia, Bogota, Colombia. ²⁶⁰Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy. ²⁶¹Public Health Unit, University Health Agency Giuliano-Isontina (ASUGI), Trieste, Italy. ²⁶²College of Public Health, Medical, and Veterinary Sciences, James Cook University, Townsville, Queensland, Australia. ²⁶³Department of Public Health, University of Mataram, Mataram, Indonesia. ²⁶⁴Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia. ²⁶⁵School of Public Health, University of Hong Kong, Hong Kong, China. ²⁶⁶Department of Biotechnology, Adamas University, Kolkata, India. ²⁶⁷Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, Chuncheon, South Korea. ²⁶⁸State Disease Investigation Laboratory, Animal Resources Development Department, Agartala, India. ²⁶⁹Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong, China. ²⁷⁰Department of Anesthesiology and Perioperative Medicine, University of Rochester, Rochester, NY, USA. ²⁷¹Department of Biology, Al-Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. ²⁷²Faculty of Humanities and Health Sciences, Curtin University, Miri, Malaysia. ²⁷³Clinical Research Center, Zhujiang Hospital of Southern Medical University, Guangzhou, China. ²⁷⁴Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. ²⁷⁵Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, China. ²⁷⁶Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ²⁷⁷Division of Cardiovascular Medicine, Harvard University, Boston, MA, USA. ²⁷⁸Division of Infectious Diseases, Virginia Commonwealth University, Richmond, VA, USA. ²⁷⁹Department of Public Health, Administration, and Social Sciences, Cayetano Heredia University, Lima, Peru. ²⁸⁰Iraq Field Epidemiology Training Program (I-FETP), Ministry of Health, Baghdad, Iraq. ²⁸¹The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China. ²⁸²Department of Community Medicine, Jawaharlal Nehru Medical College, Wardha, India. ²⁸³Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA. ²⁸⁴Department of Pulmonary Medicine, Christian Medical College and Hospital (CMC), Vellore, India. ²⁸⁵The Interdisciplinary Research Group on Biomedicine and Health, VNU International School (VNUIS), Hanoi, Vietnam. ²⁸⁶Faculty of Applied Sciences, VNU International School (VNUIS), Hanoi, Vietnam. ²⁸⁷Department of Molecular Parasitology and Tropical Diseases, Taipei Medical University, Taipei, Taiwan. ²⁸⁸Department of Paediatric Surgery, Federal Medical Centre, Umuahia, Nigeria. ²⁸⁹Department of Health Behavior, Texas A&M University, College Station, TX, USA. ²⁹⁰School of Nursing and Midwifery, University of Technology Sydney, Sydney, New South Wales, Australia. ²⁹¹Health Effects Institute, Boston, MA, USA. ²⁹²Nova Medical School, Nova University of Lisbon, Lisbon, Portugal. ²⁹³Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal. ²⁹⁴Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal. ²⁹⁵School of Nursing, Federal University of Minas Gerais, Belo Horizonte, Brazil. ²⁹⁶Research Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates. ²⁹⁷Faculty of Medicine, University of Aleppo, Aleppo, Syria. ²⁹⁸Research Center for Child Psychiatry, University of Turku, Turku, Finland. ²⁹⁹Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, Iran. ³⁰⁰School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China. ³⁰¹School of Pharmacy and Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia. ³⁰²Institute for Health Sciences, Mid Sweden University, Sundsvall, Sweden. ³⁰³Department of Public Health, Haramaya University, Harar, Ethiopia. ³⁰⁴Ophthalmology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ³⁰⁵Ophthalmology Department, Emergency University Hospital Bucharest, Bucuresti, Romania. ³⁰⁶Department of Geography and Environmental Management, University of Toronto, Waterloo, Ontario, Canada. ³⁰⁷Department of Medicine, Universitat Jaume I, Castellon, Spain. ³⁰⁸Chettinad Hospital & Research Institute, Chettinad Academy of Research and Education, Chennai, India. ³⁰⁹Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³¹⁰JSS Medical College Department of Biochemistry, Jagadguru Sri Shivarathreeswara University, Mysuru, India. ³¹¹Statistics Discipline, Khulna University, Khulna, Bangladesh. ³¹²Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. ³¹³Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India. ³¹⁴Research and Development Cell, Dr D. Y. Patil Vidyapeeth, Pune (Deemed to be University), Pune, India. ³¹⁵Department of Community Medicine, University of Peradeniya, Peradeniya, Sri Lanka.

³¹⁶Institute of Occupational, Social and Environmental Medicine, Goethe University, Frankfurt am Main, Germany. ³¹⁷Department of Life Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy. ³¹⁸Department of Epidemiology, Sunway University, Selangor, Malaysia. ³¹⁹Department of Epidemiology, Maastricht University, Maastricht, The Netherlands. ³²⁰Faculty of Science, National Autonomous University of Mexico, Mexico City, Mexico. ³²¹College of Medicine, University of Florida, Gainesville, FL, USA. ³²²Department of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. ³²³Department of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam. ³²⁴Department of Public Health, Jazan University, Jazan, Saudi Arabia. ³²⁵Independent Consultant, South Plainfield, NJ, USA. ³²⁶Department of Epidemiology and Biostatistics, University of Health and Allied Sciences, Ho, Ghana. ³²⁷Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands. ³²⁸College of Medicine, Ajman University, Ajman, United Arab Emirates. ³²⁹Toront Centre for Liver Diseases, University of Toronto, Toronto, Ontario, Canada. ³³⁰School of Health Sciences, Universiti Sains Malaysia (University of Science Malaysia), Kubang Kerian, Malaysia. ³³¹Research Center for Public Health and Nutrition, National Research and Innovation Agency, Jakarta, Indonesia. ³³²Iran University of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. ³³³Ishenberg School of Management, University of Massachusetts Amherst, Amherst, MA, USA. ³³⁴Department of Medicine, Aga Khan University, Karachi, Pakistan. ³³⁵Department of Public Health and Community Medicine, Tanta University, Tanta city, Egypt. ³³⁶School of Public Health, Texila American University, Georgetown, Guyana. ³³⁷Department of Pediatric Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia. ³³⁸Pediatric Dentistry and Dental Public Health Department, Alexandria University, Alexandria, Egypt. ³³⁹Department of Basic Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ³⁴⁰Anatomy and Embryology, Mansoura University, Mansoura, Egypt. ³⁴¹Deanship of Preparatory Year and Supporting Studies, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ³⁴²Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates. ³⁴³Faculty of Medicine, University of Tripoli, Tripoli, Libya. ³⁴⁴Houston Methodist Hospital, Houston, TX, USA. ³⁴⁵Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China. ³⁴⁶Department of Animal Medicine, Zagazig University, Zagazig, Egypt. ³⁴⁷Department of Pediatrics, University of Texas, Dallas, TX, USA. ³⁴⁸Department of Public Health and Tropical Medicine, James Cook University, Townsville, Queensland, Australia. ³⁴⁹Pathology and Laboratory Medicine, Brown University, Providence, RI, USA. ³⁵⁰Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran. ³⁵¹Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran. ³⁵²Gastroenterology and Hepatology Department, Mayo Clinic, Rochester, MN, USA. ³⁵³Department of Occupational Health and Safety Engineering, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁵⁴Department of Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. ³⁵⁵Department of Biotechnology, University of the Western Cape, Cape Town, South Africa. ³⁵⁶Research Centre for Healthcare and Community, Coventry University, Coventry, UK. ³⁵⁷Department of Oral Biology, Riphah International University, Islamabad, Pakistan. ³⁵⁸Medicine and Society, Independent Consultant, Male, Maldives. ³⁵⁹Director of the Scientific and Technological Park, Kazakh National Medical University, Almaty, Kazakhstan. ³⁶⁰Department of Medicine, Korea University, Seoul, South Korea. ³⁶¹Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁶²Pediatric Institute, Cleveland Clinic, Cleveland, OH, USA. ³⁶³Department of Psychology, Federal University of Sergipe, São Cristóvão, Brazil. ³⁶⁴School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ³⁶⁵Endocrinology and Metabolism Research Institute, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran. ³⁶⁶Department of Plastic and Reconstructive Surgery, Hamad Medical Corporation, Doha, Qatar. ³⁶⁷Department of Medicinal Chemistry, Hamadan University of Medical Sciences, Hamadan, Iran. ³⁶⁸Charité University Berlin, Charité Universitätsmedizin Berlin (Charité University Medical Center Berlin), Berlin, Germany. ³⁶⁹University Institute of Radiological Sciences and Medical Imaging Technology, The University of Lahore, Lahore, Pakistan. ³⁷⁰Centre for Public Health, Equity and Human Flourishing, Torrens University Australia, Adelaide, South Australia, Australia. ³⁷¹Institute of Resource Governance and Social Change, Kupang, Indonesia. ³⁷²Center for Public Health Research, University of Milan Bicocca, Monza, Italy. ³⁷³Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, Italy. ³⁷⁴Department of Social Sciences, University of Nicosia, Nicosia, Cyprus. ³⁷⁵Institute of Public Health, Charité Universitätsmedizin Berlin (Charité University Medical Center Berlin), Berlin, Germany. ³⁷⁶Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria. ³⁷⁷Clinical Science Department, Nigerian Institute of Medical Research, Lagos, Nigeria. ³⁷⁸Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. ³⁷⁹Department of Neurology, Public Health and Disability, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ³⁸⁰Innovation in Healthcare and Social Services Department, Emilia-Romagna Region, Bologna, Italy. ³⁸¹Department of Neuroscience, Multiple Sclerosis Research Center, Ravenna, Italy. ³⁸²Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. ³⁸³Department of Radiology, University of Southern California, Los Angeles, CA, USA. ³⁸⁴Department of Medicine, Iran University of Medical Sciences, Tehran, Iran. ³⁸⁵Department of Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China. ³⁸⁶Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, India. ³⁸⁷Department of Community Medicine, Bayero University Kano, Kano, Nigeria. ³⁸⁸Department of Community Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria. ³⁸⁹Department of Medicine, Nazarbayev University, Astana, Kazakhstan. ³⁹⁰Department of Medical Epidemiology, Mario Negri Institute for Pharmacological Research, Milan, Italy. ³⁹¹Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Nagpur, India. ³⁹²School of Public Health, Institute of Health & Management, Melbourne, Victoria, Australia. ³⁹³University Hospital Basel, Department of Ophthalmology, University of Basel, Basel, Switzerland. ³⁹⁴Department of Pharmacology, Indore Institute of Pharmacy, Indore, India. ³⁹⁵Department of Midwifery, Adigrat University, Adigrat, Ethiopia. ³⁹⁶Department of Medical Laboratory Science, Addis Ababa University, Addis Ababa, Ethiopia. ³⁹⁷School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁹⁸Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁹⁹Tropical Health Department, Alexandria University, Alexandria, Egypt. ⁴⁰⁰Family and Community Medicine Department, King Khalid University, Abha, Saudi Arabia. ⁴⁰¹Department of Statistics, Ronin Institute, Montclair, NJ, USA. ⁴⁰²Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁰³Obstetrics and Gynecology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴⁰⁴Department of Biology, Government Institute of Science, Nagpur, India. ⁴⁰⁵Department of Clinical Research, National Institute for Research in Reproductive and Child Health, Mumbai, India. ⁴⁰⁶Country Office, World Health Organization (WHO), Astana, Kazakhstan. ⁴⁰⁷Division of General Internal Medicine, Howard University, Washington DC, USA. ⁴⁰⁸Department of Community and Family Medicine, Howard University, Washington DC, USA. ⁴⁰⁹Department of Nursing, Aksum University, Aksum, Ethiopia. ⁴¹⁰Department of Health Systems and Policy Research, Indian Institute of Public Health, Gandhinagar, India. ⁴¹¹Family Medicine Department, Shiraz University of Medical Sciences, Shiraz, Iran. ⁴¹²Tuberculosis Biomarker Research Unit, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (Institute for Scientific Research and High Technology Services), City of Knowledge, Panama. ⁴¹³Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA. ⁴¹⁴Institute of Public Health, United Arab Emirates University, Al Ain, United Arab Emirates. ⁴¹⁵Department of Public Health and Preventive Medicine, Charles University, Prague, Czech Republic. ⁴¹⁶Research Division, Joslin Diabetes Center, Boston, MA, USA. ⁴¹⁷School of Population Health, Curtin University, Perth, Western Australia, Australia. ⁴¹⁸Post Graduate School of Public Health, University of Siena, Siena, Italy. ⁴¹⁹Department of Clinical Science, University Of Sulaimani, Sulaimani, Iraq. ⁴²⁰Department of the Health Directorate, Local Health Authority of Bologna, Bologna, Italy. ⁴²¹Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ⁴²²Department of Thoracic Surgery, Cleveland Clinic, Cleveland, OH, USA. ⁴²³Department of Community Medicine,

University of Peradeniya, Kandy, Sri Lanka. ⁴²⁴Department of Urban Planning and Design, University of Hong Kong, Hong Kong, China. ⁴²⁵Department of Nephrology, Max Super Speciality Hospital, New Delhi, India. ⁴²⁶Non-communicable Diseases Division (NCD), Indian Council of Medical Research, New Delhi, India. ⁴²⁷Department of Public Health, Torrens University Australia, Melbourne, Victoria, Australia. ⁴²⁸Department of Anaesthesia, Maulana Azad Medical College, New Delhi, India. ⁴²⁹Department of Preventive Cardiology & Medicine, Eternal Heart Care Centre & Research Institute, Jaipur, India. ⁴³⁰Department of Medicine, Mahatma Gandhi University Medical Sciences, Jaipur, India. ⁴³¹School of Medicine, Deakin University, Geelong, Victoria, Australia. ⁴³²Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia. ⁴³³Department of Biomedical Gerontology, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil. ⁴³⁴Global Virus Network, Middle East Region, Shiraz, Iran. ⁴³⁵Department of Health in Emergencies and Disasters, Tehran University of Medical Sciences, Tehran, Iran. ⁴³⁶Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran. ⁴³⁷Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. ⁴³⁸Department of Public Health, Charité Institute of Public Health, Berlin, Germany. ⁴³⁹Biochemistry Department, Ain Shams University, Cairo, Egypt. ⁴⁴⁰Department of Medical and Technical Information Technology, Bauman Moscow State Technical University, Moscow, Russia. ⁴⁴¹Department of Preventive Medicine, Chungnam National University School of Medicine, Daejeon, South Korea. ⁴⁴²Department of Health and Education, Torrens University Australia, Melbourne, Victoria, Australia. ⁴⁴³Department of Epidemiology Population Biostatistics and Health Promotion, Universitas Airlangga (University of Airlangga), Surabaya, Indonesia. ⁴⁴⁴Research Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain. ⁴⁴⁵Department of Mental Health, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain. ⁴⁴⁶Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. ⁴⁴⁷Department of Biochemistry and Molecular Biology, Tejgaon College, Dhaka, Bangladesh. ⁴⁴⁸Department of Public Health, Tropical Disease and Health Research Center, Dhaka, Bangladesh. ⁴⁴⁹Department of Ophthalmology, Iran University of Medical Sciences, Tehran, Iran. ⁴⁵⁰Department of Medical Surgical, Shahroud University of Medical Sciences, Shahrekord, Iran. ⁴⁵¹Ajman University, Ajman, United Arab Emirates. ⁴⁵²Center for International Health (CIH), University of Bergen, Bergen, Norway. ⁴⁵³Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway. ⁴⁵⁴Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. ⁴⁵⁵Institute of Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany. ⁴⁵⁶Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. ⁴⁵⁷Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. ⁴⁵⁸Institute of Psychology, University of Wrocław, Wrocław, Poland. ⁴⁵⁹Meta Research Centre, University of Wrocław, Wrocław, Poland. ⁴⁶⁰Department of Medicine, MedStar Health, Washington DC, USA. ⁴⁶¹Department of Medicine, Georgetown University, Washington DC, USA. ⁴⁶²Graduate School of Medicine, University of Tokyo, Tokyo, Japan. ⁴⁶³Faculty of Public Health, Vietnam National University, Hanoi, Vietnam. ⁴⁶⁴Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. ⁴⁶⁵Department of Pulmonology, Yokohama City University, Yokohama, Japan. ⁴⁶⁶National Human Genome Research Institute (NHGRI), National Institutes of Health, Bethesda, MD, USA. ⁴⁶⁷Department of Statistics, Shahjalal University of Science and Technology, Sylhet, Bangladesh. ⁴⁶⁸School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. ⁴⁶⁹Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada. ⁴⁷⁰School of Computer Science, Duy Tan University, Da Nang, Vietnam. ⁴⁷¹Jadara Research Center, Jadara University, Irbid, Jordan. ⁴⁷²Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁴⁷³Department of Clinical Legal Medicine, National Institute of Legal Medicine Mina Minovici, Bucharest, Romania. ⁴⁷⁴Department of Health Services Administration, China Medical University, Taichung, Taiwan. ⁴⁷⁵Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. ⁴⁷⁶Department of Public Health and Community Medicine, Shaikh Zayed Postgraduate Medical Institute, Lahore, Pakistan. ⁴⁷⁷Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA. ⁴⁷⁸Nephrology and Urology Research Center, Baqiyyatallah University of Medical Sciences, Tehran, Iran. ⁴⁷⁹Department of Biological Sciences and Chemistry, University of Nizwa, Nizwa, Oman. ⁴⁸⁰Department of Biomolecular Sciences, University of Zakho, Zakho, Iraq. ⁴⁸¹Artur Riggs Diabetes & Metabolism Research Institute, Cancer Prevention and Research Institute, Duarte, CA, USA. ⁴⁸²Zagazig University, Zagazig, Egypt. ⁴⁸³College of Health Sciences, VinUniversity, Hanoi, Vietnam. ⁴⁸⁴School of Health Care Administration, Taipei Medical University, Taipei, Taiwan. ⁴⁸⁵International Master Program for Translational Science, Taipei Medical University, Taipei, Taiwan. ⁴⁸⁶Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan. ⁴⁸⁷Department of Occupational Therapy, Asia University, Taiwan, Taichung, Taiwan. ⁴⁸⁸Department of Safety and Bioethics, Università Cattolica del Sacro Cuore, Rome, Italy. ⁴⁸⁹Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria. ⁴⁹⁰Science and Technology Park, Kazakh National Medical University, Almaty, Kazakhstan. ⁴⁹¹Division of Infectious Diseases, Veterans Affairs Greater Los Angeles, Los Angeles, CA, USA. ⁴⁹²West Africa RCC, Africa Centre for Disease Control and Prevention, Abuja, Nigeria. ⁴⁹³Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ⁴⁹⁴Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia. ⁴⁹⁵Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana. ⁴⁹⁶Faculty of Health and Life Sciences, University of Exeter, Exeter, UK. ⁴⁹⁷Faculty of Public Health, Universitas Muhammadiyah Aceh, Banda Aceh, Indonesia. ⁴⁹⁸Department of Microbiology, University of Maiduguri, Maiduguri, Nigeria. ⁴⁹⁹Department of Biotechnology, Sharda University, Greater Noida, India. ⁵⁰⁰School of Pharmacy, BRAC University, Dhaka, Bangladesh. ⁵⁰¹Department of Clinical Pharmacy & Pharmacy Practice, Asian Institute of Medicine, Science and Technology, Bedong, Malaysia. ⁵⁰²Malaysian Academy of Pharmacy, Puchong, Malaysia. ⁵⁰³Department of Allergology, Kazakh National Medical University, Almaty, Kazakhstan. ⁵⁰⁴Department of Microbiology, Central University of Punjab, Bathinda, India. ⁵⁰⁵Department of Physical and Medicine, Université Paris Cité, Paris, France. ⁵⁰⁶Research and Development Unit, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, Spain. ⁵⁰⁷Department of Immunology, Kerman University of Medical Sciences, Kerman, Iran. ⁵⁰⁸Department of Immunology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ⁵⁰⁹College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain. ⁵¹⁰Ministry of Health, Manama, Bahrain. ⁵¹¹Statistics Unit, Riga Stradins University, Riga, Latvia. ⁵¹²Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA. ⁵¹³Department of Medicine, AMA School of Medicine, Makati, Philippines. ⁵¹⁴The World Academy of Sciences UNESCO, Trieste, Italy. ⁵¹⁵Shaanxi University of Technology, Hanzhong, China. ⁵¹⁶Department of General Surgery, Tehran University of Medical Sciences, Tehran, Iran. ⁵¹⁷Department of Pharmacology, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. ⁵¹⁸Centre of Studies and Research, Ministry of Health, Muscat, Oman. ⁵¹⁹Department of Biochemistry, Government Medical College, Mysuru, India. ⁵²⁰Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital (CMC), Vellore, India. ⁵²¹Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. ⁵²²Department of Epidemiology and Health Promotion, Yonsei University, Seoul, South Korea. ⁵²³Department of Community Medicine, Dr Baba Saheb Ambedkar Medical College & Hospital, Delhi, India. ⁵²⁴Department of Community Medicine, Banaras Hindu University, Varanasi, India. ⁵²⁵Department of Public Health Sciences, University of Rochester, Rochester, NY, USA. ⁵²⁶Department of Health Economics, Fudan University, Shanghai, China. ⁵²⁷Department of Orthopedics, Wuhan University, Wuhan, China. ⁵²⁸Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China. ⁵²⁹Rothschild Foundation Hospital, Institut Français de Myopie, Paris, France. ⁵³⁰Singapore Eye Research Institute, Singapore Eye Research Institute, Singapore, Singapore. ⁵³¹Health Services Management Training Centre, Semmelweis University, Budapest, Hungary. ⁵³²Hungarian Health Management Association, Budapest, Hungary. ⁵³³Department of Community Medicine, Jubilee Mission Medical College & Research Institute, Thrissur,

Thrissur, India. ⁵³⁴Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India. ⁵³⁵Department of Life Science, Parul University, Vadodara, India. ⁵³⁶Health Economics Unit, Flinders University, Adelaide, South Australia, Australia. ⁵³⁷College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. ⁵³⁸School of Public Health, University College Cork, Cork, Ireland. ⁵³⁹Department of Environmental and Occupational Health, University of Gondar, Gondar, Ethiopia. ⁵⁴⁰Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India. ⁵⁴¹Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. ⁵⁴²Department of Rehabilitation Sciences, Qatar University, Doha, Qatar. ⁵⁴³T. H. Chan School of Public Health, Harvard University, Boston, MA, USA. ⁵⁴⁴Poche Centre for Indigenous Health, The University of Queensland, Brisbane, Queensland, Australia. ⁵⁴⁵Regional Institute for Population Studies, University of Ghana, Accra, Ghana. ⁵⁴⁶Faculty of Dentistry, University of Puthisastra, Phnom Penh, Cambodia. ⁵⁴⁷Office of the Executive Director, Cephas Health Research Initiative Inc., Ibadan, Nigeria. ⁵⁴⁸Department of Respiratory Medicine, King George's Medical University, Lucknow, India. ⁵⁴⁹The Hansjörg Wyss Department of Plastic and Reconstructive Surgery, NYU Langone Health, New York, NY, USA. ⁵⁵⁰Cleft Lip and Palate Surgery Division, Global Smile Foundation, Norwood, MA, USA. ⁵⁵¹Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, India. ⁵⁵²Endocrine Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁵⁵³Department of Echocardiography, Iran University of Medical Sciences, Tehran, Iran. ⁵⁵⁴Surgery Research Unit, University of Oulu, Oulu, Finland. ⁵⁵⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. ⁵⁵⁶Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA. ⁵⁵⁷Open, Distance and eLearning Campus, University of Nairobi, Nairobi, Kenya. ⁵⁵⁸Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan. ⁵⁵⁹Amity Institute of Forensic Sciences, Amity University, Noida, India. ⁵⁶⁰Department of Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates. ⁵⁶¹Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt. ⁵⁶²Department of Biostatistics, Mazandaran University of Medical Sciences, Sari, Iran. ⁵⁶³Halal Research Center of the Islamic Republic of Iran (IRI), Iran Food and Drug Administration, Tehran, Iran. ⁵⁶⁴Population Science Department, Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh. ⁵⁶⁵Department of Public Health, University of Sydney, Sydney, New South Wales, Australia. ⁵⁶⁶Epidemiology Program, Jazan University, Jazan, Saudi Arabia. ⁵⁶⁷Family Medicine Department, United Arab Emirates University, Al Ain, United Arab Emirates. ⁵⁶⁸Primary Care Department, NHS North West London, London, UK. ⁵⁶⁹Department of Health, Nepal Development Society, Chitwan, Nepal. ⁵⁷⁰Department of Preventable Non Communicable Disease, Menzies School of Health Research, Alice Springs, Northern Territory, Australia. ⁵⁷¹College of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, UK. ⁵⁷²College of Arts and Sciences, Ohio University, Zanesville, OH, USA. ⁵⁷³Department of Basic Medical Sciences, Yarmouk University, Irbid, Jordan. ⁵⁷⁴Department of Biochemistry, Liaquat University Of Medical and Health Sciences, Jamshoro, Pakistan. ⁵⁷⁵Department of Health Management and Economics, Qom University of Medical Sciences, Qom, Iran. ⁵⁷⁶Department of Health Economics, Iran University of Medical Sciences, Tehran, Iran. ⁵⁷⁷Graduate School of Public Health, Kosin University, Busan, South Korea. ⁵⁷⁸School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia. ⁵⁷⁹Millennium Prevention, Inc., Westwood, MA, USA. ⁵⁸⁰Department of Nursing, Salale University, Fitch, Ethiopia. ⁵⁸¹School of Health Sciences, Kristiania University College, Oslo, Norway. ⁵⁸²Department of International Health and Sustainable Development, Tulane University, New Orleans, LA, USA. ⁵⁸³Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway. ⁵⁸⁴Department of Brain Sciences, University College London, London, UK. ⁵⁸⁵Department of Public Health, University of Helsinki, Helsinki, Finland. ⁵⁸⁶School of Public Health, University of Sydney, Sydney, New South Wales, Australia. ⁵⁸⁷Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. ⁵⁸⁸Centre for the Business and Economics of Health, The University of Queensland, Brisbane, Queensland, Australia. ⁵⁸⁹Department of Epidemiology and Evidence-Based Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. ⁵⁹⁰Department of General Practice and Family Medicine, Kharkiv National Medical University, Kharkiv, Ukraine. ⁵⁹¹Department of Epidemiology, IQVIA, Frankfurt am Main, Germany. ⁵⁹²University Hospital Marburg, Marburg, Germany. ⁵⁹³Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur, India. ⁵⁹⁴Department of Anthropology, Panjab University, Chandigarh, India. ⁵⁹⁵Hellenic Parliament, Hellenic Parliament, Athens, Greece. ⁵⁹⁶School of Nursing, University of Peloponnese, Sparta, Greece. ⁵⁹⁷Department of Biochemistry, University of Hail, Hail, Saudi Arabia. ⁵⁹⁸Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland. ⁵⁹⁹Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ⁶⁰⁰Research and Publication Activity Division, Kazakh National Medical University, Almaty, Kazakhstan. ⁶⁰¹Center of Medicine and Public Health, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan. ⁶⁰²Department of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, India. ⁶⁰³Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ⁶⁰⁴College of Public Health & Health Informatics, University of Hail, Hail, Saudi Arabia. ⁶⁰⁵Department of Public Health, Griffith University, Gold Coast, Queensland, Australia. ⁶⁰⁶Section of Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada. ⁶⁰⁷Translational Health Sciences, University of Bristol, Bristol, UK. ⁶⁰⁸Department of Clinical Subjects, Al Farabi Kazakh National University, Almaty, Kazakhstan. ⁶⁰⁹Faculty of Health and Life Sciences, Coventry University, Coventry, UK. ⁶¹⁰Department of Medicine, McMaster University, Hamilton, Ontario, Canada. ⁶¹¹Faculty of Medicine and Health Science, Universitas Kristen Satya Wacana, Salatiga, Indonesia. ⁶¹²School of Nursing, Taipei Medical University, Taipei, Taiwan. ⁶¹³Department of Environment and Public Health, University of Environment and Sustainable Development, Somanya, Ghana. ⁶¹⁴Clinical Research Center, Turku University Hospital, Turku, Finland. ⁶¹⁵Heart Center, University of Turku, Turku, Finland. ⁶¹⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ⁶¹⁷Department of Nursing Science, Bayero University Kano, Kano, Nigeria. ⁶¹⁸Division of Evidence Synthesis, Foundation for People-Centric Health Systems, New Delhi, India. ⁶¹⁹Division of Lifestyle Medicine, Centre for Health: The Specialty Practice, New Delhi, India. ⁶²⁰Department of Occupational and Environmental Health, Huazhong University of Science and Technology, Wuhan, China. ⁶²¹Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou, China. ⁶²²NEVES Society for Patient Safety, Budapest, Hungary. ⁶²³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. ⁶²⁴Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. ⁶²⁵Centre for Family Welfare, University of Indonesia, Depok, Indonesia. ⁶²⁶Department of Global Health and Health Security, Taipei Medical University, Taipei, Taiwan. ⁶²⁷Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran. ⁶²⁸International Society of Doctors for the Environment, Arezzo, Italy. ⁶²⁹Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. ⁶³⁰Department of Cardiovascular Research, Methodist Hospital, Merrillville, IN, USA. ⁶³¹University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. ⁶³²Independent Consultant, Ho Chi Minh City, Vietnam. ⁶³³Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. ⁶³⁴Department of Precision Medicine, Sungkyunkwan University, Suwon-si, South Korea. ⁶³⁵Department of Family Medicine, University of Texas Medical Branch, Galveston, TX, USA. ⁶³⁶Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, Kaiserslautern, Germany. ⁶³⁷Department of Cardiothoracic Surgery, University of Patras, Patras, Greece. ⁶³⁸Faculty of Science, Universiti Brunei Darussalam (University of Brunei Darussalam), Bandar Seri Begawan, Brunei. ⁶³⁹School of Nursing, Johns Hopkins University, Baltimore, MD, USA. ⁶⁴⁰Department of Health Promotion and Health Education, National Taiwan Normal University, Taipei, Taiwan. ⁶⁴¹Department of Psychiatry, Yale University, New Haven, CT, USA. ⁶⁴²Department of Pharmaceutical Regulatory Affairs and Management, Manipal Academy of Higher Education, Manipal, India. ⁶⁴³International Centre for Future Health Systems, University of New South Wales, Sydney, New South Wales, Australia. ⁶⁴⁴WHO Collaborating Centre for Public Health Education and Training, Imperial College London, London, UK. ⁶⁴⁵Department of

Food Science and Human Nutrition, Iowa State University, Ames, IA, USA. ⁶⁴⁶College of Public Health, China Medical University, Taichung, Taiwan. ⁶⁴⁷Asbestos Diseases Research Institute, Concord, New South Wales, Australia. ⁶⁴⁸Department of Public Health, La Trobe University, Melbourne, Victoria, Australia. ⁶⁴⁹School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia. ⁶⁵⁰Department of Epidemiology and Biostatistics, Peking University, Beijing, China. ⁶⁵¹Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ⁶⁵²Department of Quantitative Health Science, Case Western Reserve University, Cleveland, OH, USA. ⁶⁵³School of Medicine, Universidad Espíritu Santo, Samborondón, Ecuador. ⁶⁵⁴Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile. ⁶⁵⁵Department of Medicine, University of São Paulo, São Paulo, Brazil. ⁶⁵⁶School of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil. ⁶⁵⁷Huazhong University of Science and Technology, Wuhan, China. ⁶⁵⁸Centre for Public Health and Wellbeing, University of the West of England, Bristol, UK. ⁶⁵⁹Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. ⁶⁶⁰Department of Microbiology and Parasitology, Faculty of Veterinary Medicine, King Salman International University, South of Sinai, Egypt. ⁶⁶¹Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁶⁶²Tehran University of Medical Sciences, Tehran, Iran. ⁶⁶³Department of Electrical Engineering, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia. ⁶⁶⁴Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ⁶⁶⁵Department of Maternal-Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil. ⁶⁶⁶Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ⁶⁶⁷Corporate Nursing and Midwifery Research Department, Hamad Medical Corporation, Doha, Qatar. ⁶⁶⁸Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. ⁶⁶⁹School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy. ⁶⁷⁰Laboratory of Public Health, Instituto Auxologico Italiano IRCCS (Italian Auxological Institute), Milan, Italy. ⁶⁷¹Department of Biotechnology, Tribhuvan University, Kathmandu, Nepal. ⁶⁷²Department of Biomedical Engineering, University of Isfahan, Isfahan, Iran. ⁶⁷³Automatic Control Department (ESAI) and Institute for Research and Innovation in Health (IRIS), Universitat Politècnica de Catalunya (Barcelona Tech - UPC), Barcelona, Spain. ⁶⁷⁴Department of Infectious Diseases, Instituto Nacional de Nutrición Salvador Zubirán (Salvador Zubirán National Institute of Medical Sciences and Nutrition), Mexico City, Mexico. ⁶⁷⁵Faculty of Public Health, Universitas Airlangga (University of Airlangga), Surabaya, Indonesia. ⁶⁷⁶Indonesian Public Health Association, Surabaya, Indonesia. ⁶⁷⁷Department of Nutrition and Dietetics, University of Concepción, Concepción, Chile. ⁶⁷⁸Centre for Healthy Living, University of Concepción, Concepción, Chile. ⁶⁷⁹Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. ⁶⁸⁰Medical Clinic V, Heidelberg University, Mannheim, Germany. ⁶⁸¹Faculty of Humanities and Health Sciences, Curtin University, Sarawak, Malaysia. ⁶⁸²Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia. ⁶⁸³Medical Scientist Training Program, Northwestern University, Chicago, IL, USA. ⁶⁸⁴Department of Pharmacology, Shahrood University of Medical Sciences, Shahrood, Iran. ⁶⁸⁵Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia. ⁶⁸⁶Department of Anatomy, Genetics and Biomedical Informatics, University of Colombo, Colombo, Sri Lanka. ⁶⁸⁷Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK. ⁶⁸⁸North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK. ⁶⁸⁹Department of Community Medicine, Geetanjali Medical College and Hospital, Udaipur, India. ⁶⁹⁰Department of Social Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. ⁶⁹¹Department of Epidemiology, Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand. ⁶⁹²Nuffield Department of Medicine, University of Oxford, Oxford, UK. ⁶⁹³Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, Catania, Italy. ⁶⁹⁴Department of Infectious Disease Epidemiology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. ⁶⁹⁵Department of Tropical Medicine, Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. ⁶⁹⁶Australian Centre for Health Services Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia. ⁶⁹⁷Digital Health and Informatics Directorate, Queensland Health, Brisbane, Queensland, Australia. ⁶⁹⁸Department of Healthcare, University of Vlora, Vlora City, Albania. ⁶⁹⁹Clinic of Social and Family Medicine, University of Crete, Heraklion, Greece. ⁷⁰⁰Department of Public Health, Arba Minch University, Arba Minch, Ethiopia. ⁷⁰¹Department of Medical Laboratory Sciences, Adigrat University, Adigrat, Ethiopia. ⁷⁰²Department of Medical Laboratory Science, Bahir Dar University, Bahir Dar, Ethiopia. ⁷⁰³Department of Internal Medicine, University of Gondar, Gondar, Ethiopia. ⁷⁰⁴Johns Hopkins University, Baltimore, MD, USA. ⁷⁰⁵Division of Forensic Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ⁷⁰⁶International Dx Department, BGI Genomics, Copenhagen, Denmark. ⁷⁰⁷General Administration Department, Helsinki University Hospital, Helsinki, Finland. ⁷⁰⁸School of Health Sciences, University of Melbourne, Melbourne, Victoria, Australia. ⁷⁰⁹Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. ⁷¹⁰University of Helsinki, Helsinki, Finland. ⁷¹¹University Centre Varazdin, University North, Varazdin, Croatia. ⁷¹²Department of Pharmacology, University of Kelaniya, Ragama, Sri Lanka. ⁷¹³Clinical Medicine Department, Colombo North Teaching Hospital, Ragama, Sri Lanka. ⁷¹⁴Department of Paediatrics, University of Kelaniya, Ragama, Sri Lanka. ⁷¹⁵University Paediatrics Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka. ⁷¹⁶Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA. ⁷¹⁷Northwestern University, Chicago, IL, USA. ⁷¹⁸South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Cape Town, South Africa. ⁷¹⁹Pacific Institute for Research & Evaluation, Beltsville, MD, USA. ⁷²⁰School of Public Health, Curtin University, Perth, Western Australia, Australia. ⁷²¹Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy. ⁷²²Saveetha Dental College and Hospitals, Saveetha University, Chennai, India. ⁷²³International PhD Program in Medicine, Taipei Medical University, Taipei, Taiwan. ⁷²⁴Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan. ⁷²⁵Department of Public Health Dentistry, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India. ⁷²⁶Global Institute of Public Health, Ananthapuri Hospitals and Research Institute, Trivandrum, India. ⁷²⁷National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. ⁷²⁸Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, India. ⁷²⁹Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ⁷³⁰Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, Bhopal, India. ⁷³¹Molecular Biology Unit, Sirius Training and Research Centre, Khartoum, Sudan. ⁷³²Bio-Statistical and Molecular Biology Department, Sirius Training and Research Centre, Khartoum, Sudan. ⁷³³College of Medicine, University of Duhok, Duhok, Iraq. ⁷³⁴Skull Base Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁷³⁵QU Health, Qatar University, Doha, Qatar. ⁷³⁶Internal Medicine Department, Brown University, Providence, RI, USA. ⁷³⁷Internal Medicine Department, King Edward Medical University, Lahore, Pakistan. ⁷³⁸Institute of Clinical Physiology, National Research Council, Pisa, Italy. ⁷³⁹Department of Mathematics, The University of Jordan, Amman, Jordan. ⁷⁴⁰Nonlinear Dynamics Research Center (NDRC), Ajman University, Ajman, United Arab Emirates. ⁷⁴¹Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy. ⁷⁴²Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran. ⁷⁴³Iran University of Medical Sciences, Tehran, Iran. ⁷⁴⁴Department of Epidemiology and Biostatistics, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁷⁴⁵International Laboratory for Air Quality and Health, Queensland University of Technology, Brisbane, Queensland, Australia. ⁷⁴⁶Facultad de Salud, Universidad Santiago de Cali, Santiago de Cali, Colombia. ⁷⁴⁷Department of Health Policy, London School of Economics and Political Science, London, UK. ⁷⁴⁸Department of Surgery and Cancer, Imperial College London, London, UK. ⁷⁴⁹Department of Radiology, University of Tripoli, Tripoli, Libya. ⁷⁵⁰Knowledge Management Department, Prahlad Omkarwati Foundation (POF), Mumbai, India. ⁷⁵¹Changescape Consulting, Independent Consultant, New Delhi, India. ⁷⁵²Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. ⁷⁵³Department of Surgery, General University Hospital of Patras, Patras, Greece. ⁷⁵⁴Faculty of Medicine, University of Thessaly, Larissa, Greece. ⁷⁵⁵Department of Community

and Global Health, The University of Tokyo, Tokyo, Japan. ⁷⁵⁶Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Mexico. ⁷⁵⁷Postgraduate in Medical Sciences, Universidad de Colima, Colima, Mexico. ⁷⁵⁸College of Medicine, Shaqra University, Riyadh, Shaqra, Saudi Arabia. ⁷⁵⁹Department of Pediatrics & Pediatric Pulmonology, Institute of Mother & Child Care, Multan, Pakistan. ⁷⁶⁰Department of Medical Laboratory Technology, University of Tabuk, Tabuk, Saudi Arabia. ⁷⁶¹Prince Fahad bin Sultan Chair for Biomedical Research, University of Tabuk, Tabuk, Saudi Arabia. ⁷⁶²Department of Psychiatry, Seoul National University, Seoul, South Korea. ⁷⁶³Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea. ⁷⁶⁴Department of Computer Science, University of Illinois, Urbana, IL, USA. ⁷⁶⁵Department of Computer Science and IT, Torrens University, Adelaide, South Australia, Australia. ⁷⁶⁶Department Health Services Research, University of Alabama at Birmingham, Birmingham, AL, USA. ⁷⁶⁷Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia. ⁷⁶⁸Heart Failure Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ⁷⁶⁹Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ⁷⁷⁰Department of Health and Rehabilitation Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia. ⁷⁷¹Suraj Eye Institute, Nagpur, India. ⁷⁷²Mysore Medical College and Research Institute, Government Medical College, Mysore, India. ⁷⁷³National Dental Research Institute Singapore, Duke-NUS Medical School, Singapore, Singapore. ⁷⁷⁴Nursing & Midwifery Research Department (NMRD), Hamad Medical Corporation, Doha, Qatar. ⁷⁷⁵Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ⁷⁷⁶Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. ⁷⁷⁷Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ⁷⁷⁸Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia. ⁷⁷⁹Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA. ⁷⁸⁰College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. ⁷⁸¹Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. ⁷⁸²Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka. ⁷⁸³Manipal College of Nursing, Manipal Academy of Higher Education, Manipal, India. ⁷⁸⁴Department of Forensic Medicine, Manipal Academy of Higher Education, Manipal, India. ⁷⁸⁵Department of Anatomy, All India Institute of Medical Sciences, Jodhpur, India. ⁷⁸⁶Department of Health Promotion, Zahedan University of Medical Sciences, Zahedan, Iran. ⁷⁸⁷Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA. ⁷⁸⁸Center for Remote Health Technologies & Systems, Texas A&M University, College Station, TX, USA. ⁷⁸⁹Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁷⁹⁰Department of General Surgery, Emergency University Hospital of Bucharest, Bucharest, Romania. ⁷⁹¹Department of Anatomy and Embryology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁷⁹²Department of Cardiology, Cardio-Aid, Bucharest, Romania. ⁷⁹³Department of Community Medicine, Lumbini Medical College, Palpa, Nepal. ⁷⁹⁴Department of Biological Sciences, University of Embu, Embu, Kenya. ⁷⁹⁵Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, MA, USA. ⁷⁹⁶Department of Medical Engineering, University of South Florida, Tampa, FL, USA. ⁷⁹⁷Faculty of Medicine, Duy Tan University, Da Nang, Vietnam. ⁷⁹⁸Institute for Research and Training in Medicine, Biology and Pharmacy, Duy Tan University, Da Nang, Vietnam. ⁷⁹⁹Hitotsubashi Institute for Advanced Study (HIAS), Hitotsubashi University, Tokyo, Japan. ⁸⁰⁰Institute for Cancer Control, National Cancer Center, Chuo-ku, Japan. ⁸⁰¹Tuberculosis Group, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. ⁸⁰²Department of General Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. ⁸⁰³Health Department, Shiraz University of Medical Sciences, Shiraz, Iran. ⁸⁰⁴Department of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. ⁸⁰⁵Technical Department, University of Cape Town, Cape Town, South Africa. ⁸⁰⁶School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. ⁸⁰⁷Global Research Institute, Keio University, Tokyo, Japan. ⁸⁰⁸Department of Global Health Policy, University of Tokyo, Tokyo, Japan. ⁸⁰⁹Department of Paediatrics, Nnamdi Azikiwe University, Awka, Nigeria. ⁸¹⁰Department of Public Health, Wachemo University, Hossana, Ethiopia. ⁸¹¹Department of Public Health, Banten School of Health Science, South Tangerang, Indonesia. ⁸¹²Ministry of Research, Technology and Higher Education, Higher Education Service Institutions (LL-DIKTI) Region IV, Bandung, Indonesia. ⁸¹³Department of Applied Economics and Quantitative Analysis, University of Bucharest, Bucharest, Romania. ⁸¹⁴Bioinformatics Department, National Institute of Research and Development for Biological Sciences, Bucharest, Romania. ⁸¹⁵Disease Control and Elimination, Medical Research Council Unit, The Gambia, Banjul, The Gambia. ⁸¹⁶Department of Veterinary Public Health and Preventive Medicine, University of Ilorin, Ilorin, Nigeria. ⁸¹⁷PSSM Data Sciences, Pfizer Research & Development, Pfizer Inc., Groton, CT, USA. ⁸¹⁸Department of Pediatrics, University of Jos, Jos, Nigeria. ⁸¹⁹Department of Pediatrics, Jos University Teaching Hospital, Jos, Nigeria. ⁸²⁰Department of Veterinary Public Health and Preventive Medicine, University of Ibadan, Ibadan, Nigeria. ⁸²¹Department of Gynecology and Obstetrics, Emory University, Atlanta, GA, USA. ⁸²²University of Sydney, Sydney, New South Wales, Australia. ⁸²³Department of Food and Nutrition, Seoul National University, Seoul, South Korea. ⁸²⁴College of Medicine, University of Ibadan, Ibadan, Nigeria. ⁸²⁵School of Pharmacy, University of the Western Cape, Cape Town, South Africa. ⁸²⁶Department of Medical Physiology, Babcock University, Ilisan-Remo, Nigeria. ⁸²⁷Department of Medical Physiology, University of Lagos, Lagos, Nigeria. ⁸²⁸Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. ⁸²⁹Department of Psychiatry, University of Lagos, Lagos, Nigeria. ⁸³⁰Department of Nursing Science, Bowen University, Iwo, Nigeria. ⁸³¹Surgery Department, Sulaimani University, Sulaimani, Iraq. ⁸³²ENT Department, Tor Vergata University of Rome, Rome, Italy. ⁸³³Department of Public Health, Ministry of Health, Bandar Seri Begawan, Brunei. ⁸³⁴Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei. ⁸³⁵Department of Pharmacotherapy and Pharmaceutical Care, Medical University of Warsaw, Warsaw, Poland. ⁸³⁶Department of Microbiology and Immunology, University of Health and Allied Sciences, Ho, Ghana. ⁸³⁷Sickle Cell Unit, Ho Teaching Hospital, Ho, Ghana. ⁸³⁸Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz, Madrid, Spain. ⁸³⁹Department of Medicine, Autonomous University of Madrid, Madrid, Spain. ⁸⁴⁰One Health Global Research Group, Universidad de las Americas (University of the Americas), Quito, Ecuador. ⁸⁴¹School of Medicine, Western Sydney University, Bathurst, New South Wales, Australia. ⁸⁴²Department of Optometry and Vision Science, University of KwaZulu-Natal, KwaZulu-Natal, South Africa. ⁸⁴³Faculty of Medicine, University Ferhat Abbas of Setif, Setif, Algeria. ⁸⁴⁴Division of Infectious Diseases, University Hospital of Setif, Setif, Algeria. ⁸⁴⁵Division of Medicine, University College London, London, UK. ⁸⁴⁶Department of Life and Medical Science, University of Hertfordshire, Hatfield, UK. ⁸⁴⁷Department of Respiratory Medicine, Jagadguru Sri Shivarathreeswara University, Mysore, India. ⁸⁴⁸National School of Public Health, Institute of Health Carlos III, Madrid, Spain. ⁸⁴⁹Department of Ophthalmology, Heidelberg University, Heidelberg, Germany. ⁸⁵⁰Centre for Research and Development, Chandigarh University, Punjab, India. ⁸⁵¹Division of Research and Development, Lovely Professional University, Phagwara, India. ⁸⁵²Division of Ophthalmology & Visual Sciences, University of Nottingham, Nottingham, UK. ⁸⁵³School of Medicine - First Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁸⁵⁴Department of Neurology, University of Bern, Bern, Switzerland. ⁸⁵⁵Department of Neurology, University of Cyprus, Nicosia, Cyprus. ⁸⁵⁶Department of Science and Mathematics, Deree-The American College of Greece, Athens, Greece. ⁸⁵⁷Department of Biophysics, University of Athens, Athens, Greece. ⁸⁵⁸Department of Community Medicine, All India Institute of Medical Sciences, Jammu, India. ⁸⁵⁹Division of Health Policy and Management, University of Minnesota, Minneapolis, MN, USA. ⁸⁶⁰Department of Medical Humanities and Social Medicine, Kosin University, Busan, South Korea. ⁸⁶¹Department of Health Policy and Management, Korea University, Seoul, South Korea. ⁸⁶²School of medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ⁸⁶³Department of Medical Sciences, University of Torino, Torino, Italy. ⁸⁶⁴Department of Imaging, AOU Città della Salute e della Scienza di Torino, Torino, Italy. ⁸⁶⁵College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, USA. ⁸⁶⁶Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁸⁶⁷Faculty of

Humanities and Social Sciences, Tribhuvan University, Kathmandu, Nepal. ⁸⁶⁸IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy. ⁸⁶⁹Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. ⁸⁷⁰Center for Research and Innovation, Ateneo De Manila University, Pasig City, Philippines. ⁸⁷¹Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia. ⁸⁷²Social and Economic Survey Research Institute, Qatar University, Doha, Qatar. ⁸⁷³Department of Food, Environmental and Nutritional Sciences, University of Milan, Milano, Italy. ⁸⁷⁴Facultad de Medicina (Faculty of Medicine), Universidad Diego Portales (Diego Portales University), Santiago, Chile. ⁸⁷⁵School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. ⁸⁷⁶Department of Internal Medicine, University of Arizona, Tucson, AZ, USA. ⁸⁷⁷Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. ⁸⁷⁸School of Pharmacy, University of Nizwa, Nizwa, Oman. ⁸⁷⁹College of Health Sciences (CHS), VinUniversity, Hanoi, Vietnam. ⁸⁸⁰Clinical Academic Department of Pediatrics, University Medical Center (UMC), Astana, Kazakhstan. ⁸⁸¹Department of Medical and Surgical Oncology, Miami Cancer Institute, Miami, FL, USA. ⁸⁸²University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁸⁸³Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia. ⁸⁸⁴Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA. ⁸⁸⁵Department of Biochemistry, Jagadguru Sri Shivarathreeswara University, Mysuru, India. ⁸⁸⁶Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA. ⁸⁸⁷Sulaimaniya Research Center, Cihan University, Sulaymaniyah, Iraq. ⁸⁸⁸Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan. ⁸⁸⁹The Second Hospital of Hebei Medical University, The Second Hospital of Hebei Medical University, Shijiazhuang, China. ⁸⁹⁰The First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China. ⁸⁹¹Department of Community Medicine, ESI Post Graduate Institute of Medical Science and Research, Bengaluru, India. ⁸⁹²Department of Medical Oncology, Cancer Institute (WIA), Chennai, India. ⁸⁹³Department of Immunology, Mazandaran University of Medical Sciences, Sari, Iran. ⁸⁹⁴Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran. ⁸⁹⁵Department of Biostatistics and Epidemiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ⁸⁹⁶Department of Epidemiology, Iran University of Medical Sciences, Tehran, Iran. ⁸⁹⁷Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh. ⁸⁹⁸College of Medicine and Health Sciences, National University of Science and Technology, Sohar, Oman. ⁸⁹⁹Institute of Health and Wellbeing, Federation University Australia, Berwick, Victoria, Australia. ⁹⁰⁰Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁹⁰¹Dr Rajendra Prasad Government Medical College, Tanda, Dr Rajendra Prasad Government Medical College, Tanda, Kangra, India. ⁹⁰²Department of Community Medicine, Employees' State Insurance Model Hospital, Chennai, India. ⁹⁰³Department of Community and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, India. ⁹⁰⁴Centre for Chronic Disease Control, New Delhi, India. ⁹⁰⁵Department of Cardiology, Mansoura University, Mansoura, Egypt. ⁹⁰⁶Department of Anatomy, Govt Siddhartha Medical College, Vijayawada, India. ⁹⁰⁷Department of Radiology, Stanford University, Stanford, CA, USA. ⁹⁰⁸School of Nursing & Health Sciences, Hong Kong Metropolitan University, Hong Kong, China. ⁹⁰⁹Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. ⁹¹⁰Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁹¹¹Translational Health Research Institute, Western Sydney University, Sydney, New South Wales, Australia. ⁹¹²Department of Research, Eastern Scientific LLC, Richmond, KY, USA. ⁹¹³Planetary Health Research Centre (PHRC), Kathmandu, Nepal. ⁹¹⁴Centre for Clinical Pharmacology, University of Defence in Belgrade, Belgrade, Serbia. ⁹¹⁵Centre for Clinical Pharmacology, Medical College of Georgia at Augusta University, Belgrade, Serbia. ⁹¹⁶Department of Health Innovation, Manipal Academy of Higher Education, Udipi, India. ⁹¹⁷Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India. ⁹¹⁸Iranian Research Center on Aging, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. ⁹¹⁹Department of Research, Baylor Scott and White Research Institute, Dallas, TX, USA. ⁹²⁰Baylor University, Dallas, TX, USA. ⁹²¹Department of Family Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka. ⁹²²Department of Primary Care and Public Health, Imperial College London, London, UK. ⁹²³Academic Public Health England, Public Health England, London, UK. ⁹²⁴School of Health, Medical and Applied Sciences, CQ University, Sydney, New South Wales, Australia. ⁹²⁵Department of Biological Sciences, King Abdulaziz University, Jeddah, Egypt. ⁹²⁶Department of Protein Research, Research and Academic Institution, Alexandria, Egypt. ⁹²⁷Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ⁹²⁸Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan. ⁹²⁹Unisabana Center for Translational Science, Universidad de La Sabana (Savannah University), Chia, Colombia. ⁹³⁰Critical Care Department, Clinica Universidad De La Sabana (Savannah University Clinic), Chia, Colombia. ⁹³¹Department of Epidemiology and Biostatistics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ⁹³²Community Health Department, Federal University of Ceará, Fortaleza, Brazil. ⁹³³Department of Nursing in Women's Health, Federal University of São Paulo, São Paulo, Brazil. ⁹³⁴Vaccination Research Observatory, Federal University of Minas Gerais, Belo Horizonte, Brazil. ⁹³⁵Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia. ⁹³⁶Warwick Medical School, University of Warwick, Coventry, UK. ⁹³⁷Department of Clinical Research, University of São Paulo, Ribeirão Preto, Brazil. ⁹³⁸Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon. ⁹³⁹Department of Community Medicine, Government Medical College, Chandigarh, India. ⁹⁴⁰Department of Immunology, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. ⁹⁴¹Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran. ⁹⁴²Miyam Research Institute, Miyam Research Institute, International University of Business Agriculture and Technology, Dhaka, Bangladesh. ⁹⁴³Department of Analytical and Applied Economics, Utkal University, Bhubaneswar, India. ⁹⁴⁴RUSA Centre of Excellence in Public Policy and Governance, Utkal University, Bhubaneswar, India. ⁹⁴⁵Department of Biochemistry and Food Analysis, Patuakhali Science and Technology University, Patuakhali, Bangladesh. ⁹⁴⁶Department of Labour, Directorate of Factories, Government of West Bengal, Kolkata, India. ⁹⁴⁷Research Department, Indian Institute of Public Health, Delhi, India. ⁹⁴⁸Department of Epidemiology, Florida International University, Miami, FL, USA. ⁹⁴⁹Department of Critical Care Anesthesiology, University of Alabama Birmingham, Birmingham, AL, USA. ⁹⁵⁰Department of Population and Health, University of Cape Coast, Cape Coast, Ghana. ⁹⁵¹Department of Medical Pharmacology, Cairo University, Giza, Egypt. ⁹⁵²Department of Biology, University of Hail, Hail, Saudi Arabia. ⁹⁵³Operational Research Center in Healthcare, Near East University (NEU), Nicosia Cyprus, Turkey. ⁹⁵⁴International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan. ⁹⁵⁵Department of Nursing and Midwifery, Saveh University of Medical Sciences, Saveh, Iran. ⁹⁵⁶Department of Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁹⁵⁷Clinical Research Development Center (CRDC), Qom University of Medical Sciences, Qom, Iran. ⁹⁵⁸Department of Psychosocial Science, University of Bergen, Bergen, Norway. ⁹⁵⁹Sharjah Institute of Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ⁹⁶⁰Center for Global Health Research, Saveetha University, Chennai, India. ⁹⁶¹Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ⁹⁶²Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bathinda, India. ⁹⁶³Department of Nutrition and Dietetics, Cihan University-Erbil, Erbil, Iraq. ⁹⁶⁴Department of Health and Kinesiology, University of Illinois, Urbana-Champaign, IL, USA. ⁹⁶⁵Department of Statistics, University of Gujrat, Gujrat, Pakistan. ⁹⁶⁶Department of Integrated Health Education, Federal University of Espirito Santo, Vitória, Brazil. ⁹⁶⁷Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. ⁹⁶⁸Department of Biochemistry, University of Medical Sciences, Ondo, Ondo City, Nigeria. ⁹⁶⁹Surgical Department, North Colombo Teaching Hospital, Ragama, Sri Lanka. ⁹⁷⁰Department of Community Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. ⁹⁷¹Pre-Clinical Affairs, College of Nursing, QU Health Sector, Qatar University, Lusail, Qatar. ⁹⁷²Department of Entomology, Ain Shams University, Cairo, Egypt. ⁹⁷³Medical Ain Shams Research Institute (MASRI), Ain

Shams University, Cairo, Egypt. ⁹⁷⁴Department of Microbiology, Saveetha University, Chennai, India. ⁹⁷⁵School of Public Health and Health Management, University of Belgrade, Belgrade, Serbia. ⁹⁷⁶Department of Infectious Diseases and Tropical Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. ⁹⁷⁷Indira Gandhi Medical College and Research Institute, Puducherry, India. ⁹⁷⁸Department of Oral Pathology and Microbiology, Dr D. Y. Patil Vidyapeeth, Pune (Deemed to be University), Pune, India. ⁹⁷⁹Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. ⁹⁸⁰Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK. ⁹⁸¹Department of Medicine, Bangalore Medical College and Research Institute, Bangalore, India. ⁹⁸²UGC Centre of Advanced Study in Psychology, Utkal University, Bhubaneswar, India. ⁹⁸³Udyam-Global Association for Sustainable Development, Bhubaneswar, India. ⁹⁸⁴Department of Medical Informatics, Kagawa University, Miki-cho, Japan. ⁹⁸⁵Food Processing and Nutrition, Karnataka State Akkamahadevi Women's University, Vijayapura, India. ⁹⁸⁶Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA. ⁹⁸⁷Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. ⁹⁸⁸National Centre for Epidemiology and Population Health, Australian National University, Acton, Australian Capital Territory, Australia. ⁹⁸⁹Faculty of Business and Computing, University of the Fraser Valley, Abbotsford, British Columbia, Canada. ⁹⁹⁰Department of Finance, International School of Management, Paris, France. ⁹⁹¹Department of Physiotherapy, Federal University of Santa Catarina, Araranguá, Brazil. ⁹⁹²Department of Microbiology, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁹⁹³Dr D. Y. Patil Dental College & Hospital, Dr D. Y. Patil Vidyapeeth, Pune (Deemed to be University), Pune, India. ⁹⁹⁴Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia. ⁹⁹⁵School of Pharmacy, Curtin University, Perth, Western Australia, Australia. ⁹⁹⁶Department of Biomedical Sciences, Gulf Medical University, Ajman, United Arab Emirates. ⁹⁹⁷Fourth Department of General Surgery, Emergency University Hospital Bucharest, Bucharest, Romania. ⁹⁹⁸Department of Medicine, Swami Vivekanand Subharti University, Meerut, India. ⁹⁹⁹Division of Population Medicine, Cardiff University, Cardiff, UK. ¹⁰⁰⁰Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰⁰¹Dongguan Key Laboratory of Computer-Aided Drug Design, Guangdong Medical University, Dongguan, China. ¹⁰⁰²State Key Laboratories of Chemical Resources Engineering, Beijing University Of Chemical Technology, Beijing, China. ¹⁰⁰³School of Health Sciences, Universiti Sains Malaysia (University of Science Malaysia), Kota Bharu, Malaysia. ¹⁰⁰⁴Research Centre for Health Sciences (RCHS), The University of Lahore, Lahore, Pakistan. ¹⁰⁰⁵Center for Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates. ¹⁰⁰⁶Independent Consultant, Karachi, Pakistan. ¹⁰⁰⁷School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. ¹⁰⁰⁸Department of Pathobiology, Shahid Bahonar University of Kerman, Kerman, Iran. ¹⁰⁰⁹Science Department, Kazakh National Medical University, Almaty, Kazakhstan. ¹⁰¹⁰Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia. ¹⁰¹¹Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University of Groningen, Groningen, The Netherlands. ¹⁰¹²Department of Safety Services, Baim Institute for Clinical Research, Boston, MA, USA. ¹⁰¹³Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA. ¹⁰¹⁴Department for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria. ¹⁰¹⁵Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰¹⁶Department of Social and Behavioral Health, University of Nevada Las Vegas, Las Vegas, NV, USA. ¹⁰¹⁷Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India. ¹⁰¹⁸Yenepoya Research Center, Yenepoya University, Mangalore, India. ¹⁰¹⁹Department of Pharmacology, Manipal Academy of Higher Education, Manipal, India. ¹⁰²⁰Department of Biology, Morgan State University, Baltimore, MD, USA. ¹⁰²¹Department of Environmental Health Sciences, Tulane University, New Orleans, LA, USA. ¹⁰²²Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Mangalore, India. ¹⁰²³Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, Mangalore, India. ¹⁰²⁴Department of Public Health, Dambi Dollo University, Dembi Dollo, Ethiopia. ¹⁰²⁵Department of Epidemiology, Jimma University, Jimma, Ethiopia. ¹⁰²⁶National Institute of Infectious Diseases, Tokyo, Japan. ¹⁰²⁷Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Sokoto, Nigeria. ¹⁰²⁸Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ¹⁰²⁹Center for Technology and Innovation in Cardiovascular Informatics, Iran University of Medical Sciences, Tehran, Iran. ¹⁰³⁰Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰³¹Department of Research and Academics, Kathmandu Cancer Center, Bhaktapur, Nepal. ¹⁰³²Monash University, Box Hill, Victoria, Australia. ¹⁰³³Melbourne School of Population & Global Health, University of Melbourne, Melbourne, Victoria, Australia. ¹⁰³⁴Unit of Basic Medical Sciences, University of Khartoum, Khartoum, Sudan. ¹⁰³⁵Department of Medical Microbiology and Infectious Diseases, Erasmus University, Rotterdam, The Netherlands. ¹⁰³⁶Department of Physiotherapy, Galgotias University, Greater Noida, India. ¹⁰³⁷Galgotias Multidisciplinary Research & Development Cell, Galgotias University, Greater Noida, India. ¹⁰³⁸Sport Physical Activity and Health Research & Innovation Center (SPRINT), Polytechnic Institute of Guarda, Guarda, Portugal. ¹⁰³⁹CICS-UBI Health Sciences Research Center, University of Beira Interior, Covilhã, Portugal. ¹⁰⁴⁰Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India. ¹⁰⁴¹Department of Biochemistry, Central University of Punjab, Bathinda, India. ¹⁰⁴²Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India. ¹⁰⁴³School of Medicine, Baylor College of Medicine, Houston, TX, USA. ¹⁰⁴⁴Department of Medicine Service, US Department of Veterans Affairs (VA), Houston, TX, USA. ¹⁰⁴⁵Research Department, Hamad Medical Corporation, Doha, Qatar. ¹⁰⁴⁶Department of Internal Medicine, University of Indonesia, Jakarta Pusat, Indonesia. ¹⁰⁴⁷Department of Internal Medicine, Dr Cipto Mangunkusumo National Hospital, Jakarta Pusat, Indonesia. ¹⁰⁴⁸Department of Infectious Diseases and Epidemiology, Pirogov Russian National Research Medical University, Moscow, Russia. ¹⁰⁴⁹Department of Infectious Diseases, Kharkiv National Medical University, Kharkiv, Ukraine. ¹⁰⁵⁰Clinical Science Line, Ludwig Boltzmann Institute of Osteologie, Vienna, Austria. ¹⁰⁵¹Department of Biochemistry, American University of Integrative Sciences, Bridgetown, Barbados. ¹⁰⁵²Faculty of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia. ¹⁰⁵³Department of Medicinal Chemistry, University of Sharjah, Sharjah, United Arab Emirates. ¹⁰⁵⁴Department of Endocrinology, Case Western Reserve University, Cleveland, OH, USA. ¹⁰⁵⁵Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran. ¹⁰⁵⁶School of Medicine, Babol University of Medical Sciences, Babol, Iran. ¹⁰⁵⁷Department of Global Health, University of Washington, Seattle, WA, USA. ¹⁰⁵⁸Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (Autonomous University of Madrid), Madrid, Spain. ¹⁰⁵⁹Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain. ¹⁰⁶⁰Hull York Medical School, University of Hull, Hull City, UK. ¹⁰⁶¹3rd Department of Cardiology, University of Athens, Athens, Greece. ¹⁰⁶²Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. ¹⁰⁶³Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. ¹⁰⁶⁴Occupational and Environmental Medicine Department, University of Gothenburg, Gothenburg, Sweden. ¹⁰⁶⁵Department of Medical Sciences, Sunway University, Subang Jaya, Malaysia. ¹⁰⁶⁶Institute of Integrated Intelligence and Systems, Griffith University, Brisbane, Queensland, Australia. ¹⁰⁶⁷Department of Biomedical Sciences, Universiti Putra Malaysia, Selangor, Malaysia. ¹⁰⁶⁸Department of Neurology, King George's Medical University, Lucknow, India. ¹⁰⁶⁹Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland. ¹⁰⁷⁰Collegium Medicum, John Paul II Catholic University of Lublin, Lublin, Poland. ¹⁰⁷¹Department of Medical Informatics, Mashhad University of Medical Sciences, Mashhad, Iran. ¹⁰⁷²Clinical Research Development Unit, Mashhad University of Medical Sciences, Mashhad, Iran. ¹⁰⁷³Department of Basic Medical Sciences, Islamic Azad University, Mashhad, Iran. ¹⁰⁷⁴Department of Internal Medicine, Islamic Azad University, Mashhad, Iran. ¹⁰⁷⁵Centre for Global Health Research, Saveetha University, Chennai, India. ¹⁰⁷⁶Department of Pathology and Immunology, Washington University in St Louis, St Louis, MO, USA. ¹⁰⁷⁷Living Systems Institute, University of Exeter, Exeter, UK. ¹⁰⁷⁸Department of Environmental, Agricultural and Occupational Health, University of Nebraska Medical Center, Omaha, NE, USA. ¹⁰⁷⁹Sri Ramachandra Medical College and Research Institute, Chennai, India.

¹⁰⁸⁰Department of Pathology, Alexandria University, Alexandria, Egypt. ¹⁰⁸¹Department of Epidemiology, Stellenbosch University, Cape Town, South Africa. ¹⁰⁸²Department of Medicine, Northlands Medical Group, Omuthiya, Namibia. ¹⁰⁸³Department of Surgery, National University of Singapore, Singapore, Singapore. ¹⁰⁸⁴Taking Our Best Shot, Houston, TX, USA. ¹⁰⁸⁵Department of Research and Innovation, Enventure Medical Innovation, Houston, TX, USA. ¹⁰⁸⁶Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰⁸⁷Public Health, Debre Markos University, Debre Markos, Ethiopia. ¹⁰⁸⁸Department of Nursing, Bahir Dar University, Bahir Dar, Ethiopia. ¹⁰⁸⁹Public Health Department, Amrita Institute of Medical Sciences, Kochi, India. ¹⁰⁹⁰Department of Obstetrics and Gynecology, St John's National Academy of Health Sciences, Miami, FL, USA. ¹⁰⁹¹Department of Family and Preventive Medicine, Emory University, Atlanta, GA, USA. ¹⁰⁹²Department of Physiology, All India Institute of Medical Sciences, New Delhi, India. ¹⁰⁹³Systems Neuroscience, Tohoku University, Sendai, Japan. ¹⁰⁹⁴Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India. ¹⁰⁹⁵Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland. ¹⁰⁹⁶Agency for Health Technology Assessment and Tariff System, Warsaw, Poland. ¹⁰⁹⁷School of Medicine, Indiana University, Indianapolis, IN, USA. ¹⁰⁹⁸School of Biomedical Engineering, University of Technology, Sydney, Sydney, New South Wales, Australia. ¹⁰⁹⁹Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan. ¹¹⁰⁰Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. ¹¹⁰¹Department of Business Analytics, University of Massachusetts Dartmouth, Dartmouth, MA, USA. ¹¹⁰²Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. ¹¹⁰³Department of Health Sciences, University of Leicester, Leicester, UK. ¹¹⁰⁴Adult Learning Disability Service, Leicestershire Partnership National Health Service Trust, Leicester, UK. ¹¹⁰⁵Faculty of Medicine, Tan Tao University, Long An, Vietnam. ¹¹⁰⁶Department of Internal Medicine, Wake Forest University, Winston-Salem, NC, USA. ¹¹⁰⁷Department of Biosciences and Biotechnology, University of Medical Sciences, Ondo, Ondo, Nigeria. ¹¹⁰⁸Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman. ¹¹⁰⁹Institute of Public Health and Social Sciences (IPH&SS), Khyber Medical University, Peshawar, Pakistan. ¹¹¹⁰International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. ¹¹¹¹Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria. ¹¹¹²School of Government, Pontificia Universidad Católica de Chile (Pontifical Catholic University of Chile), Santiago, Chile. ¹¹¹³Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, National Institute of Health, Rome, Italy. ¹¹¹⁴Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India. ¹¹¹⁵Section of Advanced Heart Failure and Transplant Cardiology, Mayo Clinic, Rochester, MN, USA. ¹¹¹⁶Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium. ¹¹¹⁷UKK Institute, Tampere, Finland. ¹¹¹⁸Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ¹¹¹⁹Department of Zoology, Central University of Punjab, Bathinda, India. ¹¹²⁰Department of Human Genetics & Molecular Biology, Bharathiar University, Coimbatore, India. ¹¹²¹Department of Surgery, University of Southampton, Southampton, UK. ¹¹²²College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. ¹¹²³Department of Biomedical Sciences for Health, University of Milan, Milano, Italy. ¹¹²⁴Department of Physiotherapy, Universidad Europea de Madrid (European University of Madrid), Villaviciosa de Odón, Spain. ¹¹²⁵Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ¹¹²⁶Occupational Medicine Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy. ¹¹²⁷College of Agriculture, Northwest A&F University, Xianyang City, China. ¹¹²⁸School of Life Course and Population Sciences, King's College London, London, UK. ¹¹²⁹Faculty of Sciences, The University of Lahore, Lahore, Pakistan. ¹¹³⁰Key Laboratory of Computer-Aided Drug Design, Guangdong Medical University, Dongguan, China. ¹¹³¹Department of Biotechnology and Genetic Engineering, Hazara University Mansehra, Mansehra, Pakistan. ¹¹³²Competence Center of Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany. ¹¹³³Department of Medical Surgical Nursing, Gadjah Mada University, Yogyakarta, Indonesia. ¹¹³⁴Department of Surgery, University of Colombo, Colombo, Sri Lanka. ¹¹³⁵Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University Innsbruck, Innsbruck, Austria. ¹¹³⁶Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ¹¹³⁷Department of Research, Cancer Registry of Norway, Oslo, Norway. ¹¹³⁸Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway. ¹¹³⁹Department of Emergency Medicine and Critical Care Nursing, Bahir Dar University, Bahir Dar, Ethiopia. ¹¹⁴⁰Western Institute of Digital-Intelligent Medicine, Chongqing Medical University, Chongqing, China. ¹¹⁴¹School of Public Health, Xuzhou Medical University, Xuzhou, China. ¹¹⁴²Cardiovascular Program, The George Institute for Global Health, Sydney, New South Wales, Australia. ¹¹⁴³School of Medicine, Kunming University of Science and Technology, Kunming, China. ¹¹⁴⁴Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Macquarie Park, NSW, Australia. ¹¹⁴⁵Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. ¹¹⁴⁶Faculty of Medicine, Juntendo University, Tokyo, Japan. ¹¹⁴⁷Department of Biostatistics and Data Science, Osaka University, Suita, Japan. ¹¹⁴⁸The George Institute for Global Health, Imperial College London, London, UK. ¹¹⁴⁹National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. ¹¹⁵⁰The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. ¹¹⁵¹Biostatistics, Epidemiology, and Science Computing Department, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. ¹¹⁵²Department of Biostatistics, University of Toyama, Toyama, Japan. ¹¹⁵³Department of Public Health, Juntendo University, Tokyo, Japan. ¹¹⁵⁴Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. ¹¹⁵⁵Internal Medicine Department, Arkansas Department of Health, Greenville, TX, USA. ¹¹⁵⁶Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China. ¹¹⁵⁷Faculty of Medicine and Health Sciences, Hodeidah University, Hodeidah, Yemen. ¹¹⁵⁸Department of Computer Science and Software Engineering, United Arab Emirates University, Al Ain, United Arab Emirates. ¹¹⁵⁹Department of Bioengineering and Therapeutical Sciences, University of California, San Francisco, San Francisco, CA, USA. ¹¹⁶⁰Department of Administration, PG&AI, San Francisco, CA, USA. ¹¹⁶¹College of Pharmacy, Department of Clinical Practice, Northern Border University, Rafha, Saudi Arabia. ¹¹⁶²Pharmacy Practice Department, Hodeidah University, Hodeidah, Yemen. ¹¹⁶³School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China. ¹¹⁶⁴School of Public Health, Wuhan University of Science and Technology, Wuhan, China. ¹¹⁶⁵Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China. ¹¹⁶⁶School of Public Health, Wuhan University, Wuhan, China. ¹¹⁶⁷School of Global Health, Shanghai Jiao Tong University, Shanghai, China. ¹¹⁶⁸National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China. ¹¹⁶⁹Harvard Medical School, Harvard University, Boston, MA, USA. ¹¹⁷⁰Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. ¹¹⁷¹School of Medicine, Stanford University, Palo Alto, CA, USA. ¹¹⁷²School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China. ¹¹⁷³Atchabarov Scientific-Research Institute of Fundamental and Applied Medicine, Kazakh National Medical University, Almaty, Kazakhstan. ¹¹⁷⁴Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹¹⁷⁵Institute of Public Health and Social Sciences, Khyber Medical University, Peshawar, Pakistan. ¹¹⁷⁶Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Warsaw, Poland. ¹¹⁷⁷College of Medicine, Sulaiman Alrajhi University, Al Bukayriyah, Saudi Arabia. ¹¹⁷⁸Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. ¹¹⁷⁹Clinical Research Centre, An-Najah National University Hospital, Nablus, Palestine.

Methods

Overview

The GBD 2023 provides an updated assessment of the burden of 375 diseases and injuries and 88 risk factors in 204 countries and territories between 1990 and 2023⁴. As part of the GBD Collaborative Network, this study evaluates the chronic respiratory disease estimates of GBD 2023 by age, sex, location, year, and SDI and presents the potential policy impact of the estimates. This study followed the guidelines for accurate and transparent health estimate reporting (GATHER) statements (Supplementary Table 2). Detailed descriptions of the methodology and statistical codes for the GBD estimation can be found elsewhere^{4,38}. Below, we provide a comprehensive summary of the relevant methods, which are based on the standardized framework outlined in the official publication of GBD 2023.

Case definition and input data

For chronic respiratory diseases, GBD 2023 produced estimates for four categories: COPD, asthma, pneumoconiosis, and ILD and pulmonary sarcoidosis^{2,3}. COPD is defined in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria^{4,36}. Asthma is a chronic respiratory condition induced by allergic reactions or hypersensitivity that results in bronchial spasms and breathing difficulties. Pneumoconiosis is a chronic lung disease that results from lung scarring and interstitial damage caused by prolonged exposure to dust and other contaminants; GBD 2023 estimated pneumoconiosis by incorporating diagnoses of specific conditions such as silicosis, asbestosis, silicosis, coal workers' pneumoconiosis, and other related diseases. ILD and pulmonary sarcoidosis encompass various chronic respiratory conditions that affect lung function and oxygen absorption owing to scarring and/or inflammation. The definition provided by the American Thoracic Society for ILD is the gold standard. In addition to the chronic respiratory disease discussed earlier, there are other chronic respiratory diseases and their associated complications.

For data processing and quality control, outlier criteria were applied to ensure reliability across data sources. Data points were excluded if they (1) were implausibly high or low, (2) clearly conflicted with established age or temporal patterns, or (3) substantially conflicted with other data sources from the same or similar locations, as determined by the SDI. Further details, including International Classification of Diseases (ICD) codes for each disease, are provided in the Supplementary Table 3⁴.

Classification of geographic locations

GBD produced estimates for territories of 204 countries, grouped into 21 regions and 7 super regions. The seven super-regions are Central Europe, Eastern Europe, and Central Asia; high-income; Latin America and the Caribbean; North Africa and the Middle East; South Asia; Southeast Asia, East Asia, and Oceania; and Sub-Saharan Africa. The twenty-one GBD regions include East Asia, Oceania, Southeast Asia, Central Asia, Central Europe, Eastern Europe, Australasia, High-income Asia Pacific, High-income North America, Southern Latin America, Western Europe, Andean Latin America, Caribbean, Central Latin America, Tropical Latin America, North Africa and the Middle East, South Asia, Central sub-Saharan Africa, Eastern sub-Saharan Africa, Southern sub-Saharan Africa, and Western sub-Saharan Africa. Countries corresponding to each GBD super region and region are shown in the Supplementary Table 4.

Non-fatal estimates

GBD 2023 used population-representative surveys, small-scale prevalence studies identified through systematic literature reviews, and hospital-based data sources to derive the non-fatal estimates of chronic respiratory diseases³⁹. To integrate these diverse data sources and generate consistent estimates across sex, location, year, and age groups, DisMod-MR 2.1 was employed. This Bayesian meta-regression tool

integrates epidemiological information from various sources using a differential equation framework, ensuring internal consistency among key metrics such as prevalence, incidence, remission, and mortality³⁹.

The modeling process for GBD 2023 incorporated adjustments for disability weights and the complications of sequelae, enabling more refined and comprehensive estimates for chronic respiratory diseases^{2,3}. Specifically, non-fatal estimates for COPD were determined by integrating spirometry-based studies and data reflecting severity distributions and applying correction factors for case definitions based on bronchodilator use, as well as incorporating prior estimates of excess mortality informed by healthcare access and quality indices through MR-BRT models. Asthma estimates were refined by incorporating additional data from 81 new geographies, thereby enhancing bias adjustment for heterogeneous case definitions. Additionally, pneumoconiosis estimates were improved by including occupational exposure covariates, and ILD and pulmonary sarcoidosis estimates were enhanced through the application of MEPS-derived severity distributions and differentiation between narrow and broad case definitions based on ICD coding⁴. Moreover, DisMod-MR 2.1 generated estimates across five levels of the GBD geographic hierarchy and produces estimates for locations lacking raw epidemiological data⁴¹. In GBD 2023, model inputs were further refined by replacing internal correction factors with externally applied adjustments through MR-BRT, and by increasing the minimum prior uncertainty (coefficient of variation raised from 0.4 to 0.8) to better capture true variance across heterogeneous data sources.

Mortality estimates

The modeling framework for mortality estimation is described briefly below with further detail provided in the summary cause of death publication for GBD 2023³⁶. The cause-of-death ensemble model (CODEm) was used to simulate the majority of cause-of-death estimates for illnesses and injuries. CODEm tests covariate combinations based on out-of-sample performance metrics and integrates them into an ensemble to estimate mortality by cause, location, age, sex, and year⁴². To address heterogeneity in data availability and quality, CODEm was run separately for each sex, incorporating covariates related to health system performance, data completeness, and socioeconomic development to account for differences across locations, thereby reducing the propagation of uncertainty³⁹. This methodology adheres to ICD-9 and 10, attributing each mortality to the underlying cause and initiating the chain of events leading to mortality^{2,3}. Chronic respiratory disease mortality estimates are post-processed through the CoDCorrect algorithm, which scales these estimates to align with the all-cause mortality envelope to ensure internal consistency. In GBD 2023, improved noise-reduction algorithms and expanded outlier-detection procedures were applied to enhance data quality, including more rigorous filtering based on implausible age patterns, abrupt year-on-year fluctuations, and inter-source inconsistencies³⁶.

The mortality estimates are derived primarily from vital registration and surveillance data, with verbal autopsy information being integrated into the overall disease model. Covariate inclusion was optimized based on the predictive validity of each model, and the level and expected direction of effect for each covariate were assessed systematically across causes and age-sex groups³⁶. Specific considerations for each disease are as follows: for COPD, covariates such as cumulative smoking, indoor and outdoor air pollution, and altitude are incorporated, and verbal autopsy were refined using updated redistribution algorithms before integration, and high-resolution exposure maps were applied to enhance spatial granularity; for asthma, sex-specific models account for bias adjustments related to case definitions and include relevant covariates such as cumulative smoking and healthcare access and quality index, which were updated using new MR-BRT-based exposure transformations; for pneumoconiosis, separate models are developed for the overall condition and for individual subtypes

(for example, silicosis, asbestosis, and coal worker's pneumoconiosis), incorporating additional covariates that reflect occupational exposure, including per capita asbestos consumption and coal production, were incorporated at higher resolution; and for ILD and pulmonary sarcoidosis, sex-specific models integrate relevant covariates—including smoking prevalence, cumulative smoking, indoor and outdoor air pollution, and altitude—while incorporating MR-BRT-based crosswalk adjustments to harmonize narrow and broad case definitions derived from ICD coding, with final estimates aligned to the all-cause mortality envelope using CoDCorrect and refined through enhanced noise filtering and verbal autopsy redistribution procedures³⁶.

DALY estimates

DALYs are the primary measures of total health loss due to fatal and non-fatal disease burdens, allowing comparisons across diseases and injuries³⁹. To estimate DALYs for GBD 2023, years of life lost (YLLs) were combined with years lived with disability (YLDs) across age-sex-location groups for each year considered⁴. YLLs were calculated by multiplying the global standard life expectancy at the time of death by the number of deaths per 100,000 population. To estimate YLDs, the combined frequency and duration of an illness or injury are weighted by a disability weight, a measure of disease severity that ranges from 0 (full health) to 1 (fatal severity). Consequently, DALYs, calculated as the total of YLLs and YLDs, quantify the equivalent of one lost year of healthy life per DALY for a population. To account for uncertainty, 250 draws were generated by summing the matched draws of YLLs and YLDs (for example, the first draw of each, the second draw of each, and so on), and 95% UIs were defined as the 2.5th and 97.5th values from the ordered distribution of these draws⁴³.

Risk factor analysis

The GBD 2023 Comparative Risk Assessment framework was used to quantify the attributable burden of chronic respiratory diseases^{8,38,42}. GBD risk factors are categorized into a four-level hierarchy, from broad categories (behavioral, environmental/occupational, and metabolic) at level 1 to specific categories (for example, PM_{2.5} pollution) at level 4 (refs. 4,38).

Theoretical minimum risk exposure level (TMREL) is defined in the GBD study as the ideal population exposure level with the lowest risk and served as the benchmark for calculating attributable burden. In GBD 2023, TMREs were specified as uniform distributions to account for scientific uncertainty, and mediation analyses were more extensively integrated to improve the estimation of overlapping risk pathways. The modeling process included the following steps: (1) estimating the relative risk (RR) for potential risk-outcome pairs through a comprehensive analysis of previously published studies, (2) estimating exposure levels using population-based datasets and modeled estimates for missing data, (3) defining TMREL based on epidemiological evidence, (4) calculating the population attributable fraction (PAF) using exposure data and RR, considering latency periods for risk factors with delayed effects on health outcomes, (5) adjusting disease prevalence or mortality data by incorporating RR, and applying the PAF to estimate the attributable burden, and (6) combining multiple risk factors using a multiplicative PAF approach while incorporating mediation analysis to account for overlapping pathways and interactions. To address data heterogeneity and uncertainty, the MR-BRT model was applied, providing refined estimates for risk-outcome relationships³⁸. The selection of risk-outcome pairs was established based on the presence of strong or probable evidence, evaluated according to the methods and criteria set by the World Cancer Research Fund⁴, availability of exposure data, feasibility of behavioral changes, and public health relevance.

For each disease, risk factors for chronic respiratory diseases were estimated differently. For COPD, eight factors were identified: ambient ozone pollution; PM_{2.5} pollution; smoking; secondhand smoke;

occupational exposure to particulate matter, gases, fumes; household air pollution from solid fuels; and high and low temperatures. Six factors were identified for asthma: high BMI, smoking, occupational asthma, secondhand smoke, childhood sexual abuse and nitrogen dioxide (NO₂) pollution. Pneumoconiosis is associated with three factors: occupational exposure to asbestos, silica, and particulate matter, gases, and fumes. No risk factors for ILD or pulmonary sarcoidosis were identified^{4,38}.

For COPD, ambient ozone pollution was quantified using satellite remote sensing data (for example, from European Centre for Medium-Range Weather Forecasts Reanalysis version 5 (ERA5)) combined with ground-based measurements, whereas PM_{2.5} pollution estimates were derived from a fusion of ground monitor observations, reanalysis products and chemical transport model simulations, with updated inputs from satellite-based land-use regression models and enhanced resolution rasters. Smoking and secondhand smoke exposures were assessed through nationally representative surveys and vital registration data, with adjustments for self-report bias and temporal trends implemented using MR-BRT methods. Occupational exposures to particulate matter, gases, and fumes were characterized using International Labour Organization data and industry-specific exposure assessments, and household air pollution from solid fuels was estimated based on data from sources like the WHO Household Energy Database, Demographic and Health Surveys, and Living Standards Measurement Surveys. Exposure to high and low ambient temperatures was determined using ERA5 reanalysis data in combination with high-resolution population data from WorldPop to capture deviations from the TMREL, with additional uncertainty modeling applied to temperature-attributable burden estimation. For asthma, BMI was estimated using a global survey series and systematic literature reviews, whereas NO₂ pollution exposure was generated by integrating satellite-based measurements with ground monitoring data and chemical transport model outputs; GBD 2023 incorporated updated global NO₂ exposure rasters based on land-use regression and chemical transport models. Secondhand smoke and childhood sexual abuse were newly classified as risk factors for asthma in the GBD 2023 iteration, reflecting the expanding epidemiological evidence on psychosocial and environmental determinants of disease burden. For pneumoconiosis, the risk was primarily attributed to occupational exposures to asbestos, silica, and other particulate matter, gases, and fumes—derived from mesothelioma mortality data, CARcinogen EXposure databases, and International Labour Organization occupational exposure information³⁸.

Disease burden in pre-COVID-19 and pandemic periods

To investigate temporal trends before (2010–2019) and during (2020–2023) the pandemic, we calculated the AAPC for each disease^{44,45}. AAPC is a summary measure derived from the APC, which reflects the year-over-year rate of change in incidence or mortality, averaged over a specified time^{44,46}. The APC was estimated using a log-linear regression model, and AAPC was calculated as the weighted average of APCs over the specified time intervals, with weights proportional to the number of years in each interval:

$$AAPC = \frac{\sum(w_i \times APC_i)}{\sum w_i}$$

where AAPC_{*i*} is the APC for each interval *i*, and *w_i* represents the number of years in that interval. This approach ensures a more stable estimate of temporal trends over multiple time periods.

SDI

The SDI is a composite measure of the social and economic factors that influence health outcomes in each region⁴⁷. In essence, the SDI is calculated as the geometric mean of three indices: TFU25 (total fertility rate

under age 25), EDU15+ (average educational attainment of individuals aged 15 and older) and LDI (delayed distributive income per capita). Each of these indices has a range of 0 to 1. Based on its value, the SDI is divided into five categories: high SDI, high-middle SDI, middle SDI, low-middle SDI and low SDI⁴⁸.

Data presentation

The GBD world population age standard was applied to calculate age-standardized rates for prevalence, death and DALY of chronic respiratory diseases. To assess changes over time, we calculated the percentage change in the rates between the start and end of the time period, with the change expressed as the difference between the new and old rates divided by the old rate. All rates presented are age-standardized unless specifically indicated as age-specific rates. All modeling was conducted for 500 draws^{4,38}, and the UI was calculated using the 2.5th and 97.5th percentiles of the draws. Analyses were performed using Python (version 3.10.4; Python Software Foundation) and R (version 4.2.1; R Foundation).

Ethics and inclusion statement

The GBD framework ensures that estimates are derived from diverse data sources, including population-based registries and national health surveys, covering 204 countries and territories. The research team included collaborators from various regions who contributed expertise in epidemiology, disease modeling and health policy. All authors agreed upon roles and responsibilities at the outset of the study.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The findings from this study were produced using data available in public online repositories or in the published literature, as well as data that are publicly available from the data provider under certain conditions. Details on data sources can be found on the GHDx website, including information about the data provider and links to where the data can be accessed (where available). Citations and metadata for all input sources used in this analysis are available for download at <https://ghdx.healthdata.org/gbd-2023/sources>. Most GBD data can be accessed directly upon visiting the GHDx website, and some datasets may require agreement to a data use policy before download. Access is typically granted immediately upon completion of these steps.

Code availability

Our study follows the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER; Supplementary Table 4). All code used for this analysis is publicly available online at <https://github.com/CenterForDH/Chronic-respiratory-diseases.git>.

References

- GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* **403**, 2133–2161 (2024).
- Shin, Y. H. et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Allergy* **78**, 2232–2254 (2023).
- Patwardhan, V. et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. *Lancet Public Health* **9**, e282–e294 (2024).
- Kim, S. et al. Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. *eClinicalMedicine* **79**, 102985 (2025).
- Wang, H. et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. *Lancet* **399**, 1513–1536 (2022).
- Lee, S. et al. Global, regional, and national trends in maternal mortality ratio across 37 high income countries from 1990 to 2021, with projections up to 2050: a comprehensive analysis from the WHO Mortality Database. *J. Korean Med. Sci.* **40**, e85 (2025).
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1789–1858 (2018).
- Institute for Health Metrics and Evaluation (IHME) *Global Burden of Disease Study 2021 (GBD 2021) Socio-Demographic Index (SDI) 1950–2021* (IHME, 2024).

Acknowledgements

This study was funded by the Gates Foundation, Australian National Health and Medical Research Council, and Queensland Department of Health, Australia. This work was supported by the Yonsei Fellowship, funded by Lee Youn Jae (J.I.S.). This research was supported by the Ministry of Science and ICT (RS-2024-00509257 and IITP-2024-RS-2024-00438239 to D.K.Y.) and the Ministry of Health & Welfare (RS-2025-02220492 to D.K.Y.), Republic of Korea. The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. All authors had full access to the study data and had final responsibility for the decision to submit for publication.

Author contributions

J.O., S. Kim, Y. Yim, M.S.K., S.I.H., J.I.S. and D.K.Y. conceptualized and designed the study. These authors also developed the methodology and acquired the data. J.O., S. Kim, Y. Yim, M.S.K., S.I.H., J.I.S. and D.K.Y. conducted the statistical analysis and curated the data. S.I.H., J.I.S. and D.K.Y. validated the findings, interpreted the data and created the visualizations. They also managed the estimation or publications process. J.O., S. Kim and Y. Yim prepared the original draft. All authors reviewed and edited the paper and provided critical revisions. S.I.H., J.I.S. and D.K.Y. supervised the work and oversaw project administration. These same authors secured the funding. Contributions by the GBD 2023 Global Chronic Respiratory Disease and COVID Collaborators are described in the Supplementary Information.

Competing interests

S. Ansari reports grants or contracts from the Australian Government Department of Health Medical Research Future Fund and Royal Australian College of General Practitioners (payment made to UNSW Sydney, administering institution for the grants); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Asthma Australia toward participation in the Quality Use of Medicines for Chronic Airways Disease Program funded by the Australian Government Department of Health and Honoraria from the National Health and Medical Research Council for participation in two Grant Assessment Committees for the Australian Government Department of Health; support for attending meetings and/or travel from Asthma Australia toward participation in the Quality Use of Medicines for Chronic Airways Disease Program design thinking workshop in Brisbane, Australia; and other support from UNSW Sydney through two Australian Government Medical Research Future Fund

grants, outside the submitted work. A. Min reports patents planned, issued or pending: US20200253891A1 Method of Liver Cancer Treatment with Safranal-Based Formulations (Pending); US20200254049A1 Combination Therapy for Cancer (Pending); and US20200253890A1 Suppression and Inhibition of CDC25B with Safranal-Based Formulations (Pending), outside the submitted work. R. Anuceanu reports consulting fees from AbbVie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Laropharm, Reckitt and Merck Romania; and support for attending meetings and/or travel from Merck Romania and Reckitt, outside the submitted work. J. A. Al-Tawfiq reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a member of the executive board of the International Society for Infectious Diseases, outside the submitted work. M. Asghariahmadabad reports support for attending meetings and/or travel from the ASNR member in training travel grant to attend ASNR 2025, outside the submitted work. E.F.A. reports support for the present manuscript from the following grants: NIH/NHLBI K23 HL129888, Fred Hutch/UW CFAR [AIO27757](#) and NIH/NHLBI R03 HL160251 (all grant funding payments made to institution). M. Ausloos reports support for the present manuscript from the project 'A better understanding of socio-economic systems using quantitative methods from physics' funded by European Union—NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania, contract no. 760034/23.05.2023, code PNRR-C9-I8-CF 255/29.11.2022, through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, 'Investment I8'. A. Beloukas reports grants or contracts from Gilead (Research Grant and Sponsorship to the University of West Attica) and GSK/ViiV (Research Grant and Sponsorship to the University of West Attica); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and GSK (paid to the University of West Attica); support for attending meetings and/or travel from Gilead and GSK (paid to the University of West Attica); and receipt of equipment, materials, drugs, medical writing, gifts or other services from Cepheid, outside the submitted work. E.J.B. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Korean Diabetes Association, International Society for the Diabetic Foot, Diabetes Association of the R.O.C. (Taiwan) and the American Diabetes Association and support for attending meetings and/or travel from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan) and the International Society for the Diabetic Foot, outside the submitted work. P.J.G.B. reports the following patents planned, issued or pending: WO2020229805A1, BR112021022592A2, EP3965809A1, OA1202100511, US2023173050A1, EP4265271A2, EP4275700A2, outside the submitted work. A.J.C. reports support for the present manuscript from the Health Effects Institute. J.C. reports grants or contracts from the European Research Council Starting Grant (ERC-StG-2019-848325) and patents planned, issued or pending SURFACTANT-BASED HYDROGEL, METHODS AND USES THEREOF (Universidade Nova de Lisboa), outside the submitted work. N.C.-M. reports consulting fees from Signant Health outside the submitted work. X.D. reports support for the present manuscript from the Institute for Health Metrics and Evaluation, University of Washington. A. Faro reports support for the present manuscript from the National Council for Scientific and Technological Development, CNPq, Brazil, Researcher Grant (Bolsa Produtividade). R.F.G. reports other support from Elsevier as an associate editor outside the submitted work. Z. Guan reports grants or contracts from Dementia Centre of Excellence, Curtin enAble Institute and Curtin University outside the submitted work. I.M.I. reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia (no. 451-03-137/2025-03/200110). M.D.I. reports

support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia (no. 451-03-47/2023-01/200111). N.E.I. reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as The Bursar and Council Member of Malaysian Academy of Pharmacy and as Committee Member of Education Chapter, Malaysian Pharmacists Society, outside the submitted work. T. Joo reports support for the present manuscript from the National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security). M. Kivimaki reports grants or contracts from the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (MR/Y014154/1), the National Institute on Aging (National Institutes of Health grants R01AG056477 and R01AG062553) and the Research Council of Finland (350426) outside the submitted work. K. Krishan reports non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University (Chandigarh, India) outside the submitted work. M.-C.L. reports support for the present manuscript from the National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002), and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as technical editor, *Journal of the American Heart Association*, outside the submitted work. G. Liu reports grants or contracts from Al & Val Rosenstrauss Fellowship from Rebecca L. Cooper Medical Research Foundation, Australia, outside the submitted work. J. Liu reports support for the present manuscript from the National Natural Science Foundation (grant 72122001). A. Malinovschi reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Chiesi and receipt of sensors for exhaled nitric oxide measurements from NIOX in an investigator-initiated study from Uppsala University outside the submitted work. H. R. Marateb reports grants or contracts from The Beatriu de Pinós postdoctoral program from the Office of the Secretary of Universities and Research from the Ministry of Business and Knowledge of the Government of Catalonia program: 2020 BP 00261, and by the LLaVOR A grant, funded by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, under the Programa Indústria del Coneixement: PREPARE (2024 LLaV 00083), outside the submitted work. S. Martini reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from the Indonesian Public Health Association, outside the submitted work. A.G.M. reports consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GlaxoSmithKline; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as chair, European Respiratory Society (ERS) Airway Diseases Pharmacology and Treatment Group (5.1); stock or stock options in Health Networks; and other non-financial support from Verona Pharma, outside the submitted work. R. J. Maude reports support for the present manuscript from Wellcome Trust (grant number 220211). A.-F.A.M. reports grants or contract funding from 'MilkSafe: A novel pipeline to enrich formula milk using omics technologies', a research cofinanced by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE (project code: T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860) (both outside of the present manuscript); payment for expert testimony as an external peer-reviewer for Fondazione Cariplo, Italy; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as editorial board member for *Systematic Reviews and Annals of Epidemiology* and as associate editor for *Translational Psychiatry*; stocks on a family winery; and other support from having been a senior scientific officer at BGI Group

(Shenzhen, China), outside the submitted work. L. Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017) and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. L. Muccioli reports support for attending meetings and/or travel from Jazz Pharma and Angelini, outside the submitted work. S. Nomura reports support for the present manuscript from grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663) and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8). B.O. reports grants or contracts from the Ministry of Research, Innovation and Digitization, project PNRR-18 no. 842027778, contract no. 760096, outside the submitted work. A. Ortiz reports grants from Sanofi to institution IIS-FJD UAM and to Universidad Autonoma de Madrid (UAM); consulting fees from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Lilly, Chiesi, Otsuka, Novo Nordisk and Sysmex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; support for attending meetings and/or travel from Astellas, AstraZeneca, Fresenius Medical Care, Boehringer Ingelheim, Bayer, Sanofi-Genzyme, Chiesi, Sobi and Bayer; participation on a Data Safety Monitoring Board or Advisory Board from Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Chiesi, Otsuka, Novo Nordisk and Sysmex; and leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as Council ERA SOMANE, outside the submitted work. R.P. reports participation on a Data Safety Monitoring Board or Advisory Board as a member of the Data Safety Monitoring Board dello studio 'Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients'—FIL, Fondazione Italiana Linfomi, Alessandria; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as a member of the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (F), and as a past member 2020–2023 (biostatistician) of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC; outside the submitted work. V.C.F.P. reports grants or contracts from Sanofi Consumer Healthcare to conduct research on self-care in the Philippines and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Zuellig Family Foundation to write papers on health systems strengthening, outside the submitted work. M.J.P. reports stock or stocks options from Health-Ecore and PAG BV, outside the submitted work. L. Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017) and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. L.F.R. reports grants or contracts from GSK, MSK and Pfizer; consulting fees from GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK; and support for attending meetings and/or travel from GSK and Pfizer, outside the submitted work. B. Sartorius reports grants or contracts from the Australian National Health and Medical Research Council Fellowship (grant number 2034827), outside the submitted work. B.M.S. reports grants or contracts from Else Kröner-Fresenius Foundation Research Grant, Deutsche Forschungsgemeinschaft Research Grant and PharmaCept GmbH research grant; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca; and support for attending meetings and/or travel from Bayer AG, outside the submitted work. V. Sharma reports other support from DFSS (MHA)'s research project

(DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University (Chandigarh, India), outside the submitted work. J.I.S. reports other financial or non-financial interests from Yonsei Fellowship, funded by Lee Youn Jae (JIS), outside the submitted work. L.M.L.R.S. reports grants or contracts with SPRINT, Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300-559 6 Guarda, Portugal, and collaborations with RISE-UBI, Health Sciences Research Centre, University of Beira Interior (6201-506 Covilhã, Portugal), outside the submitted work. J.A.S. reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulo, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MediQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, Practice Point Communications and the National Institutes of Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events as a member of the speaker's bureau of Simply Speaking; support for attending meetings and/or travel as a past steering committee member of OMERACT; participation on a Data Safety Monitoring Board or Advisory Board from the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT (an international organization that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies); stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Bio Solutions, Acumen Pharmaceuticals, TPT Global Tech, Vaxart Inc., Aytu BioPharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Abeona Therapeutics and Charlotte's Web Holdings; and previously owned stock options in Amarin, Viking and Moderna, outside the submitted work. J.B.S. reports pharmaceutical company grants from 2021 to 2025 from Chiesi, GSK, Linde and Novartis via Hospital Universitario de La Princesa and participated in speaking activities, advisory committees and consultancies from 2021 to 2025 sponsored by Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, CNPT, ERS, FTH, Gebro, Grifols, GSK, IHME, Laminar Pharma, Linde, Lipopharma, Menarini, Mundipharma, Novartis, OMS/WHO, Pfizer, ResApp, RiRL, ROVI, SEPAR, Seqirus, WHO EUR, Takeda and Zambon. J.S.B. did not receive funding, directly or indirectly, from tobacco manufacturers or their affiliates. I.N.S. reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid as Trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom, outside the submitted work. S.J.T. reports grants or contracts from Jazz Pharmaceuticals related to reviewing the impact of medicinal cannabis on patients with the epilepsy syndromes Lennox-Gastaut syndrome and Dravet syndrome and the 2023 Adult Psychiatric Morbidity Survey team, collecting epidemiological data on community-based adults living in England. This is a contracted study from NHS Digital, via the Department of Health and Social Care; the National Institute for Health and Care Research related to reviewing a national training program for health and social care professionals relating to learning disability and autism (all paid to the University of Leicester); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as academic secretary for the Neurodevelopmental Psychiatry Special Interest Group and Psychiatry of Intellectual Disability Faculty at the Royal College of Psychiatrists, editorial board member for *Progress in Neurology and Psychiatry*, *Advances in Mental Health and Intellectual Disabilities*, *Advances in Autism* and *BMC Psychiatry*, and editor of *Psychiatry of Intellectual Disability Across Cultures* (Oxford University Press), outside the submitted work. E.U. reports the following published patents,

that is, A system and method of reusable filters for anti-pollution mask, A system and method for electricity generation through crop stubble by using microbial fuel cells, A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method, A novel herbal pharmaceutical aid for formulation of gel and method thereof, and Herbal drug formulation for treating lung tissue degenerated by particulate matter exposure, and the filed patent, that is, A method to transform cow dung into the wall paint by using natural materials and composition thereof, and reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as executive council member, Indian Meteorological Society (Jaipur Chapter, India), and member secretary of DST PURSE Program, outside the submitted work. P.W. reports consulting fees from Novartis Pharmaceuticals outside the submitted work. Y. Yasufuku reports grants or contracts from Shionogi outside the submitted work. M. Zielińska reports other financial support as an Alexion, AstraZeneca Rare Disease, employee outside the submitted work. The other authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s41591-025-04077-9>.


Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-025-04077-9>.

Correspondence and requests for materials should be addressed to Jae Il Shin or Dong Keon Yon.


Peer review information *Nature Medicine* thanks Atul Malhotra, Feng Sha, Ting Yang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ming Yang, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.


A. Prevalence




B. Change rate of prevalence



C. Death




D. Change rate of death




Extended Data Fig. 1 | World map of age-standardized prevalence (A) and death rates (C) of chronic respiratory disease in 2023 and percentage change (B, D) from 1990 to 2023. The figure displays the worldwide age-standardized prevalence rate (A) and death rate (per 100,000 population) (C) of chronic respiratory diseases in 2023, alongside the respective change rates in prevalence

(B) and death (D) from 1990 to 2023. The color gradient, ranging from dark purple (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.


A. 2023




B. Change rate (1990-2023)



C. 2023




D. Change rate (1990-2023)




Extended Data Fig. 2 | World map of age-standardized prevalence rates for COPD (A, B) and asthma (C, D) in 2023 and percentage change from 1990 to 2023. Abbreviation: COPD, chronic obstructive pulmonary disease. The figure displays the worldwide age-standardized prevalence rate (per 100,000 population) of COPD (A) and asthma (C) in 2023, alongside the respective change rates of COPD (B) and asthma (D) in prevalence from 1990 to 2023. The color

gradient, ranging from dark blue or red (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.


A. 2023




B. Change rate (1990-2023)



C. 2023




D. Change rate (1990-2023)




Extended Data Fig. 3 | World map of age-standardized prevalence rates for pneumoconiosis (A, B) and interstitial lung diseases and pulmonary sarcoidosis (C, D) in 2023 and percentage change from 1990 to 2023. The figure displays the worldwide age-standardized prevalence rate (per 100,000 population) of pneumoconiosis (A) and interstitial lung diseases and pulmonary sarcoidosis (C) in 2023, alongside the respective change rates of pneumoconiosis

(B) and interstitial lung diseases and pulmonary sarcoidosis (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark purple or green (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.


A. 2023




B. Change rate (1990-2023)



C. 2023




D. Change rate (1990-2023)




Extended Data Fig. 4 | World map of age-standardized death rates for COPD (A, B) and asthma (C, D) in 2023 and percentage change from 1990 to 2023. Abbreviation: COPD, chronic obstructive pulmonary disease. The figure displays the worldwide age-standardized death rate (per 100,000 population) of COPD (A) and asthma (C) in 2023, alongside the respective change rates of COPD (B) and asthma (D) in prevalence from 1990 to 2023. The color gradient,

ranging from dark blue or red (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.


A. 2023




B. Change rate (1990-2023)



C. 2023




D. Change rate (1990-2023)




Extended Data Fig. 5 | World map of age-standardized death rates for pneumoconiosis (A, B) and interstitial lung diseases and pulmonary sarcoidosis (C, D) in 2023 and percentage change from 1990 to 2023. The figure displays the worldwide age-standardized death rate (per 100,000 population) of pneumoconiosis (A) and interstitial lung diseases and pulmonary sarcoidosis (C) in 2023, alongside the respective change rates of pneumoconiosis (B) and

interstitial lung diseases and pulmonary sarcoidosis (D) in prevalence from 1990 to 2023. The color gradient, ranging from dark purple or green (high value) to pale yellow (low value), indicates the magnitude of each metric. The small insets beneath the main map provide magnified views of the Caribbean and Central America, the Persian Gulf, the Balkan Peninsula, Southeast Asia, West Africa, the Eastern Mediterranean, and Northern Europe.


(A) COPD




(B) Asthma



(C) Pneumoconiosis




(D) ILD and pulmonary sarcoidosis



Extended Data Fig. 6 | See next page for caption.


Extended Data Fig. 6 | Global age-sex-specific COPD (A), asthma (B), pneumoconiosis (C), ILD and pulmonary sarcoidosis (D) prevalence rates, 1990–2023. Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease. The figure presents the 1990–2023 global age- and sex-specific prevalence rate trends for COPD (A), asthma (B), pneumoconiosis (C), and ILD and pulmonary sarcoidosis (D). Blue indicates male, and pink indicates female. The bold line represents the mean prevalence rate (derived from the GBD

2023 draws), and the lighter shading denotes the 95% uncertainty interval (UI). For age groups whose trends are not clearly visible due to y-axis scaling, inset figures are provided. These data are population-level estimates (no separate biological or technical replicates), and the unit of study is the entire population in each region-year. No control group was used, as this is an observational, population-based analysis.




Extended Data Fig. 7 | Global age-sex distribution of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases (ILD) and pulmonary sarcoidosis (D) prevalence rates in 2023. Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease. The figure presents the 2023 global age- and sex-specific prevalence rates (per 100,000 population) of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases and

pulmonary sarcoidosis (D). Each bar represents the mean prevalence rate derived from the GBD 2023 draws for each region, with the thin black lines indicating the 95% uncertainty intervals (UI). Blue bars represent males, pink bars represent females. These estimates are population-level data (no separate biological or technical replicates), and the unit of study is the entire population in each region. No control group was used, as this is an observational, population-based analysis.



Extended Data Fig. 8 | Global age-sex distribution of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases (ILD) and pulmonary sarcoidosis (D) death rates in 2023. Abbreviation: COPD, chronic obstructive pulmonary disease; ILD, interstitial lung diseases. The figure presents the 2023 global age- and sex-specific death rates (per 100,000 population) of COPD (A), asthma (B), pneumoconiosis (C), and interstitial lung diseases and pulmonary

sarcoidosis (D). Each bar represents the mean death rate derived from the GBD 2023 draws for each region, with the thin black lines indicating the 95% uncertainty intervals (UI). Blue bars represent males, and pink bars represent females. These estimates are population-level data (no separate biological or technical replicates), and the unit of study is the entire population in each region. No control group was used, as this is an observational, population-based analysis.



Extended Data Fig. 9 | AAPC of age-standardized incidence and death rates for chronic respiratory diseases by GBD region during the pre-COVID-19 (2010–2019) and the pandemic period (2020–2023). The figure presents the average annual percentage changes in age-standardized incidence and death

rates (per 100,000 population) of CRDs by GBD region for the pre-COVID-19 period (2010–2019) and the pandemic period (2020–2023). Purple bars represent the pre-pandemic period (2010–2019), and green bars represent the pandemic period (2020–2023).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The findings from this study were produced using data available in public online repositories or in the published literature, as well as data that are publicly available from the data provider under certain conditions. Details on data sources can be found on the GHDx website, including information about the data provider and links

to where the data can be accessed (where available). Citations and metadata for all input sources used in this analysis are available for download at <https://ghdx.healthdata.org/gbd-2023/sources>. Most GBD data can be accessed directly upon visiting the GHDx website, and some datasets may require agreement to a data use policy before download. Access is typically granted immediately upon completion of these steps.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	No primary data collection was carried out for this analysis, so the study does not involve human research participants. As stated in the methods overview, estimates were stratified by sex.
Reporting on race, ethnicity, or other socially relevant groupings	Not applicable.
Population characteristics	Not applicable.
Recruitment	Not applicable.
Ethics oversight	This study was approved by the University of Washington IRB Committee.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was defined as the population of every location used in our analysis. State-, country-, region-, super-region, and global-level populations are estimated as part of the Global Burden of Disease Study 2021. Detailed methods are described in https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00757-8/fulltext .
Data exclusions	We carefully evaluated all data sources for inclusion in our study. Sources were excluded if they lacked necessary survey weight factors or crucial demographic information such as sex or age variables. Additionally, we omitted data deemed unreliable, based on assessments by survey administrators or through our own detailed examination. This careful selection process ensured the quality and completeness of the information used in our analysis.
Replication	This is a systematic analysis of existing studies with many years of cohort and other existing data. Reproducibility of this work can be achievable with access to the data and the publicly available code at https://ghdx.healthdata.org/gbd-2021/code .
Randomization	Randomization was not relevant to this study. This analysis is a meta-analysis of existing studies and thus, there were no experimental groups.
Blinding	Blinding was not relevant to this study, as it was an observational study using survey and surveillance data.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- | n/a | Involvement |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Plants |

- | n/a | Involvement |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.